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Message from the President 
I am delighted to welcome you to Galway for the second annual IPU National Pharmacy 
Conference. Yet again, this is a superb event, providing both valuable learning opportunities 
and an enjoyable social occasion. A showcase for the best aspects of the community pharmacy 
profession in Ireland, this conference is the culmination of the extraordinary efforts of a small 
group of people who deserve our thanks and our congratulations for a job well done.
These remain difficult times, both for pharmacists and for our wider society. The FEMPI Act 
remains in place, with its implicit threat of yet further cuts in our payments, and uncertainty 
surrounds the likely impact on pharmacists of both a new IPHA/HSE agreement and the 
impending introduction of Reference Pricing. Retail sales continue to decline as consumers 
become ever more fearful of spending and the general economic outlook shows no sign of 
improvement.
However, despite the dark clouds, there are some reasons to be positive as our quest to 
deliver a broader range of convenient, accessible and cost-effective healthcare services to our 
patients and the public begins to show results. 
Following the successful introduction of the Emergency Contraception service in pharmacies 
early last year, the Minister for Health James Reilly then legislated in the autumn to allow 
pharmacists to provide seasonal influenza vaccination for the first time.
Notwithstanding the limited time available, the IPU worked with other stakeholders to 
ensure the profession would be ready: organising vaccination training, getting it accredited 
by Trinity College Dublin against PSI standards, and also producing protocols and SOPs for 
members to use in their pharmacies. The professional manner in which pharmacists delivered 
the vaccination service, particularly the way we dealt with the issues which arose, proved our 
capacity to deliver high quality and safe primary healthcare to the public.  
The IPU has no agenda other than to further the interests of its members and of the pharmacy 
profession. We will continue to engage constantly and constructively with Government and 
with the public to ensure the potential of pharmacy is realised. Ours is a worthy profession, 
one which is valued and appreciated by our patients. As we face up to the significant 
challenges ahead, the Union will seek out and seize every opportunity to secure the future of 
community pharmacy services.
The Union continues to communicate with members through the monthly IPU Review and 
General Memoranda, the weekly e-newsletters and occasional text updates. We have a very 
comprehensive website on which you will find an abundance of information and also a 
Members’ Forum. I encourage you all to make the best use of the resources which the Union 
provides, to keep yourself informed and to participate in Union activities. Be sure to share any 
ideas you may have for improvement.
Your representatives on the Union’s committees continue to apply themselves with genuine 
dedication and unity of purpose for the benefit of the profession. They are ably assisted by 
the excellent staff in Butterfield House, all of whom remain passionate about supporting and 
advocating for you, the Union’s members.  On your behalf, I thank all of them most sincerely 
for their efforts and their enthusiasm.
As I hand over the chain of office, I would like to express my gratitude to our Secretary General, 
Séamus Feely, and to my Vice-President Rory O’Donnell and Treasurer Kathy Maher for their 
advice, support and friendship during my two years as IPU President, and also to my family 
for their fortitude and forbearance throughout that time. 
I congratulate Rory and Kathy on their recent election as President and Vice-President 
respectively and wish them well in their new roles. I know that they, and our new Honorary 
Treasurer, John Gleeson, will serve us well and do us proud in the coming months and years. 
Darragh O’Loughlin MPSI
Darragh O’LOughLin, President, iPu
rOry O’DOnneLL, Vice-President, iPu
Kathy Maher, hon. treasurer, iPu
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Executive Committee 2010 – 2012
Executive Committee 2012 – 2014
President:  Darragh O’Loughlin
Vice-President:  Rory O’Donnell
Honorary Treasurer:  Kathy Maher
Regional Representatives (8)
John MacNamara  East
Kathy Maher  North East
Conan Burke  North West
Tadhg O’Leary  South
Niall Mulligan  South East
Michelle Concannon  Midland
Vacant  West
John Gleeson  Mid West 
Community Employee Group (3)
David Carroll
Fearghal O’Nia
Catriona O’Riordan
Past President
Liz Hoctor
Co-Options
Ann Marie Horan
Michael Kennelly
Sean Reilly
President:  Rory O’Donnell
Vice-President:  Kathy Maher
Honorary Treasurer:  John Gleeson
Regional Representatives (8)
Sean Reilly  East
Kathy Maher  North East
Conan Burke  North West
TBA  South
Niall Mulligan  South East
Michelle Concannon  Midland
Joanne Hynes  West
John Gleeson  Mid West 
Community Employee Group (3)
David Carroll
Catriona O’Riordan
Past President
Darragh O’Loughlin
Co-Options
Ann Marie Horan
John MacNamara
nB: up to five members may be co-opted by the executive Commitee
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Irish Pharmacy Union 
Financial Reports and Accounts for Year Ended 31 December 2011
In accordance with the Constitution of the Union, the Executive Committee submits the audited accounts for consideration by 
members.
The full details of the Accounts have been circulated to members with the Summary of the 2012 Annual Report of the IPU 
Executive Committee.
If the Accounts are approved by the meeting after their presentation, members will be asked to formally adopt the Accounts 
for the year ended 31 December 2011 and agree the election of Auditors. In this context, the following motions will be put to the 
meeting: 
l  “that the executive Committee report and audited Statement of accounts of the irish Pharmacy union for the year ended 31 
December 2011 as submitted to this meeting, be and are hereby adopted.”
l  “that this meeting agrees to the election of Baker tilly ryan glennon for a further year as auditors for the iPu and iPu 
Services Ltd.”
Membership Subscriptions
Subscriptions have been reduced by 38% over the past two years and no further change will be made at this time.
IPU Services Limited 
Financial Reports and Accounts for Year Ended 31 December 2011
At this Annual General Meeting of IPU Services Ltd, members are asked to consider the Report of the Directors and the 
Auditors’ Report on the Accounts for Year Ended 31 December 2011.
The accounts and financial reports have been circulated to all members.
If the Accounts are approved, members will be asked to resolve: 
“that the Directors’ report and audited Statement of accounts for the year ended 31 December 2011 as submitted to this meeting, 
be and are hereby adopted.”
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Report of the 38th Annual General Meeting of the Irish Pharmacy 
Union and IPU Services Ltd Lyrath Estate Hotel, Co Kilkenny 8 May 2011
Present: The President, Mr Darragh O’Loughlin, and 82 members.
In Attendance:  Mr Seamus Feely, Ms Ciara Enright, Ms Ger Gahan, Mr Gerard Howlin, Mr Darren Kelly, Ms Pamela Logan, 
Ms Jill Lyons, Ms Wendy McGlashan, Ms Roisin Molloy, Ms Caroline Mulligan and Ms Aoibheann Ni 
Shúilleabháin.
Apologies: Apologies were received from 17 members.
[a full report of the 2011 agM is available from the iPu offices.]
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1.  The President welcomed the attendance to the 38th 
Annual General Meeting of the Irish Pharmacy Union.
2.  On the proposal of the President all present stood in 
silence in memory of deceased members and their 
families, including former President Charlie Roche, and all 
those who had died since the 2010 AGM. 
3. Financial Reports and Accounts 2010
 a.  Kathy Maher (Honorary Treasurer) presented the 
Union’s Financial Report and drew members’ attention 
to Page 31 of the Annual Report.  
   Following the presentation, the following motion 
approving the accounts was proposed by Dermot 
Twomey, seconded by Niall Mulligan and carried: 
   “that the executive Committee report and audited 
Statement of accounts for the irish Pharmacy union for 
the year ended 31 December 2010 as submitted to this 
meeting be and are hereby adopted.”
 b.  The following motion was proposed by Mike Walsh, 
seconded by Peter Harty and carried.
   “that this meeting agrees to the election of Baker tilly 
ryan glennon for a further year as auditors for the iPu 
and iPu Services Ltd.”
 c.  It was announced that the Executive Committee 
had agreed not to change the annual subscription 
payable.
4. IPU Services Ltd AGM
 The minutes of the 2010 AGM were taken as read.
  The Honorary Treasurer presented the accounts of IPU 
Services Ltd. to the meeting.
  On the proposal of Morgan Power, seconded by Brian 
Walsh, it was resolved:
  “that the Directors’ report and audited Statement of 
accounts for the year ended 31 December 2010 as submitted 
to this meeting, be and are hereby adopted.”
 This motion was carried.
5. Report of 37th AGM
  The report of the 37th Annual General Meeting was 
approved as a true and accurate record. The report had 
been circulated to all members prior to the meeting.
6. Report on Motions from 2010 AGM
  The report on motions from the 37th Annual General 
Meeting was taken as read and agreed. 
7. President’s Address
  Mr D O’Loughlin, President addressed the meeting and 
thanked members and the staff of the Union for their 
support during the year. 
8. Union Secretariat Report
  The Union Secretariat Report was circulated to all 
members, prior to the meeting, as part of the Executive 
Committee report. The Secretary General, Mr Seamus 
Feely, introduced the Secretariat report. 
9. Group Reports
 a. Pharmacy Contractors Committee (PCC) Report
   This report was introduced by Mr Liam Butler, 
Chairman of the Pharmacy Contractors’ Committee.
   A summary of the report was circulated in advance 
of the meeting and the full report published on the 
members’ section of www.ipu.ie. 
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 b. Community Pharmacy Committee (CPC) Report
   This report was presented by Mr Stephen Nolan, 
Chairman of the Community Pharmacy Committee.
   A summary of the report was circulated in advance 
of the meeting and the full report published on the 
members’ section of www.ipu.ie. 
 c. Employee Pharmacists’ Committee (EPC) Report 
   This report was delivered by Ms Louise Begley, 
Chairperson of the Employee Pharmacists’ Committee. 
   A summary of the report was circulated in advance 
of the meeting and the full report published on the 
members’ section of www.ipu.ie. 
 d. Public Relations Report 
   This report was circulated in the Annual Report and 
was taken as read. 
 e. International Pharmacy Matters 
   This report was circulated in the Annual Report and 
was taken as read. 
10. 2010 AGM Motions
  The 2011 Motions and action taken on them are on Pages 
6 to 8 of this report.
11. A.O.B
  The Past President, Ms Liz Hoctor, commended Noeleen 
Harvey for her time as President in the Pharmaceutical 
Society of Ireland. After two terms as President, she is now 
stepping down. 
  Diarmuid O’ Donovan thanked the Conference Committee, 
all the Union Committees and IPU Staff for all their hard 
work.
  Richard Collis questioned the deregulation of Norlevo and 
suggested that any further changes should be done on 
a phased basis. He did not think the IMB’s reaction was 
acceptable and believes the Union needs to take action 
on this. Pamela Logan explained the situation around 
the Patient Group Directions and the IMB’s opinion. The 
Union wrote to the IMB to highlight their concerns about 
the short notice given to pharmacists when Norlevo was 
deregulated. The IMB has now established a Committee 
to review deregulation. The Union will continue to follow 
this matter up with the IMB to ensure this type of situation 
does not occur again. 
  The President then closed the 38th Annual General 
Meeting of the Irish Pharmacy Union.
2011 AGM Motions and Report  
on Action Taken
The following motions, proposed in accordance with Article 
29 of the Constitution, were brought before the 2011 AGM for 
consideration:
1. Proposed: Liam Butler 
 Seconded: Grainne O’Leary
  “that this agM calls on the Minister to recognise that 
there is no scope for any further unilateral and arbitrary 
cuts to pharmacy payments and to engage substantially 
with the iPu, under a process similar to that set out 
and agreed with the health Service executive and 
the Department in april 2008, to review all existing 
administrative, contractual and payment arrangements.”
 This motion was carried unanimously 
  Action: In October 2011 the Minister announced a further 
FEMPI Review of the Pharmacy Payments. The IPU was 
invited to make a submission to the Review. 
  The IPU made a submission to the Minister as part of the 
Review. The IPU stressed that the community pharmacy 
business model continues to come under serious threat 
due to a variety of policy, environmental and regulatory 
developments. In particular, the reductions in payments 
which have been implemented under FEMPI Act since 
2009 continue to have a fundamental impact on the 
profitability, stability and viability of the community 
pharmacy sector, and therefore on the sustainability of 
services to patients. The IPU put forward the case that 
there was no scope for any further cuts. The IPU also 
reiterated these points to the Department during their 
presentation in November.
  In January 2012 the Minister confirmed that there would 
be no further cuts to pharmacy income at that time.
  While the IPU welcomed the decision for no further cuts 
it was, however, disappointed that the Review had not 
addressed a number of issues raised by the IPU during 
the consultation process - the continuing loss on fridge 
items to contractor, the low regressive fees and the 
reimbursement price of medicines. The IPU has recently 
written to the Minister setting out these issues again 
and seeking a meeting with the Minister.
2. Proposed: Louise Begley 
 Seconded: Bernard Duggan
  “that the iPu welcomes the recent irish Medicines 
Board decision to reclassify the emergency hormonal 
contraception product norlevo from prescription to non-
prescription status and calls on the iMB to reclassify other 
appropriate medicines in order to improve the public’s 
access to medicines.”
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  The following amendment was proposed by Jack 
Shanahan and seconded by Mary-Rose Burke.
  “that the iPu welcomes the recent irish Medicines 
Board decision to reclassify the emergency hormonal 
contraception product norlevo from prescription to 
non-prescription status and calls on the iMB to reclassify 
other appropriate prescription-only human and veterinary 
medicines in order to improve the public’s access to 
medicines from their pharmacist”. 
 The motion, as amended, was carried unanimously.
  Action: The IPU is a key stakeholder on the Switch On 
to Self-Care Working Group which, in October 2010, 
published a paper, A Self-Care Framework for Ireland, 
advocating that the range of medicines available to 
patients should be expanded through switching from 
prescription to non-prescription status. In February 2012, 
the Working Group reconvened and met with the IMB 
who informed us of the Consultation Panel that has 
been set up to review the classification of medicines, 
following a public consultation by the IMB in July 2011. 
In March 2012, the Working Group met with the Chief 
Pharmacist and Deputy Chief Medical Officer to discuss 
the recommendations outlined in the paper. It is now 
intended to have a public launch of the paper, hopefully 
supported by Minister Shortall, to highlight that patients 
in Ireland should have the same access to medicines as in 
other jurisdictions.
  Following the lack of notice given to pharmacists 
following the reclassification of Norlevo in February 2011, 
the IPU wrote to the IMB on 30 March 2011, proposing 
that a more appropriate length of time is allowed 
between announcing the switching of a medicine and its 
availability on the market. 
  PGEU published a statement on the Role of Community 
Pharmacists in Self-Care, designed to encourage the 
European Medicines Agency to centrally reclassify more 
medicines to non-prescription status.   
3. Proposed: Caitriona O’Riordan 
 Seconded: Fearghal O’Nia
  “that the iPu calls on the irish Medicines Board, hSe 
and Department of health to take all  necessary steps, 
including the adoption in ireland, as in other european 
countries, of a public service obligation, to ensure the 
uninterrupted supply of prescription medicines to 
patients.”
  The following amendment was proposed by Caitriona 
O’Riordan and seconded by Fearghal O’Nia and carried.
  “that the iPu calls on the irish Medicines Board, hSe and 
Department of health to take all necessary steps, including 
the adoption in ireland, as in other european countries, 
of a public service obligation, to ensure the uninterrupted 
supply of prescription medicines to pharmacies.”
 The motion, as amended, was carried by a majority vote.  
 There was one abstention.
  Action: The IPU wrote to the Department of Health, HSE 
and IMB on 25 February 2011 in relation to the number 
of medicines shortages currently being experienced 
in community pharmacies. Following last year’s AGM, 
there was significant press coverage of this issue in 
newspapers and on the radio. The IPU met with the 
IMB in November 2011 to further discuss the issue. 
The IMB indicated that they take the issue seriously 
and intervened when there were supply issues with 
medicines supplied by Movianto. 
4. Proposed: Rory O’Donnell 
 Seconded: Noel Stenson
  “that this agM calls on the Minister to act on his 
proposition to enable pharmacists to provide a vaccination 
service; including for swine flu, seasonal flu, travel vaccines.”
  This motion was carried by a majority vote. There were 
two abstentions.
  Action: The IPU wrote to the Department of Health 
on 28 March 2011 to request a meeting to discuss how 
pharmacists could supply and administer seasonal 
influenza vaccines in the autumn. On 18 July 2011, 
following a meeting with the IPU, the Minister for 
Health announced that pharmacists would be facilitated 
in participating in the seasonal influenza vaccination 
service for 2011. The legislation which gave effect to this 
was signed on 14 October 2011.
  The IPU partnered with Hibernian Healthcare to develop 
a vaccination training programme. The course was 
accredited by the PSI and the School of Pharmacy, Trinity 
College Dublin. Over 1400 pharmacists completed the 
training in 20 venues around the country. 550 pharmacies 
indicated to the PSI and HSE that they were providing a 
vaccination service. 
  The IPU produced SOP templates to assist pharmacies 
in delivering the vaccination service. The IPU also 
sent weekly and monthly updates to members over 
September, October and November to keep them up 
to date on progress with the roll out of the service and 
to assist them in setting up the pharmacy service. The 
IPU produced and sent out posters and leaflets to all 
pharmacies to assist in promoting the service to patients. 
5. Proposed: Kathy Maher 
 Seconded: Morgan Power
  “that the iPu calls on the Minister for health to engage 
positively with the iPu to agree a time-lined series of 
specific steps to deliver a better and more cost-effective 
primary care system for patients, which must necessarily 
include an enhanced role for community pharmacists as 
the single most accessible part of ireland’s primary care 
network.”
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 The motion was carried unanimously.
  Action: At a meeting with the Minister for Health in 
July 2011, the IPU expressed its desire to work with the 
Government to deliver a more cost-effective system for 
patients. At that time the Minister had been eager that 
discussions on a new pharmacy contract would begin 
shortly.
  The IPU used the IPU Submission to the Minister’s 
FEMPI Review in November 2011 to again highlight to 
the Minister that community pharmacy could play 
an expanded role in the healthcare sector. The recent 
roll-out of new services had been welcomed by the 
profession, the Government and patients alike. The IPU 
stated that the greater use of community pharmacy in 
delivering care and treatment will give patients more 
choice and more access and will give Ireland a more 
efficient healthcare system. The IPU requested the 
development of an agreed framework to facilitate a fair 
pricing model for pharmacy services and which should 
form an integral part of the discussion on a new contract, 
which should get underway shortly. However, the IPU 
was informed in late 2011 that discussions on a new 
contract may not begin until 2013 at the earliest.
  In January 2012, the IPU also met the Minister of State 
with responsibility for Primary Care, Roisin Shortall and 
highlighted its desire to work with the Government as 
part of the primary care network. The IPU will continue 
to lobby for a more enhanced role for pharmacists and 
inclusion in to the Primary Care System.
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IPU Secretariat Report
1. INTRODUCTION 
  The IPU commitment is to deliver services and supports to you, our members, to assist you in your professional and 
business activities. The Union belongs to its members and all policy decisions are taken by members on the various 
national committees. It is my job, and those of my colleagues, to ensure that those policies are implemented and that 
your interests are well served by our actions. It is through these structures and processes that we maintain our focus in 
ensuring the continuing viability of your businesses and the expansion of the professional role of pharmacists. I would 
like to thank all my colleagues, the Officers of the Union and members for their continuing support. 
  Looking to the year ahead, the commercial challenge remains as you cope with the ongoing challenge of doing more 
for less while, at the same time, ensuring that a professional service is delivered to your patients. At the time of going 
to print we are awaiting the introduction of legislation to deal with generic substitution and reference pricing. Talks on 
the price of medicines with the pharmaceutical industry are also ongoing. These developments will have a major impact 
on the business and profession of pharmacy and we will keep you informed in the months ahead. Next year we will also 
see the first steps being taken to introduce mandatory professional development and the IPU will be taking a number of 
initiatives to facilitate you in complying with these requirements.
2. MEMBERSHIP & PHARMACy OWNERSHIP (AS AT 14 MARCH 2012)
(1) Membership of the IPU 
  Community Proprietors 877
 Industry & Wholesale 7
 Community Employees 893
 Hospital 7
 Army, Academic & Admin 3
 Associate Members   8 1795
(2) Number of Community Pharmacies 
 Pharmacist Owned:
 Single shops 755
 Chains 592 1347
 Non-Pharmacist Owned:
 Single shops  73
 Chains  118 191 (1538)
(3) Total Number of Chains (2 and over) 
       Pharmacist  Non-Pharmacist
 Two pharmacies 114 4  236
 Three 33 1  102
 Four  12   48
 Five 7   35
 Six 5 2  42
 Eight 2 1  24
 Nine 2   18
 Twelve  1  12
 Thirteen  1  13
 Fourteen 1   14
 Sixteen 1   16
 Seventeen 1   17
 Twenty 1   20
 Twenty-Five 1   25
 Twenty -Six 1   26
 Sixty Two  62  62
  (592) (118)  (710)
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3. PRODUCT FILE UNIT
  The IPU Product File is managed by Fiona Hannigan 
and her team: Ger Gahan and Eilish Barrett. As well as 
supplying price updates and product information for 
members, they provide the following services and advice: 
 l Product sourcing
 l General queries on the IPU Product File
 l GMS pricing issues
 l Short Supply and Discontinued Lists
  The IPU also provides a Drug Interaction File and 
information files on drug use in Pregnancy and 
Breastfeeding, produced by the School of Pharmacy 
in Trinity College Dublin. These are based on the 
ATC classification system and are designed to warn 
pharmacists of the possibility of an interaction. 
  The following areas are a priority in the Product File area 
during 2012.
 l Reference Pricing/Generic Substitution
  •  Consultant engaged to assist in developing the 
IPU Product File 
 l Electronic Download of Product File
  •  User Manuals printed and posted to members 
January 2012
  •  Usernames and passwords posted to members 
January 2012
  • CDs ceased from 1 February 2012
 l IPU Comms move to broadband
  •  Brentech engaged to work with the IPU to ensure 
that any changes are right for our members
  • Forum with relevant stakeholders set up
  •  Due to be piloted first quarter 2012 and live by 
end of year
 l BNF Warning Codes
  •  Pharmacist engaged to assist in updating IPU 
Product File with new BNF warning codes
 l Linking IPU Product File to IMB Website
  •  IPU Product File updated to distinguish PA/PPA/
DRP and EU products
  • Sample fields sent to vendors for testing
 l Marketing of IPU Product File
  • Flyer printed and posted to all hospitals
  •  Advert placed in IPU Review and IPU Yearbook 
2012 
4. ADMINISTRATION UNIT
  The Administration Unit has three staff members:
  Patrice O’Connor, who works part-time, looks after 
reception and assists in the day-to-day running of the 
office; Ciara Enright, who works part-time as the Union’s 
accountant, is Secretary to the Finance Committee. She 
maintains books of account and advises members on 
a range of taxation and accountancy problems. Roisín 
Molloy is responsible for all aspects of membership and 
the management of the Secretary General’s office. 
5. CONTRACTUAL AND OTHER RELATED ISSUES 
  Jill Lyons and Aoife Garrigan deal with a wide range of 
contractual issues. Jill Lyons is Secretary to the Pharmacy 
Contractors’ Committee (PCC). Jill has played a key role in 
developing many of the key PCC initiatives throughout 
the year and in the resolution of problems with the 
Health Service Executive, Primary Care Reimbursement 
Service and the Department of Health. Throughout 2011 
Jill Lyons was involved in preparing the submission and 
the oral presentation to the FEMPI Review in November 
2011, working with the HSE and the Elton John AIDS 
Foundation on the implementation of the Needle 
Exchange Programme through Community Pharmacy, 
and preparing for the implementation of the Influenza 
Vaccination HSE Browser. Jill also represents the Union 
at the PGEU Economic Working Group. Jill and Aoife 
have spent much of the year participating in the Joint 
Consultative Group with the HSE as well as addressing 
contractual queries that arise. Aoife also deals with 
remuneration queries, compiling information on raids 
on pharmacies and collecting information on stolen and 
forged prescriptions. 
6. POLICy AND PUBLIC AFFAIRS 
  Jim Curran joined the IPU on 20 February 2012 as Director 
of Communications and Strategy. His responsibilities 
include promoting the interests of the IPU and the 
membership through effective communications with 
members, media, agencies and other parties that 
influence the sector. He is also responsible for events, 
business and policy research. Over the next number of 
months Jim will be overseeing the introduction of a new 
strategy statement for the IPU, which will replace the 
existing Statement of Strategy 2010-2012.
7. MEDIA AND COMMUNICATIONS 
  Wendy McGlashan is Secretary to the Executive 
Committee and is responsible for IPU publications, 
including the production of the IPU Review, weekly 
e-newsletter and co-production of the IPU Yearbook.
  Aoibheann Ní Shúilleabháin works on the co-ordination 
of all communications activities, organises events, 
manages the IPU website and also works on national and 
regional media coverage for the Union, public opinion 
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research and IPU advertising campaign. She is Secretary 
to the Organising Committee for the IPU National 
Pharmacy Conference and is an editorial associate of the 
IPU Review.
 Communications
 l  Market Research: The Union undertook market 
research amongst the general public and the results 
will be presented at the IPU National Pharmacy 
Conference.
 l  Advertising and Public Relations: The Union ran 
advertising campaigns in June and October-
December, which included radio ads, in-store 
materials and an online element. The ads aimed to 
promote the role of the pharmacist and encouraged 
people to ‘ask your pharmacist first’. Public relations 
activities also raised the profile of pharmacists in the 
media, with interviews on national tv and radio, as 
well as in regional media, highlighting the role of the 
pharmacist. 
 l  Communications with Members: Communications 
with members continues to improve with the IPU 
website, IPU News (the weekly e-newsletter) and 
@ipumail all seeing an increase in uptake from 
members. In the last year, new services have been 
launched such as an SMS Service, Members’ Forum 
on the IPU website and a Facebook page. A booklet, 
On your Side and at your Side, was also sent to 
members highlighting the support and services that 
the IPU provides to members.
 l  Publications 
The IPU Review, Yearbook and a weekly e-newsletter 
are all produced in-house rather than through 
external contractors for efficiency reasons.
8. PHARMACy SERVICES
  The Director of Pharmacy Services, Pamela Logan, co-
ordinates all Professional, IT and Training matters within 
the IPU. Pamela acts as Secretary to CPC and details 
of issues covered by this Committee can be found in 
the CPC report. She works with relevant departments 
and agencies, both nationally and internationally, 
to promote the role of the pharmacist. Pamela also 
represents the IPU at ICCPE, PGEU and FIP. Liz Hoctor 
joined the IPU in January this year as CPD & IT Manager 
to support members in their engagement with 
continuing professional development and to manage the 
development of IT systems to support members in the 
delivery of new pharmacy services.
9. TRAINING DEPARTMENT 
  Susan McManus, Training and HR Manager, organises 
and co-ordinates a range of training courses for 
pharmacy staff. Janice Burke assists Susan in this 
department. The Pharmacy Technicians’ Course saw 104 
students graduating in March 2012. There are currently 
209 students participating in Year 1 and 100 students in 
Year 2 of the course. In addition, 141 students completed 
the MCA Course in 2011 in Cork, Dublin, Galway, Killarney, 
Limerick, Sligo, Tullamore, and Waterford. 106 students 
completed the Interact course and 44 completed the 
Interact Plus course. The FÁS Pharmacy Sales Traineeship 
course was administered in Baldoyle and Loughlinstown, 
Dublin; Douglas, Cork; and Mervue, Galway and to 
Senior Colleges in Dun Laoghaire, Dublin; Monaghan 
Institute; Limerick College of Further Education; and St 
John’s College, Cork. Susan also acts as Secretary to the 
Employee Pharmacists’ Committee, co-produces the IPU 
Yearbook and Diary and advises members on HR issues.
10. BUSINESS SERVICES
  The Business Development Manager, Darren Kelly, is 
responsible for business services to members. In 2011 
“Strategies for growth” business training was held 
around the country to help members understand their 
business and maximise their profits. A number of affinity 
schemes have been negotiated for members on a range 
of products and services and details can be found on 
www.ipu.ie. Members are kept up-to-date with current 
legislation through notices in the IPU Review, Yearbook, 
E-Newsletter and General Memoranda. Darren also 
produces Business Newsletters on specific relevant 
topics which are sent out to members throughout the 
year. Darren set up the IPU Retail Review Consultancy 
Service, which is available to members at a discounted 
rate. Details of this service can be found on www.ipu.ie 
and in the IPU Review. Darren also oversees the general 
maintenance and upkeep of Butterfield House.
11. EXTERNAL CONSULTANTS
  Gordon MRM (PR Consultants); Coolamber (IT 
Consultants); John Behan (Industrial Relations Advisor) 
and Sean McHugh (Industrial Relations Advisor); provide 
advice and support to the Union as requested on an 
ongoing basis. Leaf Environmental has been retained 
as consultants to the Union on matters regarding 
environmental and waste management issues.
12. MAILINGS TO MEMBERS
  The number of mailings to members over recent years 
were: 2003, 25; 2004 19; 2005, 20; 2006, 24; 2007, 47; 
2008, 59; 2009, 53; 2010, 38; 2011, 30.
11
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13. MAIN COMMITTEE MEETINGS
 The number of committee meetings was:
    ‘11 ‘10 ‘09
 Executive Committee 6 6 9
 Community Pharmacy Committee 5 5 6
 Pharmacy Contractors’ Committee 5 8 8
 Finance Sub Committee 7 7 7
 All Committee Meetings 0 0   3
 Employee Pharmacists’ Committee 4 4 3
14. UNION PUBLICATIONS
 The following are sent to members, on a regular basis:
 l IPU Review
 l IPU Weekly E-Newsletter
 l General Memoranda
 l Price Index List Updates
 l IPU Product File by email and on Disk and CD
 l Yearbook & Diary
 l Wall Planner 
 l Training Course Updates
 l Employee Pharmacists’ Committee Newsletter
 l Reap the Rewards of IPU Membership
15. PENSIONS AND INSURANCE 
  AIC (Corporate) Ltd, Pharmacy Insurance Ireland and 
Liberty Asset Management provide insurance and 
pension services for members.
16. SUBMISSIONS
  The following submissions were made during the year. 
Extracts of some of these submissions are published in 
the appendices to this report and all are available on the 
IPU website.
 2011
 l ESRI on Drug Distribution – Jun 2011
 l Minister for Health Paper – Jul 2011
 l Classification of Medicinal Products – IMB – Jul 2011
 l Roisin Shortall Paper – Aug11
 l  Review of Integrated Discharge Planning Code of 
Practice – HSE – Aug 2011 
 l Budget 2012 – DoF – Oct 2011
 l FEMPI Review – DoH – Nov 2011
 2012 
 l eHealth Interoperability Standards – HIQA – Jan 2012
 l  Risk Review Group on Underdosing of Seasonal 
Influenza Vaccine – PSI – Jan 2012
 l  Classification of Veterinary Medicines – IMB – Jan 
2012
17. IPU REVIEW
  The IPU Review is produced in-house by Jim Curran, 
Wendy McGlashan and Aoibheann Ní Shúilleabháin. 
18. CONCLUSION
  Finally, I would like to thank all the staff of the Union for 
their commitment and hard work on behalf of members 
throughout the past year. 
Seamus Feely, 
Secretary General.
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The Pharmacy Contractors’ Committee, under the 
Chairmanship of Liam Butler, took office following the 2010 
Annual General Meeting (AGM) in April. Morgan Power was 
elected Vice-Chairman. The PCC met five times in 2011 since 
the AGM. 
In February 2012 the new Committee took office with 
Morgan Power elected as Chairman and Brian Walsh elected 
Vice-Chairman. The new Committee has met twice since the 
beginning of the year.
Over the past year the PCC’s energies have been focussed on 
preparing a review under the Financial Emergency Measures 
in the Public Interest Act 2009 (FEMPI), the implementation 
of the Influenza Vaccination through pharmacy, the 
implementation of the Needle Exchange Programme along 
with many other urgent issues which have arisen during the 
year.  
THE MAIN ITEMS ON THE COMMITTEE’S AGENDA 
SINCE THE LAST AGM:
Department of Health (DoH) Matters:
l  Preparing the Submission and Oral Presentation in the 
context of the Review carried out under the FEMPI Act in 
November 2011;
l  Communicating with members and gathering 
information from them in advance of the FEMPI Act 
review; 
l  Communicating with members in the aftermath of the 
FEMPI Act review.
l  Implementation of Influenza Vaccination Service through 
pharmacy;
l  Monitoring the implementation of the Prescription Levy;
l  Monitoring progress on Reference Pricing; 
l  Meetings with the Minister for Health James Reilly and 
the Minister for State Roisin Shortall; and
l  The impact of the reductions in the reimbursement price 
of fridge items.
Health Service Executive (HSE) Matters:
l  The implementation of the Needle Exchange Programme 
with the HSE and Elton John AIDS Foundation; 
l  Participating in the Joint Consultative Group with the 
HSE; 
l  Negotiating and finalising the extension of the 
Incomplete Claims Protocol with the HSE and ensuring all 
outstanding claims were paid;
l  Monitoring the recoupment of the Advance Payments;
l  Monitoring all Community Drugs Schemes and all 
pharmacy payments;
l  Monitoring and influencing changes to the Psychiatric 
Scheme that were implemented in 2012;
l  Liaising with the HSE and DoHC to resolve issues around 
the Community Pharmacy Contractors’ Contract;
l  Ongoing HSE PCRS Administration issues; and
l  Working with individual members in resolving problems 
with payments.
Monitoring the Cost of Medicines:
l  Monitoring the reduction in the cost of medicines in 2011;
l  Strongly making the case to the Department for 
sufficient notice of any change in the price of medicines;
l  Advising members on the reductions.
FEMPI Legislation 
The PCC prepared submissions and presentations for 
the FEMPI Review in November 2011. All developments 
were communicated to the membership in a timely and 
straightforward manner. The PCC liaised with PwC to provide 
a Ready Reckoner to assist members is assessing the impact 
of the cuts which were introduced in June 2011.
While there were cuts to pharmacy payments of the order of 
E36m in June 2011, the PCC achieved a successful outcome in 
the second FEMPI Review in November 2011. In January 2012 
the Minister confirmed that there would be no further cuts 
to pharmacy income.
The PCC continues to follow up with the DoH and HSE on the 
fridge item issue and on a number of other issues that the 
FEMPI Review did not address. 
Vaccination
The PCC worked with the HSE and DoH on the 
implementation of the Influenza Vaccination Service and 
put forward its views on the recommended remuneration 
for pharmacists participating in the programme. The PCC 
also liaised with the HSE on the implementation of the 
programme. However, there was insufficient interaction with 
the PCC by the HSE (PCRS) on the development of the HSE 
Browser and this gave rise to a number of problems. The PCC 
will pursue this matter in advance of the next vaccination 
campaign.
Prescription Levy 
The Minister has indicated that he is not in a position to 
abolish the prescription levy because of the economic 
situation. The PCC wrote to the Minister requesting 
amendments to the legislation to exclude certain cohorts 
of patients and this is something that we will continue to 
pursue. 
Pharmacy Contractors’ Committee (PCC) Report 2011
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Reference Pricing 
The PCC has been advocating for the introduction of generic 
substitution since 2003. The PCC has more recently sought 
to influence the manner in which generic substitution might 
be introduced in light of the Government’s commitment 
to introduce legislation for the implementation of generic 
substitution and reference pricing. The PCC has made the 
case that generic substitution be introduced in advance of 
reference pricing. The PCC will continue to follow up on this 
matter in 2012. Equally, we will continue to make the case 
that any reference price must not jeopardise continuity 
of supply or further undermine the viability of pharmacy 
businesses.
The PCC expects legislation to be published shortly.
Meetings with the Minister
The PCC met with the Minister for Health during 2011. There 
was also a meeting with Minister Roisin Shortall, Minister of 
State at the Department of Health in early 2012.
New Pharmacy Contract
The PCC held two meetings of the PCC Sub Group on 
Contract Negotiations in 2011. We built on the work to date, 
including updating the draft contract originally drafted in 
2008. The PCC sought discussions on new contract with the 
HSE, DoH and Minister at every opportunity during 2011. 
We were informed by the DoH that they did not envisage 
that there would be talks on a new contract until 2013 at 
the earliest. However, the HSE is anxious to change current 
contractual arrangements and the PCC will continue to 
advocate that these must be addressed in the context of a 
wider engagement on contractual arrangements.
HSE MATTERS:
Roll out of the NEX Programme
Throughout 2011 the PCC worked with the HSE and the 
Elton John AIDS Foundation to roll out the Needle Exchange 
Programme.  The programme was rolled out in a number 
of pharmacies in November and December 2011. Due to 
the arguments put forward by the PCC, the fee paid to 
pharmacists for needle exchange is E5 and not part of 
the sliding scale of fees (E5, E4.50 and E3.50). The PCC 
is providing support to pharmacists participating in the 
programme through regular contact. There is also a specific 
area on the IPU website for comments and feedback on 
the programme. The PCC had been advocating for further 
support for pharmacists located outside the Eastern Region. 
In response to this request a National Pharmacy Co-ordinator 
for outside the Eastern Area was appointed in September 
2011. This was a very successful outcome from the Union’s 
perspective.
The extension of the Incomplete Claims Protocol
The IPU negotiated the Incomplete Claims Protocol, 
which ensures that pharmacists get paid for all medicines 
dispensed in good faith to medical card patients. This 
protocol continues to be monitored by the IPU and HSE 
at the JCG. The PCC also managed to negotiate for the 
extension of this Protocol into 2012. This was a very 
successful outcome to a long running problem for members.
Adherence to Pharmacy Contract 
The PCC continued to monitor the HSE/DoH adherence 
to conditions of Pharmacy Contract and followed up on a 
number of individual member’s queries throughout 2011 and 
2012.
Advance Payments 
The Advance Payments was withdrawn by the HSE in 2011. 
The PCC liaised with PCRS on this matter and ensured that 
members were granted an extension to recoupment period 
from four to five months. The PCC also sought and obtained 
a commitment from the PCRS that where a pharmacy was 
encountering hardship in paying the payment back, then 
they would extend the recoupment period to 12 months. 
There are 14 pharmacies availing of these arrangements. 
Liaising with the HSE 
The PCC met with the HSE as part of the Joint Consultative 
Group four times during 2011. In addition while working on 
the implementation of the needle exchange programme 
and the vaccination service, there were numerous meetings 
with HSE and DoH officials. Overall, there is good interaction 
between both sides and our aim is to continue to have a 
constructive relationship with the HSE and the DoH.
Legal Advice / Cases 
The Advance Payments Case was closed in 2011. The FEMPI 
Appeal is being kept under review. The Mullally Case is 
awaiting a decision from the Hickey Case in relation to a 
Supreme Court appeal. The IPU liaises with solicitors from 
Beauchamps and Mason Hayes & Curran on all these cases 
to ensure that PCC Committee decisions are implemented 
and result in the best outcome for members, where possible.
MONITORING THE COST OF MEDICINES:
Reductions to the Cost of Medicines  
There were two significant reductions in the price medicines 
reductions during 2011 and 2012 under IPHA and APMI 
agreements with the HSE/Department. The PCC sought a 
deferral on each implementation date by at least one month. 
This was not granted because of the current state of the 
public finances. However, we were given more notice of 
the reductions on the APMI medicines and members were 
given an opportunity to reduce their stock accordingly. The 
IPU communicated to members to warn them of the need 
to reduce stock levels in order to minimise the loss in stock 
value as a consequence of the current consultations between 
the DoH and IPHA. 
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Conclusion
This is a summary of some of the major issues dealt with 
throughout the year. However, officials of the IPU intervened 
in many other matters on a daily basis including individual 
issues for members.  
The PCC is actively working with the HSE on members’ 
behalf. Progress can be slow and discussions take time. There 
are often difficult issues to resolve, but at all times, the PCC 
continues to pursue issues on behalf of members until, 
ultimately, a resolution is found.
Morgan Power, 
Chairman PCC.
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The Community Pharmacy Committee (CPC) is chaired 
by Bernard Duggan, who took over from Stephen Nolan 
in January 2012, with Daragh Connelly as Vice-Chairman, 
succeeding Bernard Duggan. CPC’s mission statement is 
CPC – working to serve and support community pharmacists 
in their practices and to promote and expand their role as 
pharmacists by continually developing professional, ethical, 
business and technological ideals and standards.
The CPC is split into three sub-groups:
Professional Development Steering Group
Louise Begley, Oonagh Harnett, Ultan Molloy, Sarah Magner 
(replacing Ross McEntegart in March 2012), Niamh Murphy
Business Steering Group
Roy Hogan, Daragh Connelly, Elizabeth Lang, Michael Tierney, 
Aidan Walsh 
IT Steering Group
Stephen Nolan, Rory O’Donnell, Jack Shanahan. Sean Reilly 
(Exec) and Michael Walsh (PCC) have also been co-opted onto 
ITSG.
CPC has met five times since the May 2011 AGM (June, 
September, October 2011 and January, March 2012). In March 
2012, the Committee met to agree on a strategy for 2012-
2014. The Committee has dealt with a wide variety of issues 
over the past year. The following is a summary of the key 
issues dealt with during this time. 
PROFESSIONAL ISSUES
PSI Issues
The IPU has met with the PSI and written to the Department 
of Health, proposing amendments to the Pharmacy Act. The 
suggested amendments cover a range of issues such as the 
removal of bankruptcy as a prohibition of registration with 
the PSI, fees for change of ownership from sole trader to 
limited company, fees to change the name of Superintendent 
and Supervising Pharmacist, a limit to the time taken for 
Fitness to Practise (FTP) proceedings, award of costs against 
pharmacists in FTP proceedings, Garda certification of CD 
safes, and provision for storing invoices electronically. A 
further letter was sent to the PSI suggesting ways to improve 
the implementation of the Act. Suggestions included 
issues such as the FTP process, FTP costs, introduction of 
a mediation process, replacement of a Superintendent 
Pharmacist, and Standard Operating Procedures. Copies of 
the letters can be found on the IPU website.
Since the implementation of the FTP process, the IPU has 
assisted members in dealing with complaints made to the 
PSI or investigations instigated following PSI inspections. A 
number of articles have been published in the IPU Review 
covering these issues; they can be found on the IPU website. 
The IPU has met with the PSI to discuss the work programme 
of the National Forum.  The Forum has been set up by 
the PSI, as a recommendation of the Pharmacy Education 
and Accreditation Reviews (PEARS) project, to assist in the 
development and delivery of a new five-year, fully integrated 
programme of education, training and assessment leading to 
the award of a Master’s degree in pharmacy.
The IPU has met with the PSI to discuss the set-up of the 
new Irish Institute of Pharmacy to establish and implement a 
CPD infrastructure for pharmacists. The Institute will be put 
in place in the coming months and the IPU will have a seat 
on the Board. We will continue to keep you updated on this 
matter.
CE/CPD
The IPU is in the process of setting up a Continuing 
Education/Continuing Professional Development platform 
to deliver continuing education programmes to pharmacists 
and to assist them in self-monitoring of their CPD. 
Programmes will be delivered online, by distance learning 
and through face-to-face courses. It is intended to have the 
first round of programmes ready to roll out in June this year.
IPU NET
The IPU has developed a web-based platform called IPU NET 
to host a suite of modules designed to support members 
in the delivery of new pharmacy services and to provide 
research for the IPU to assist us in lobbying for extended 
roles for pharmacists. The first module launched on IPU NET 
will assist pharmacists in supplying emergency hormonal 
contraception to patients. This will be followed by modules 
to support pharmacists in health screening, vaccination and 
self-auditing their pharmacies on PSI standards.  
Extended Pharmacy Services
Vaccination
In July 2011, following a meeting with the IPU, the Minister 
for Health announced that pharmacists would be facilitated 
in participating in the seasonal influenza vaccination service 
for 2011. The legislation which gave effect to this was signed 
on 14 October 2011. The IPU partnered with Hibernian 
Healthcare to develop a vaccination training programme. The 
course was accredited by the PSI and the School of Pharmacy, 
Trinity College Dublin. Over 1400 pharmacists completed the 
training in 20 venues around the country. 550 pharmacies 
indicated to the PSI and HSE that they were providing a 
vaccination service. The IPU produced SOP templates to 
assist pharmacies in delivering the vaccination service. The 
IPU also sent weekly and monthly updates to members over 
Community Pharmacy Committee (CPC)
Annual Report 2011-12
ANNUAL REPORT 2012
17
September, October and November to keep them up to date 
on progress with the roll out of the service and to assist 
them in setting up the pharmacy service. The IPU produced 
and sent out posters and leaflets to all pharmacies to assist 
in promoting the service to patients. 
Needle Exchange Scheme
The IPU/HSE/Elton John AIDS Foundation pharmacy-based 
needle exchange scheme commenced in 65 pharmacies 
around the country in October 2011. Further expansion of 
the scheme will take place over the next three years. As 
part of the scheme, a National Pharmacy Coordinator for 
methadone has been appointed by the HSE. 
Reclassification of Medicines.
The IPU is a key stakeholder on the Switch On to Self-Care 
Working Group which, in October 2010, published a paper, a 
Self-Care Framework for ireland, advocating that the range 
of medicines available to patients should be expanded 
through switching from prescription to non-prescription 
status. In February 2012, the Working Group reconvened 
and met with the IMB who informed us of the Consultation 
Panel that has been set up to review the classification of 
medicines, following a public consultation by the IMB in July 
2011. In March 2012, the Working Group met with the Chief 
Pharmacist and Deputy Chief Medical Officer to discuss the 
recommendations outlined in the paper. It is now intended 
to have a public launch of the paper, hopefully supported by 
Minister Shortall, to highlight that patients in Ireland should 
have the same access to medicines as in other jurisdictions.
Medicine Use Review Pilot
The Medicines Use Review (MUR) pilot results are currently 
being analysed by TCD. It is hoped that MURs will soon 
be rolled out nationally as part of the HSE Clinical Care 
programmes. 
Health Promotion
Three health promotion campaigns were carried out 
towards the end of 2011: Diabetes – Know Your Numbers, 
Pharmacy Vaccination Service and Antibiotic Awareness. In 
January 2012, we liaised with Diabetes Ireland and Safefood 
to provide lifestyle advice to support RTE’s Operation 
transformation. Campaigns planned for the rest of 2012 
include Depression in May, EHC in June and Antibiotic 
Awareness in November. 
SOPs / Guidelines
A range of Standard Operating Procedures, Guidelines and 
Protocols are available in the members’ only section of the 
IPU website under Professional Assistance > Guidelines and 
Protocols. These simple guidelines have been produced for 
members so that they can easily draw up protocols saving 
them money and time in doing so. Topics covered include:
l Dispensing Process (including a guide to SOPs); 
l Prescription Collection and Delivery;
l Dispensing Errors Log;
l Dispensing EEA Prescriptions;
l Parallel Imports;
l Health Screening including Lifestyle Advice;
l Medicines Sales Protocol;
l Codeine Sales Protocol;
l alli Sales Protocol;
l Levonorgestrel Sales Protocol
l Methadone Guidelines;
l Needle Exchange;
l Sharps Disposal;
l Asthma Inhaler Technique;
l Consultation Areas;
l Nursing Home Guidelines;
l Sourcing, Storage and Disposal of Medicines;
l Pharmacy Vaccination Service.
Training
The Pharmacy Technicians’ Course saw 104 students 
graduating in March 2012. There are currently 209 students 
participating in Year 1 and 100 students in Year 2 of the 
course. In addition, 141 students completed the MCA Course 
in 2011 in Cork, Dublin, Galway, Killarney, Limerick, Sligo, 
Tullamore, and Waterford. 106 students completed the 
Interact course and 44 completed the Interact Plus course. 
The FÁS Pharmacy Sales Traineeship course was administered 
in Baldoyle, Loughlinstown, Cork and Galway and to Senior 
Colleges in Dun Laoghaire, Monaghan, Limerick, and Cork. 
Direct to Pharmacy Distribution
In the last year, a number of High Tech companies have 
moved the distribution of their products to direct-to-
pharmacy (DTP): Janssen has moved Risperdal Consta 
and Eprex to Movianto; Novartis has moved all High Tech 
products to Movianto; and Actelion has moved Tracleer to 
Allphar. The IPU has written to the DoH, HSE, IMB, PSI and 
manufacturers, highlighting our concerns about this practice. 
You can read the letters on the IPU website. We would 
remind members to let us know if you have any difficulties 
sourcing these products.
BUSINESS ISSUES
Business Training
The IPU, in conjunction with Cara Healthcare, developed 
the Strategies for Growth business training programme for 
members in 2010. The programme has been updated and 
a range of sessions were delivered throughout 2011. This 
programme will continue in 2012. 
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Business Focus Groups
The Business Development Manager has held a number of 
Focus Groups throughout the regions over the past year. The 
purpose of the groups is to meet with members and discuss 
business issues affecting members. This will continue in 2012. 
Accounts for Pharmacy
Following feedback from members, the IPU, in conjunction 
with Baker Tilly Ryan Glennon, and sponsored by Teva, 
produced a number of booklets on basic book keeping in 
pharmacy.  All members received Module 1 free and can 
purchase Modules 2, 3 & 4 at a discounted price from the IPU.
Business Review Consultancy
The IPU now offers members a review of their retail business 
offering by our Business Development Manager. The aim of 
this service is to review your retail space with fresh retail eyes 
and help you get the maximum return from your front of 
pharmacy.
Group Affinity Schemes
The Business Development Manager negotiated a number 
of affinity schemes for members for a range of products and 
services including, Business Management and Coaching, 
Insurance (Business, Professional Indemnity and Travel) and 
Pharmacy Consumables, to help cut business costs. Further 
details of these and existing affinity schemes can be found in 
the members’ only section of the IPU website.
Business Policy
The Business Development Manager has met with a 
number of key stakeholders including, the Minister for Small 
Business and the National Consumer Agency with regards 
to promoting and addressing a number of business issues. 
The Business Development Manager prepared submissions 
to the Department of Jobs, Enterprise & Innovation on their 
business agenda for 2011 -2013. He also prepared submissions 
for the Department of the Environment, relevant Oireachtas 
Committees and Local Authorities with regard to planning 
issues affecting the pharmacy sector. We are also working 
with Chambers Ireland to lobby Government Departments 
on business issues such as local rates and charges. 
Business Advice to Members
The Business Development Manager developed a Business 
Review Checklist, Data Protection Policy checklist and a 
KPI Template for members to help monitor your business. 
These checklists are available on www.ipu.ie. Members were 
updated on business issues throughout the year through 
the IPU E-Newsletter and GM and through articles in the IPU 
Review. The Business Development Manager also gave advice 
to members over the phone on a range of business issues.
IT ISSUES 
The CPC IT Steering Group has been working on a range 
of IT issues to assist members in better managing their 
businesses. We are in the process of implementing a 
number of developments to the IPU Product File so that 
it continues to meet the needs of members and other 
users. Live download of the IPU Product File has now been 
implemented. The IPU Product File will soon have direct links 
to the IMB website to facilitate access to SPCs and PILs. We 
are working with frontline wholesalers and system vendors 
to allow for broadband transmission of electronic orders. 
Work has commenced on updating the IPU Product File to 
facilitate reference pricing and generic substitution.  The IT 
Steering Group will continue to monitor user requirements 
for pharmacy systems and communicate these to system 
vendors. 
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The Employee Pharmacists’ Committee (EPC) represents the 
interests of community pharmacy employee members of the 
Irish Pharmacy Union. The Committee is chaired by Louise 
Begley with Caitriona O’Riordan as Vice-Chairperson. The 
mission statement of the EPC is: “to promote the professional 
and economic interests of employee pharmacists and 
constructively engage with other Committees of the union 
and other stakeholders through the employee Pharmacists’ 
Committee.” At present there are 892 community employee 
members of the IPU members which constitute 49.4% of the 
entire membership. 
The EPC has met three times since the 2011 AGM (May, 
September and November 2011). The EPC also continues to 
have active representation on other IPU Committees, with an 
allocation of three employee representatives on the Executive 
Committee and four representatives on the Community 
Pharmacy Committee. This ensures that the views of 
employee pharmacists are expressed and heard on the other 
Committees of the Union, therefore enabling employee input 
into decisions and in the development and implementation 
of the policies of the IPU. 
Communications
The EPC has continued to communicate through regular 
articles in the iPu review magazine which have covered 
topics such as issues on health and Safety at work during 
Pregnancy, Maternity Benefits, you’re a newly qualified 
pharmacist – what route will you take, advice for interviewers, 
aspects of an economic recession and responsibilities of a 
tutor Pharmacist. The EPC feels that in the current climate 
in the community pharmacy sector, employee members 
must be provided with information on topical issues. The 
Committee is currently preparing its fifth newsletter entitled 
‘Guidance for Employee Members where the Business goes 
into Receivership, Examinership’.
Events
The EPC hosted two Employee Seminars in 2011. The first 
was in May in conjunction with the National Pharmacy 
Conference in the Lyrath Estate, Kilkenny. This seminar was 
designed specifically for employee members in regard to 
Employment Law and HR issues as they present to the 
employee. Topics included Performance Management for 
Staff, recruiting Safely and effectively, Managing a Dismissal 
and negotiating terms and Conditions. The second Seminar 
was a held in Hilton Hotel, Kilmainham in November. Again 
this Seminar was designed around relevant issues that 
included Fitness to Practise, Migraine & Pain Management 
and Performance Management. 
In September 2011 the EPC organised an information day 
for Pharmacy Interns. The day consisted of a presentation 
to the interns, which covered background information on 
the inception of the IPU, the role of the IPU and particular 
attention was afforded to the current challenging situation 
within the community pharmacy sector.  
Representation & Services
The EPC is in the early stages of its third office at the AGM. 
The current Committee will continue to pursue its objectives 
with intent and to actively represent the interests of 
employee members. It will also ensure that the IPU continues 
to provide services and support to employee members 
within the community pharmacy sector. The future years 
will be demanding for all in community pharmacy. It is 
important now, more than ever, that employee pharmacists 
have a representative body which supports on their behalf. 
The EPC will continue to be this body and it encourages 
the involvement of more employees at both a regional and 
national level within the IPU so as to strengthen the resolve 
of employee pharmacists both in the IPU and the profession.
Conclusion
The EPC encourages employee members to utilise their 
membership to the fullest and keep themselves informed 
by reading the General Memoranda, iPu review magazine 
and other information provided by the Union. In June 2010 
all IPU Members were designated with an @ipumail.ie email 
account, the EPC would recommend employee members 
who have not activated their account to do so immediately. 
The EPC would also recommend that employee members 
check the ‘Employee Pharmacists’ section of www.ipu.ie 
regularly.
I would like to thank all the members of the EPC for all 
their work over the last year and the staff of the IPU, in 
particular Seamus, Pamela, Jill and Darren for their support 
and advice on all matters. I would especially like to thank 
the Secretary to the EPC, Susan McManus, for her hard work 
and commitment to the EPC and the President, Darragh 
O’Loughlin, for all his guidance and support throughout the 
year.
Louise Begley, 
Chairperson.
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Communications activities continued to develop in the 
12 months since our last AGM. Public Relations was key in 
communicating key messages of the Irish Pharmacy Union 
and its members to the media, the public, and policy-makers. 
Communications with patients was also a major priority for 
the IPU, and this was highlighted through the advertising 
campaign that we ran.
The Communications team during the last year consisted of 
Gerard Howlin, Aoibheann Ní Shúilleabháin and our external 
advisors, who all invested huge amounts of time, effort and 
resources in working with the media to brief journalists on 
issues affecting community pharmacy. Gerard left the Union 
in November of last year. Jim Curran joined the team as 
Director of Communications and Strategy in February.
Media Relations
The IPU continued to promote issues of concern to 
pharmacists and the role of the community pharmacist in 
the media during the last year. Some of the key issues that 
arose were:
l  Flu Vaccine – following a meeting with the Minister for 
Health in July 2011, it was announced that pharmacists 
would be allowed administer flu vaccines. This was a 
welcomed announcement and interviews were carried 
in national and regional media, including RTE’s Six-One 
news and nine news. Media coverage continued when 
pharmacists announced that vaccination training had 
been put in place and called for the change in legislation. 
There was further media coverage when it was revealed 
that some doses of flu vaccines were too low and 
patients needed to be recalled. The IPU explained the 
situation and the confidence in pharmacists providing 
the vaccination remained. 
l  Pharmacist’s Advice – there were many press releases 
issued over the past year with pharmacists offering 
advice on a range of issues. Pharmacists were in the 
media advising on the dangers of getting healthcare 
advice online, headlice, antibiotic awareness, how to stay 
healthy over Christmas, medicines for children, and much 
more. These releases received media coverage on both a 
national and regional level, including RTE and TV3 News.
l  Prescription Levy – in the lead-up to the Budget, 
pharmacists continued to represent patients, calling on 
the Minister for Health to abolish the Prescription Levy 
for vulnerable patients. There was mention then that 
there would be an increase on the levy and an extra 
charge for a Medical Card. Pharmacists therefore urged 
caution as some patients would not be able to afford this 
increase.
l  Price of Medicines – there was a media flurry over the 
price of medicines in October 2011 following an article in 
a national paper. The IPU had spokespersons on national 
and regional radio discussing the issue, highlighting 
the flaws in the article, the cuts that had been made 
to community pharmacy over the previous two years, 
and of course that pharmacists do not set the price of 
medicines in Ireland. The story was short-lived as the 
IPU’s points held strong. 
The ongoing media coverage could not be achieved without 
the work of the IPU Spokespersons, who take time out from 
their pharmacies to brief journalists and be interviewed for 
national and regional media.
Advertising Campaign – ‘Ask Your Pharmacist First’
Following on from the success of previous ad campaigns, 
the 2011 ad campaign kept the consistent message of ‘Ask 
Your Pharmacist First’ message. The campaign ran in June 
and October-December. There is a noticeable rise in the 
amount of patients who are now turning to online research 
to self-diagnosis. Therefore, the IPU decided to create a 
website to capture this market and Google Search ads and 
online banners were used to highlight the website, which 
encouraged users to ‘ask your pharmacist first’. Overall, 667, 
745 people had the opportunity to see the ads, with over 
12,000 hits to the website.
The online campaign was complemented with radio ads. The 
first burst of radio ads ran in June and the subsequent bursts 
of activity ran from October to mid-December. The radio ads 
were heard by 2.1 million listeners.
We also created an identity for ‘ask your Pharmacist First’ in-
store, with window and counter posters. This created synergy 
across the campaign by linking up the radio and online to the 
experience in-store. 
Political Engagement
A delegation from the IPU met with the Minister for Health 
in July 2011, which led to the announcement of pharmacists 
providing the flu vaccination. Meetings have also taken place 
between the IPU and Roisin Shortall, Minister for State with 
responsibility for Primary Care, in August 2011 and January 
2012.
Diabetes Exhibition 
The IPU had a stand at the Diabetes Exhibition in Cork in 
November 2011. Pharmacists were on hand to give free advice 
to patients and to provide free blood pressure testing. There 
was a great turn-out at the exhibition, with pharmacists 
being the only healthcare provider offering blood pressure 
testing.
Communications to Members
Communications have developed hugely in the last two 
years and the uptake of these services continues to increase. 
Communications Report
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The IPU website is kept up-to-date and time spent on the site 
continues to increase. A Sitemap, Privacy Policy and Terms & 
Conditions were created for the website.
IPU News, the weekly e-newsletter, was revamped in 
September 2010 to include colours in line with the IPU 
Review branding. Separate newsletters were created for 
contractor and proprietor members earlier this year so that 
more targeted information was being sent to members.
The IPU moved into the realm of social media in December 
2011 with the launch of a Facebook page. The Page is another 
tool for communicating with both members and the public 
and a ‘Find us on Facebook’ button was added to the IPU 
website. 
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1.  PGEU REPORT  
The Pharmaceutical Group of the European Union (PGEU) 
is the European association representing community 
pharmacists in 31 European countries including EU Member 
States, EEA countries and EU applicant countries. Overall, 
PGEU represents over 400,000 community pharmacists in 
Europe through their professional bodies and pharmacists’ 
associations. PGEU’s objective is to promote the role of 
pharmacists as key players in healthcare systems throughout 
Europe and to ensure that the views of the pharmacy 
profession are taken into account in the EU decision-making 
process. 
The IPU is represented at PGEU by Liz Hoctor, Head of 
Delegation, Pamela Logan, Director of Pharmacy Services, 
and Jill Lyons, PCRS Contract Manager. The IPU has been 
very active within PGEU over the past year, ensuring that 
community pharmacy is considered in a wide variety of 
EU Directives. 70% of legislation in Ireland comes from EU 
Directives so it is vital that lobbying is done at this level 
rather than waiting for transposition into Irish legislation. 
Overview of 2011/12
2011/12 was yet another year of extraordinary activity in 
European pharmacy and PGEU was heavily involved in the 
shaping of European legislation. We saw the adoption of the 
Directive on Falsified Medicines and the Directive on Patient’s 
Rights. In addition, the Directive on Information to Patients 
continues to be hotly debated. 
Directives
PGEU actively worked on seven Directives throughout 2011/12:
l  Pharmacovigilance – the creation of a new system of 
managing the risks of marketed medicines;
l  Falsified Medicines – the creation of a system of 
authentication of medicines at pharmacy level and the 
regulation of the sale of medicines through the internet;
l  Patients’ Rights – the legal obligation to recognise 
prescriptions from another Member State;
l  Information to Patients – a proposal to allow the 
pharmaceutical industry to provide information on 
medicines directly to patients;
l  Professional Recognition – a revised system of 
recognition of the professional qualifications of 
pharmacists from other Member States;
l  Late Payments – the creation of a legal obligation for 
health authorities to pay contractors on time; and
l  Consumer Rights – the harmonisation of consumer rights 
in all EU countries.
Pharmacovigilance Directive
The Pharmacovigilance Directive was published in the 
Official EU Journal on 31 December 2010; Member States 
must implement the legislation by July 2012. PGEU succeeded 
in getting many of its amendments included in the final 
text, including the recognition of the role of the pharmacist 
in pharmacovigilance and pharmacists’ role in reporting 
adverse drug reactions (ADRs), including medication errors. 
Pharmacists will report to the national regulatory agency, the 
Irish Medicines Board (IMB), who will then forward collated 
reports to the European Medicines Agency (EMA). The text 
of the Directive has suggested that these reports should be 
confidential, i.e. contain no personal data; however, it will be 
up to individual Member States to clarify the scope of the 
confidentiality. 
Falsified Medicines Directive
The Falsified Medicines Directive was published in the 
Official EU Journal on 1 July 2011 and is the biggest patient 
safety initiative that has ever been introduced in the EU. 
Legislation must be transposed by January 2013; legislation 
on the internet by January 2014; and an authentication 
system must be put in place by 2017. Member States can 
choose whether to permit internet selling of Prescription-
Only Medicines (POMs) but all must allow Non-Prescription 
Medicines (NPMs) to be sold by internet. The Commission 
will develop the technical aspects for security features and 
logo for websites. The authentication system will be further 
developed by the Delegated Acts process; this will include 
the selection of safety features, list of medicines bearing 
the safety feature (POMs and NPMs), systems to verify 
safety features and management of data. The Directive also 
establishes that a system should be put in place, by July 2013, 
to recall medicines directly from the patient. 
Medicines authentication 
The Falsified Medicines Directive requires that a safety 
feature be placed on medicines open to counterfeiting and 
that pharmacists and wholesalers will authenticate. The 
European Commission is using its powers, i.e. ‘Delegated 
Acts’, gained in the Lisbon Treaty, to design the technical 
aspects of the Directive – the systems of verification and 
authentication in pharmacy. There is a reference to the need 
to respect the ownership of data to the pharmacist and the 
Directive also says that manufacturers must pay for the 
database to host the authentication system as well as the 
safety feature. The Delegated Acts process began with a 
consultation in November 2011. 
From pharmacists’ perspective, it is vital that the proposed 
system is practical and responsive; flexible at national 
level; cost effective; sensitive to the needs and rights of 
pharmacists; and delivers on its main aim – to protect 
patients.
International Pharmacy Matters 
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PGEU has signed up to a Memorandum of Understanding 
(MoU) with a range of stakeholders in order to come to 
a common position to inform on discussions with the 
Commission during the Delegated Acts process.  To date, 
the MoU has been signed by PGEU, EFPIA (industry), GIRP 
(wholesalers), EAEPC (parallel distributors), EGA (generics) 
and AESGP (self-medication industry). The MoU sets 
out proposals for a central hub (database) into which 
manufacturers will upload information; the hub allows 
for interoperability of packages crossing borders. The 
manufacturers must meet the cost of this database. This 
proposal allows national or regional systems to adopt 
different solutions to authentication. It is envisaged that 
some countries may get together to host a regional database 
rather than each country having their own, e.g. UK/Ireland, 
Nordic, Baltic, etc.     
The Directive permits the use of the safety feature to be 
extended to include reimbursement, pharmacoepidemiology 
and pharmacovigilance. If Member States wish to use the 
safety feature for these purposes, generic medicines would 
need to be included. 
There is no strict obligation on Member States to adopt 
medicines authentication, only to apply the safety feature. 
However, it is hard to argue not adopting authentication 
when all of the systems are in place to facilitate it. 
Patients’ Rights Directive 
The Cross-border Healthcare and Patients’ Rights Directive 
was published in the EU Official Journal on 4 April 2011 and 
legislation must be implemented by October 2013, although 
a system of recognition of prescriptions must be adopted by 
December 2012. The Commission is now concentrating on 
developing a list of non-exhaustive elements to be included 
in cross-border prescriptions. A number of studies have 
been set up to map national prescriptions and prescribing 
practices; to assess current practices on recognition of 
prescriptions; and to evaluate the impact of the Directive. 
These studies will influence the elements to be included 
on prescriptions. PGEU is working on building a common 
position with other stakeholders with an interest in 
recognition of prescriptions in the cross-border context, e.g. 
doctors, pharmaceutical industry.  
Information to Patients Directive
The Information to Patients Directive, which proposes 
relaxing restrictions on industry providing information 
to patients, has proved most controversial. The European 
Parliament has voted on this Directive and made it less 
centred on the industry agenda and more patient-centred. 
Information from industry must be approved by the relevant 
competent authority (IMB). The Council of Ministers 
is concerned that the proposal may give industry an 
opportunity to promote medicines directly to patients. The 
Council therefore produced a revised proposal, published 
in October 2011, which places some restrictions on the 
role of industry as an information provider. The proposal 
differentiates between the information that must be 
provided on POMs (SPCs, PILs, latest assessment reports) 
and information that may be provided (environmental 
impact, price, pack changes, instructions for use, clinical 
trials, FAQs, and other information to support the proper 
use of the medicine). There is a concern that some of the 
optional information could be abused, e.g. FAQs. There is also 
a provision that could allow industry to link information on 
diseases to categories of medicines. Another concern is that 
information produced for a website in one Member State 
and approved there can automatically be reproduced in all 
other Member States. PGEU will continue to lobby to amend 
the proposal.      
Professional Recognition Directive
This Directive was adopted in 2005 and is now being 
reviewed by the Commission. A Green Paper was published 
in June 2011 and a new proposal was published in December 
2011 which: removed the 3 year derogation; included 
knowledge of languages if direct contact with patients is 
required; and allowed a professional care or e-certificate 
to be produced by competent authorities for health 
professionals. PGEU continues to lobby to ensure that the 
extended role of the pharmacist is reflected in the new 
proposal. The proposal advocates for a minimum level of 
education for pharmacists and a minimum duration of the 
undergraduate degree/Masters. The revised Directive will 
include new skills with regard to the expanded role of the 
pharmacist, e.g. pharmaceutical care and CPD.
Late Payments Directive
The aim of this Directive is to combat late payment in 
commercial transactions.  It applies to payments received 
by pharmacies from the State. Public and private hospitals 
and health services will be allowed 60 days to pay their bills.  
Those who fail to pay in time will pay penal interest rates of 
at least 9% higher than the statutory rate as well as a fixed 
fee of €40 compensation for recovery costs. The Directive has 
been published in the Official Journal and will be transposed 
into national legislation by March 2013, although Member 
States may be requested to implement it sooner.
Consumer Rights Directive
This Directive has been on-going since October 2008 and is 
reaching conclusion. There have been a lot of disagreements 
in relation to the degree of harmonisation. PGEU has been 
successful in having pharmaceuticals removed from the 
14-day time frame for returning goods when withdrawing 
from distance-sales contracts.  The Council has also agreed 
to exclude health service contracts from the scope of this 
proposal as these require special regulations. PGEU will 
continue to look at the impact of this Directive on the 
pharmacy sector. Even though health services are out of the 
scope of this proposal, some provisions of the Directive, such 
as the ones regulating distance selling contracts and the 
right of withdrawal, could have an impact in the pharmacy 
as products other than pharmaceuticals are distributed by 
pharmacies. 
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European White Paper on Pharmacy
PGEU has produced a Blueprint for european Community 
Pharmacy to present to Ministers for Health at the FIP 
Ministerial Conference in October 2012. The Blueprint 
focuses on common challenges that patients and health 
systems are facing in Europe and how common solutions to 
those problems can be offered by community pharmacists. 
The Blueprint also sets out a common vision for European 
community pharmacy. The Blueprint doesn’t compare 
different pharmacy systems or promote certain best 
practices; rather national examples are used to illustrate 
different approaches to certain aspects of pharmacy 
practice. It is important to keep in mind that local needs 
of populations as well as healthcare systems are different 
across Europe and therefore may require different ways 
of doing things. The main objective is to show how the 
contribution of pharmacists can improve overall healthcare 
and reduce inequalities while offering cost-effective and 
quality services to patients.
2.  REPORT ON FIP CONGRESS, HyDERABAD, 
INDIA - SEPTEMBER 2011
The International Pharmaceutical Federation (FIP) Congress 
is the leading international event offering diverse learning 
opportunities for those active within all areas of pharmacy. 
The latest trends highlighting innovative and interesting 
topics are discussed under the main theme of Compromising 
Quality and Safety – a risky path. Participants are engaged in 
issues such as their role in ensuring patients receive quality 
medicines, safe medicines and increasing both the safety and 
cost-effectiveness of services.
The FIP 2012 Centenary in The Netherlands and FIP 2013 
in Dublin were formally announced during the opening 
ceremony.
In her opening address, Her Excellency, the President of 
India, highlighted the problems of poor adherence – half 
of all medication is prescribed or taken inappropriately 
– and the importance of patient counselling. She called 
upon developed countries to work closely with developing 
countries in addressing healthcare issues and sharing 
expertise and experiences. India already has the third 
largest pharmaceutical industry by volume in the world and 
it is expected to grow to a $20bn industry by 2015. Indian 
generics have helped to bring down the cost of treatment of 
various diseases worldwide.
President of FIP, Michel Buchmann, stated that it is only 
through the pursuit of excellence that the profession can 
take its rightful place as a primary healthcare provider. He 
encouraged a collaborative approach among healthcare 
providers. He strongly advocated that pharmacists become 
politically active also. Pharmacists must always have input 
into the use of medicines and must add on the professional 
services that ensure drugs become medicines that save 
lives, thereby ensuring that pharmacists are no longer seen 
as merchants but indispensable health professionals. Dr 
Buchmann listed the following priorities:
l  Eliminating counterfeit medicines;
l  Monitoring and reporting and reducing risk of ADRs;
l  Global growth of non-communicable diseases (which 
prompted the United Nations to convene a high level 
summit this month in New York);
l  Build dialogue with decision makers. 
Signing of a new Tuberculosis Initiative between  
WHO and FIP
In a landmark initiative, aimed at curbing the current TB 
epidemic, the WHO and FIP signed a joint statement on the 
role of pharmacists in TB care and control. TB is one of the 
world’s biggest infectious killers and caused 1.7m deaths in 
2009; it is also curable. Patients can be treated by completing 
a six month course of medicine and it is because pharmacists 
are often the first point of contact for people with TB 
symptoms that their frontline role is critical. The statement 
calls on TB programmes and pharmacy associations to 
engage pharmacists and use their untapped potential in the 
fight against TB by:
1.  Increasing awareness of TB and referring patients with 
TB symptoms to facilities with quality diagnosis and 
treatment.
2.  Providing patient centred treatment supervision 
to promote adherence and help prevent multidrug 
resistant TB.
3.  Promoting the rational use of anti-TB medicines.
4.  Supporting other health providers to rationalise and 
strengthen their TB management practices.
FIP position on Drug Shortages
This topic was debated by the Council of FIP, of which IPU 
President Darragh O’Loughlin was a member. Following 
the IPU AGM motion on drug shortages, this position was 
strongly supported and a position adopted. Having a strong 
FIP position on the problem of drug shortages means it will 
be prioritised and brought to the attention of the highest 
authorities worldwide, including the WHO and world 
leaders. Ultimately this can lead to national policy adoption 
worldwide.
Forum for Innovation 
This was the second of a three-year forum. Last year in Lisbon 
the forum focused on which services pharmacy should aim 
to provide. The focus this year was on the cost of providing 
pharmaceutical services. All presentations will be available 
on www.fip.org in December. Three case studies were 
presented:
l  Kaiser Permanente’s Dennis Helling discussed the 
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financial return his company receives by ensuring 
patients in their care receive appropriate medical 
management. This is in addition to the lives saved 
through MURs, chronic disease management, screening 
and anticoagulant services. Quote “quality pays big 
bucks”.
l  Arantxa from Nadal’s pharmacy in northern Spain 
provided a detailed breakdown of costs associated with 
providing monitored dose systems. The key message 
was to choose a service which differentiates you from 
the “discounters” and help to isolate the business from 
government cuts, cost out the service accurately; market 
it; involve all staff. There is no VAT on professional 
pharmacy services in Spain. 
l  Raj Patel of the NPA discussed a recent PwC survey 
carried out on behalf of the UK government to ascertain 
what it would cost to “replace every pharmacy in england, 
if they all closed in the morning.” This study revealed 
that the true cost per item dispensed is significantly 
less in independent pharmacies than large multiples or 
supermarket pharmacies. He stated that an agreement is 
now in place, following this report, which recognises and 
protects the pharmacist’s right to make a purchase profit 
and a fair return on investment, applying a weighted 
average cost of capital model. He also discussed the 
forthcoming New Medicines Service (NMS) in the UK, 
where the pharmacist dispenses up to 14 days’ supply of 
a new medicine under four categories: Asthma; Diabetes; 
Hypertension; and Hypercholesterolaemia. The patient 
is then contacted to check adherence before the next 
supply is made. The pharmacist is paid a professional fee 
for this service.
A workshop then discussed the various services and funding 
models around the world. The Swiss receive 40% of any 
saving made by generic substitution, and a fee per MUR. The 
Danes receive a fee for demonstrating inhaler technique. The 
Germans, through one of their health insurers, are paid to 
monitor blood glucose. The Spanish have funded screening 
for Bowel Cancer. 
Later in the workshop, an Australian study, presented by an 
accountant, demonstrated the costs associated with setting 
up and delivering a diabetes screening and asthma service, 
covering the cost of installing a consulting area, rent of that 
space, staffing costs, IT costs and marketing. The quote was 
“Customer engagement beats the discounters”. 
President Elect of PGEU, Isobel Adenot, gave a presentation 
which covered a system of electronic health records in France, 
known as Dossier Pharmaceutique. This covers almost all 
French pharmacies now. It is an Internet based system which 
is activated by smart card. It records medicines dispensed, 
including OTC, and is of benefit in alerting potential ADRs. 
It is used by hospital doctors and anaesthetists, is used in 
efficient batch recalls and has further potential for detecting 
healthcare trends, vaccination records and improving 
pharmacovigilance.
Symposium on Development of New Services and Innovation
This symposium, aimed at representative organisations, 
recognised that:
 1. Customers’ needs change.
 2. New technologies emerge.
 3. The structure of the industry changes continuously.
Who will be patients’ trusted partner in healthcare in the 
future? The aim is to ensure pharmacy is that partner.
There are 17,000 healthcare apps available today which 
compete with pharmacists’ advice; therefore, pharmacists 
always need a Unique Selling Proposition. Innovation drives 
growth and can provide shelter against eroding margins.
Several case studies covered innovation from around the 
world.
Vaccinations
A number of presentations focused on the aims of 
vaccination as well as past, present and future routes of 
administration. A new nanotechnology system is on the 
horizon which uses a series of tiny needles arranged in a grid 
about the size of a postage stamp. The system is some way 
off but is expected to be pain free, more targeted than an IM 
injection for immunity and will not require refrigeration. This 
will be of particular benefit in developing countries where 
cold chain issues often render a large percentage of vaccines 
inactive.
The pharmacist’s role in improving vaccination rates was 
seen to fall into the categories of education, administration 
and advocacy. Dr Betty B Chaar of Australia quoted 
vaccines as the most important medical advance of the 
nineteenth century. She outlined the damage to vaccination 
programmes arising from discredited claims surrounding 
Thiomersal and the important role of pharmacists in allaying 
fears among the public.
Tom Menighan, CEO of the American Pharmacists 
Association (APA), made a presentation covering the 
American experience of pharmacist led vaccination services. 
The APA sees the following as the three main roles for 
pharmacy:
 1.  Advocacy
 2.  Facilitator, e.g. get nurse in to vaccinate or refer to GP
 3.  As a vaccinator
20% of all flu vaccines in the USA for 2010 season were 
given through pharmacies. The American Society of Internal 
Medicine, largely composed of consultant physicians, support 
pharmacist vaccination on the basis that this improves 
vaccination rates and increases awareness. From customer 
experience, patients prefer a drop in service rather than set 
times for vaccination clinics in pharmacies. 
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A lot of states allow pharmacists to immunize from age 
three upwards. 
FIP provides delegates with a host of information. In addition 
to the various lectures and workshops, posters are on display 
covering all aspects of pharmacy research.
Meeting colleagues from around the world and discussing 
matters of mutual interest is an integral part of FIP. 
Delegates typically include community, hospital and 
industrial pharmacists and pharmaceutical scientists as well 
as members of professional, representative and regulatory 
bodies worldwide.
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The following motions, proposed in accordance with Article 
30 of the IPU Constitution, are brought before the meeting for 
consideration:
1. Proposed: Morgan Power
 Seconded: Brian Walsh
“that this agM calls on the Minister to:
l  reverse the decision to reduce the reimbursable price of 
fridge items;
l  increase the low level dispensing fees currently paid to 
contractors;
l  review the reimbursement price of medicines to 
pharmacists; 
l  review the current level of remuneration for new Services; 
and 
l  Put a proper negotiation system in place to review such 
matters.”
2. Proposed: Liam Butler
 Seconded: Dermot Twomey
“that this agM calls on the hSe PCrS to agree to an hSe-iPu 
Pharmacy Customer Charter which would set out a transparent, 
equitable and fair process in which the hSe should interact with 
pharmacy contractors on all queries.”
3. Proposed: Bernard Duggan
 Seconded: Daragh Connolly
“that this agM calls on the Department of health and hSe 
to further expand the role of the community pharmacist 
by developing a community-pharmacist-led national 
cardiovascular screening service, which incorporates accredited 
standards and training for the service and identifies a number 
of different funding options for provision of the service.”
4. Proposed: Caitriona O’Riordan
 Seconded: Sarah Magner
“that this agM calls on the irish institute of Pharmacy to 
ensure that, in its role as a management and accreditation 
body, the funding agreed between the iPu and the Department 
of health, as part of the 1996 Community Pharmacy Contractor 
agreement, will be be ring-fenced within the institute to fund 
continuing education initiatives for community pharmacists, 
who make up the largest portion of the PSi register.”
5. Proposed: Jack Shanahan
 Seconded: Sean Reilly
“that this agM calls on the hSe PCrS and Department of 
health to work with the iPu’s it Steering group, initially to 
ensure a smooth roll out of both generic substitution and 
reference pricing, and any other issues that require a pharmacy 
it change.”
2012 AGM Motions 
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EXECUTIVE SUMMARy 
The following is a summary of the main points made in this 
submission.
Current Delivery Model 
The current delivery model of manufacturer to wholesaler 
to pharmacy works well for patients, delivers excellent 
health outcomes and encompasses key strengths that are 
conspicuously lacking in many other models abroad. What 
is in principle, and very largely in practice, a good model 
does, however, have issues with medicines shortages and 
unlicensed medicines and these need to be addressed. 
Indecon Economic Consultants, when asked by the HSE to 
do an examination of the pharmaceutical wholesale sector, 
recommended caution in adjusting margins or prices in 
this area as any sudden or dramatic reduction in wholesaler 
margins would have broad negative economic effects both in 
the pharmacy sector and beyond. Market disruption would 
involve a reduction in service levels including the availability 
and quality of pharmacy services countrywide.
The existing model, while it can and should be strengthened, 
should remain as it works well and serves patients best 
in accessing medicines.  The key change required going 
forward is a binding public service obligation to prevent 
medicines shortages and unnecessary controls on supplies by 
manufacturers.  The IPU supports the system which operates 
in Germany with regard to ensuring the continuity of supply 
of medicines.  Under German Drug Law [Section 52b], there 
is a Public Service Obligation (PSO) on manufacturers and 
wholesalers to supply medicines. The legislation also includes 
the right of wholesalers to be supplied by manufacturers. It 
is the combination of these two aspects of legislation which 
ensures the uninterrupted supply of medicines to the patient.
A Highly Competitive Sector
Ireland’s community pharmacy sector is highly competitive 
by objective and measurable international standards. Ireland 
has the most liberal and competitive pharmacy market in the 
EU.  There is a higher proportion of pharmacies per head of 
population in Ireland than almost any other EU country. This 
is hardly surprising as we are one of the few countries where 
there are no restrictions on who can establish or operate a 
pharmacy; in the majority of EU States only pharmacists can 
own a pharmacy and there are population or geographical 
criteria restricting the opening of new pharmacies. We are 
one of the few counties where there are no restrictions on 
who can establish or operate a pharmacy.  
Patients are the Key Criteria
Community pharmacy plays an important part in primary 
care and is an essential part of patient safety.  Medicines 
are an essential part of treatment, and professional 
advice and oversight is an essential and lifesaving part of 
dispensing. The professional obligation on pharmacists 
is understandably high and onerous and is covered by 
regulation and is also an integral part of an individual 
pharmacist’s contract with the HSE.   
Section 9 of Regulation of Retail Pharmacy Businesses 
Regulations 2008 and Clause 9 of the pharmacy contract 
properly place onerous obligations on the community 
pharmacist.
The very high professional standards of community 
pharmacy have a significant positive impact on public 
health. For example, many adverse drug reactions have 
been prevented where, for example, patients on warfarin 
have been prescribed potentially fatal doses of interacting 
drugs. Compliance problems have been recognised and 
dealt with, such as asthma sufferers not using their 
preventative inhalers properly or at all, and patients being 
prescribed inappropriate medicines, e.g. a person working 
outdoors being prescribed medicine likely to cause skin 
photosensitivity.
Patients’ health outcomes would also be enhanced by the 
introduction of a structured Medicines Use Review (MUR) 
particularly for patients on complex medicine regimes. 
Real value is only achieved when patients take the right 
medicines and take them correctly. This is critical for patient 
care, patient safety and for the Exchequer. In addition the 
movement of medicines from prescription only to pharmacy 
only and an enhanced role for pharmacists in areas including 
vaccinations and chronic disease management will improve 
health outcomes for patients and deliver efficiencies and 
savings for the Exchequer. 
Generic Substitution and Reference Pricing
In an era of ageing populations and rising healthcare costs, 
generic medicines allow patients to access safe, effective, 
high-quality medicines at lower prices. In this way, generic 
medicines support the sustainability of healthcare provision 
and contribute to controlling pharmaceutical expenditure. 
The development of a generics medicines market needs 
to be actively sustained by a generic medicines policy and 
requires both supply-side measures relating to pricing and 
reimbursement, and demand-side incentives for pharmacists. 
Extract of Submission by the IPU to Economic and Social Research 
Institute on “a roadmap to reform the Delivering of Drugs to Consumers 
in ireland”
30 June 2011
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Different policy measures need to reinforce each other and 
be part of a coherent generic medicines policy.
In setting a reference price, it needs to be borne in mind that 
the Irish market is a relatively small market. Changes should 
not inadvertently create a situation that leads to shortages 
in the supply of medicines which will be difficult to overcome 
if competition in the market is diminished. Patients and 
pharmacists in the UK are currently struggling with severe 
medicines shortages due to poorly thought out policies.
The introduction of reference pricing therefore needs to be 
given very careful consideration. It is not at all obvious that 
opting for the cheapest price is necessarily the best approach 
as it may lead to a reduced number of suppliers, as some 
players exit the market. In this context, the initial reference 
price should not be substantially reduced overnight but on a 
gradual basis over time.  It is imperative not to set too low a 
price or players will leave the market resulting in medicines 
shortages and an increase in high cost unlicensed medicines.
Approved Treatment Protocols
Doctor Barry White, Clinical Care Director of the HSE, has set 
up a number of clinical care programmes which will develop 
clinical care pathways and treatment protocols for patients 
with chronic conditions. These have the potential to also 
contribute to the sustainability of healthcare
Direct to Pharmacy Distribution (DTP)
Direct to Pharmacy distribution (DTP) cuts out the wholesaler 
intermediary in the supply chain. The pharmaceutical 
manufacturer sells the medicines directly to the pharmacy. 
The traditional distribution model enables the pharmacist to 
source the full range of products from a single wholesaler, or 
from a combination of wholesalers.  Typically, the pharmacist 
will receive regular single deliveries comprising all medicines 
for which there is a demand. Some medicines which are 
prescribed less often and may be out of stock can be ordered 
for the next scheduled delivery. If DTP were to be adopted 
by more pharmaceutical manufacturers, wholesaling in 
its current form could become unviable. This will lead to 
the scope for competition between intermediary suppliers 
becoming significantly reduced. Pharmacists will lose the 
right to choose between competing wholesalers. The savings 
generated by such competition are an important factor in 
overall expenditure control. 
DTP has led to very significant problems in the UK including 
lack of supply, reduced choice and increased administration. 
Its introduction would be even more damaging in a small 
market like Ireland.  
Internet pharmacy
It is essential that medicines are carefully monitored and 
that a patient sees a healthcare professional before receiving 
any medication.  In the US, where internet pharmacy is 
common, there are huge problems with regard to counterfeit 
medicines. In Ireland the sale of medicines is highly regulated 
to protect the patient including the manufacture, licensing, 
advertising, wholesaling and supply of medicinal products is 
highly regulated. Internet pharmacy does not provide these 
kinds of quality guarantees to the patient.  
Value for Money 
The community pharmacy sector has contributed all it 
can; further cuts will undermine the capacity of sector to 
deliver effectively for primary care. The consequences of a 
sustained series of severe cuts on the community pharmacy 
sector have been hard. Jobs have been lost, skilled and 
talented people have been put on the dole, services have 
been reduced and pharmacies are opening for fewer hours. 
Community pharmacies are now leaner, reduced enterprises 
and some are now loss-making. The cost base of community 
pharmacy has been reduced as income has been cut. The 
capacity of highly trained professionals to provide a level of 
service that is animated by a spirit of care rather than just 
an observance of regulation is being seriously undermined 
by cumulative cuts to pharmacy income.  Since July 2009, 
cuts averaging €123,740 for every pharmacy in the country 
have been implemented. The most recent cut on 20 June 2011 
represented a further loss to the sector of €36m in a full year 
and an average loss of €22,500 per pharmacy.
Community Pharmacy and Public Planning 
It is important for public health and for public policy that 
all patient catchment areas (including less populated small 
towns and rural areas) are uniformly served by community 
pharmacy. There are many patients who do not have their 
own transport and accordingly locating a retail pharmacy 
business in an area which is not easily accessible either 
on foot or via public transport is undesirable. It is also very 
important for patients to enjoy freedom of choice in relation 
to the pharmacist with whom they deal.
The Pharmaceutical Society of Ireland (PSI) Memorandum of 
February 2011 usefully provides clarity in relation to the role 
of pharmacy in the context of wider changes in the delivery 
of primary healthcare in recent years. In particular, it provides 
assistance in terms of understanding the role of pharmacy in 
the Government strategy - “Primary Care – a new Direction” 
(2001).
The 2001 Government Strategy supported the development 
and roll out of “Primary Care teams” located on the same 
site comprising GPs, nurses, midwives, physiotherapists, 
occupational therapists and social workers, etc.  Essentially, 
the PSI supports the position that a pharmacy or retail 
pharmacy business, being part of the “Primary Care network”, 
does not need to be co-located with the medical general 
practices and the “Primary Care team” based on planning-
related and commercial considerations. In order to ensure 
that patients have a real choice between community 
pharmacies and to ensure a sustainable model of 
competition it is undesirable that pharmacies be co-located 
with primary care centres.
Roadmap – Time for a New Approach
Pharmacists are already engaged in a number of important 
patient and public health pilot programmes – including 
Health Screening, Medicine Use Reviews and Asthma 
Management.  Pharmacies have stepped up to the mark in 
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a whole range of different ways.  We have the professional 
capacity to play a greatly enhanced role in delivering a much 
better system of primary care.
The IPU recognises that it is timely to review existing 
arrangements in light of the rising demand for medicines 
resulting from population increase, population aging and 
public health trends.  The current model works well for 
patients and it is critically important going forward that 
it is enhanced and not undermined. The introduction of a 
public service obligation, generic substitution, Medicines 
Use Reviews, health screening, vaccinations and other 
services delivered through pharmacy, i.e. at the lowest level 
of complexity, can make a very significant contribution to 
the delivery of an enhanced and more cost-effective model 
of primary care. Delivery will require partnership and real 
engagement with stakeholders including the IPU.  
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Executive Summary - The Time for A New 
Approach is now 
this government is the first in the history of the State that is 
committed to developing a universal, single-tier health service, 
which guarantees access to medical care based on need, not 
income.
PROGRAMME FOR GOVERNMENT 2011
1.  INTRODUCTION
 Pharmacists are healthcare professionals who provide a 
vital service to patients. They are committed to delivering 
a quality, accessible personal and professional service 
that puts patients first and has as its primary goal the 
optimisation of the health and well-being of society. 
Pharmacists are accountable for their professional conduct 
and strive to maintain the confidence and respect of their 
patients, customers, the State and other professionals in the 
healthcare field.  
2. CURRENT ENVIRONMENT
Pharmacists have first-hand experience of this on a daily 
basis through the decline in non-dispensary sales, the very 
visible increase in the numbers of unemployed, the increased 
number of patients with medical cards and the difficulties 
in arranging finance with banks. Pharmacists recognise the 
reality of the current economic environment in which we are 
all now operating. Pharmacists have seen their payments cut 
substantially in the past two years, most recently in June of 
this year. 
3. TIME FOR DIRECT ENGAGEMENT
The Resource Allocation report highlights the need for a 
fully-integrated, coherent healthcare system, which brings 
together primary care, community/continuing care and 
acute hospital services, which are recognised internationally 
as optimal in terms of both safety and cost. Pharmacists 
can deliver on such an agenda and the potential of the 
profession to contribute more has also been addressed by 
the Oireachtas Committee on Health and Children and more 
recently by the ESRI.
In a submission to the then Minister for Health in January of 
this year, the IPU proposed that the time is now opportune 
for the Minister to engage substantially with the IPU on 
a change agenda within a defined time period to review 
all existing administrative, contractual and payment 
arrangements with a view to identifying the scope for 
pharmacists to assist with the delivery of Government health 
policies and the realisation of system-wide efficiencies 
and savings for both the HSE and pharmacists. This could 
be carried out through discussions and negotiations or 
through a process, led by an independent chairman, similar 
to the one agreed with the Health Service Executive (HSE) 
and Department of Health & Children (DoHC) in April 2008 
[Appendix I].
4. IPU PROPOSAL
Pharmacy is part of a continuum of care that is an essential 
part of the fabric of our health service.  
The IPU has proposed a 5 Point Plan to assist Government on 
delivering national health policy and, ultimately, to deliver a 
better Health service for patients. The plan proposes:
 1.  Open Door Policy to deliver better healthcare for 
patients who require access to Chronic Disease 
Management;
 2.  Generic Substitution to deliver cost savings to the 
State;
 3.  Provision of a Vaccination Service to deliver vaccines 
such as the flu vaccine through their local pharmacy; 
 4.  Medicines Use Review to deliver improved patient 
compliance and reduced costs; and
 5.  Health Promotions through pharmacies to deliver 
services including smoking cessation, weight 
management, diabetes and cholesterol screening to 
keep people healthy.
These proposals should be incorporated into discussions on 
a new contract in the context of national health policies and 
the efficient use of scarce resources. The following section 
expands further on our proposals.
5. CONCLUSIONS – TIME FOR A NEW APPROACH
Government health policy has as its central aim the 
delivery of health services in the community and creating 
capacity in other areas of the health service at the lowest 
level of complexity. Pharmacists can deliver these services. 
In that context, discussion between the DoH and the IPU 
should now take place with a view to facilitating these 
developments. There is also a need to review all existing 
administrative, contractual and payment arrangements. The 
HSE has highlighted a number of areas they wish to address 
in any new pharmacy contract and pharmacists would also 
like to reduce the level of administrative burden currently 
placed on them to enable them to spend more time treating 
their patients.
Future savings and efficiencies can be achieved by adopting 
the proposed holistic approach to all issues of concern to all 
stakeholders. Now is the time for a new approach. 
The IPU looks forward to engaging on this agenda for change 
with the Minister on this healthcare agenda. 
Extract of Paper for the Minister for Health, Dr James Reilly TD
18 July 2011
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1. THE GROWING INTEREST IN SELF CARE
Healthcare in Ireland is going through a period of significant 
change – an ever increasing ageing population, evolving 
health structures, greater private sector involvement in the 
health arena, a growing incidence of chronic diseases, ever 
increasing public expectations of the health service and the 
development of new treatments. The financial challenge to 
the State to manage this is compounded further given the 
current state of the public finances and the requirement 
to control healthcare expenditure. Patients are also feeling 
economic challenges and they try to access cost-effective 
healthcare in the current stagnant economy.
Patients are no longer passive recipients of healthcare 
and advice. Greater health literacy and greater access to 
information, combined with increased individual interest in 
personal health and personal choice, is leading to more and 
more patients actively looking after themselves. In addition, 
public awareness has increased the importance of certain 
lifestyle factors, such as avoidance of smoking and keeping 
a well-balanced diet, in maintaining health and preventing 
illness. Irish patients see health education and advice from 
the pharmacist as key ways to help them take care of their 
health and minor ailments. 
In this context, self-care can be seen as the most common 
form of healthcare. As pressure grows on the Irish healthcare 
system, self-care will be seen as a means of controlling 
and rationalising healthcare and medication costs. Recent 
research in Australia showed that if minor ailments such 
as coughs, colds and others were dealt with in community 
pharmacies, it would free up one thousand full time GPs to 
treat more serious health problems. If we are to successfully 
confront the demands on our health system as the 
population ages, we need to ensure that our citizens stay fit 
and healthy for as long as possible. In both health and fiscal 
terms, prevention is better than cure.  
2. PHARMACISTS AND SELF CARE
Self-care can be defined as the care taken by individuals 
of their own health and well-being at the lowest level of 
complexity with advice from a healthcare professional. It is 
important to note that self-care is not ‘no care’. Although 
by definition, self-care can take place without the need to 
visit a healthcare professional, effective and safe self-care 
is best undertaken with the benefit of professional advice. 
Pharmacists have the skills and training to ensure that 
patients have an open source of professional expertise in 
self-care matters. 
Non-prescription medicines are an important part of 
healthcare and, from the point of view of patient safety, must 
be treated in the same way as prescription-only medicines. 
They are not, and should not, be perceived as ordinary 
commodities. Taken inappropriately, non-prescription 
medicines can present a serious threat and imply severe 
risks for patients. There can be no doubt therefore that a 
responsible public health policy needs to understand and 
appreciate the potential risks posed by non-prescription 
medicines. 
The pharmacist has a key role in providing advice on 
appropriate self-medication, including the provision of 
product information, advice on product selection, advice 
on side effects and interactions and crucially, advice on the 
appropriateness of beginning or continuing self-care; this is 
sometimes referred to as the ‘sign-posting’ function of the 
pharmacist – advising patients to seek specialist treatment 
in cases where self-care may be ineffective or inappropriate. 
The best way to help ensure patient safety for non-
prescription medicines is to ensure they are dispensed under 
a pharmacist’s supervision within a pharmacy. 
3. EXPANDING SELF MEDICATION
For self-care to be fully effective, the range of medicines 
made available to patients should be expanded. The IPU 
welcomes the decision by the IMB to take a proactive 
approach to increased self-care through reclassifying 
medicines from prescription-only to non-prescription, also 
known as ‘switching’; indeed, the IPU has called for this for 
a number of years. Following recent switches, for example 
alli and Norlevo, the IPU has produced sales protocols and 
educational tools to assist pharmacists in the appropriate 
supply of these medicines to patients.
4. CONCLUSION
The importance of self-care is growing, driven by more 
health literate and demanding patients and supported by 
Government policy. Self-care can help to resolve some of the 
future health system challenges such as aging population 
and growing health expenditure. Community pharmacy is 
the key to the successful development of a self-care policy 
and its evolution in the future due to: the availability and 
accessibility of pharmacies with no prior appointment; the 
provision of professional advice to ensure effective and 
safe self-care; and the pharmacist’s in-depth knowledge 
on a broad range of health matters to support patients in 
self-care. The need to manage quality, safety and efficacy of 
medicines should be balanced by the positive health benefits 
to society of the increased availability of non-prescription 
medicines. However, from the point of view of patient safety, 
non-prescription medicines must be treated in the same 
way as prescription-only medicines, i.e. dispensed under the 
supervision of a pharmacist from within a pharmacy. 
Extract of IPU Submission to the Irish Medicines Board on the Legal 
Supply Classification of Medicinal Products
31 July 2011
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1.  CURRENT ENVIRONMENT
Pharmacists have first-hand experience of this on a daily 
basis through the decline in non-dispensary sales, the very 
visible increase in the numbers of unemployed, the increased 
number of patients with medical cards and the difficulties 
in arranging finance with banks. Pharmacists recognise the 
reality of the current economic environment in which we are 
all now operating. Pharmacists have seen their payments cut 
substantially in the past two years, most recently in June of 
this year. 
2.  TIME FOR DIRECT ENGAGEMENT
The Resource Allocation report highlights the need for a 
fully-integrated, coherent healthcare system, which brings 
together primary care, community/continuing care and 
acute hospital services, which is recognised internationally 
as optimal in terms of both safety and cost. Pharmacists 
can deliver on such an agenda and the potential of the 
profession to contribute more has also been addressed by 
the Oireachtas Committee on Health and Children and more 
recently by the ESRI.
In a submission to the then Minister for Health in January 
of this year, the Irish Pharmacy Union (IPU) proposed that 
the time is now opportune for the Minister to engage 
substantially with the IPU on a change agenda within a 
defined time period to review all existing administrative, 
contractual and payment arrangements with a view to 
identifying the scope for pharmacists to assist with the 
delivery of Government health policies and the realisation of 
system-wide efficiencies and savings for both the HSE and 
pharmacists. This could be carried out through discussions 
and negotiations or through a process, led by an independent 
chairman, similar to the one agreed with the Health Service 
Executive (HSE) and Department of Health (DoH) in April 
2008.
3. PHARMACy’S 5 POINT PLAN
 a.  Open Door Policy to deliver better healthcare for 
patients who require access to Chronic Disease 
Management.
   Pharmacists are already engaged in a number 
of important patient and public health pilot 
programmes – including Health Screening, Medicine 
Use Reviews and Asthma Management. There are 
pharmacies in every community across the country 
that can do more for patients and do more with 
their skills. Pharmacies are the most accessible part 
of Ireland’s health service and deliver for patients 
consistently, effectively and cost – effectively.
   Doctor Barry White, Clinical Care Director of the HSE, 
has set up twenty six clinical care programmes which 
are developing clinical care pathways and treatment 
protocols for patients with chronic conditions. These 
have the potential to contribute to the sustainability 
of healthcare. It is vitally important that the HSE 
takes a holistic approach to these programmes and 
outcomes to ensure there is consistency in their 
implementation.
   In addition, the movement of medicines from 
prescription only to pharmacy only and an enhanced 
role for pharmacists in areas including vaccinations 
and chronic disease management will improve health 
outcomes for patients as access improves at the 
lowest level of complexity and deliver efficiencies and 
savings for the Exchequer.
  b.  Generic Substitution to deliver cost savings to the 
State.
   In an era of ageing populations and rising healthcare 
costs, generic medicines allow patients to access safe, 
effective, high-quality medicines at lower prices. In 
this way, generic medicines support the sustainability 
of healthcare provision and contribute to controlling 
pharmaceutical expenditure. 
   The development of a generics medicines market 
needs to be actively sustained by a generic medicines 
policy and requires both supply-side measures 
relating to pricing and reimbursement, and demand-
side incentives for pharmacists. 
 c.  Provision of a Vaccination Service to deliver vaccines 
such as the flu vaccine through their local pharmacy.  
   Immunisations are one of the most important 
preventative health advances of the 20th century, 
leading to drastic reductions in the incidence 
of several diseases associated with substantial 
morbidity and mortality. An important challenge for 
the 21st century is providing vaccines to all people 
who should receive them. Pharmacists can help the 
HSE to meet this call by acting as vaccine educators, 
advocates and immunisers. 
   Many barriers to immunisation have been 
identified: apathy, lack of knowledge, inconvenience, 
misconceptions regarding contraindications, limited 
service hours, etc. Pharmacists can help to address 
many of these obstacles; their convenient locations 
Paper for the Minister for State with responsibility for Primary Care,  
Ms Roisin Shortall TD
16 August 2011
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and hours of service can make vaccines accessible to 
a greater number of patients.   
   Research in the USA has found that when 
pharmacists provide immunisations, they add to the 
overall number of patients being immunised, rather 
than take patients away from other immunisation 
channels. In the majority of States, pharmacists are 
involved in vaccination for influenza, pneumococcal 
disease, meningococcal disease, diphtheria, tetanus, 
pertussis, hepatitis A and B, human papillomavirus 
and travel vaccines. 
   Establishing a pharmacy-based immunisation 
programme can substantially contribute to public 
health. The broadened access to vaccines provides 
patients with convenience and increased quality of 
care. 
   To help meet the healthcare needs of the 21st 
century, pharmacists can play an increasing role in 
the prevention of disease and providing vaccination 
services is an important part of these efforts.
   In 2009, in the shadow of the H1N1 pandemic, over 
800 pharmacists were trained in administering 
vaccinations. Pharmacists are ready to participate in 
the national immunisation effort, subject to the DoH 
and the HSE implementing such a scheme.
   Following the meeting with the Minister for Health, 
Dr Reilly, on 18 July, the IPU met with the HSE PCRS 
on 11 August to discuss the implementation of a 
pharmacist-led seasonal influenza vaccination 
service. The PCRS confirmed that the service will 
commence in the last week of September and that 
they will write to pharmacies within the next couple 
of weeks, asking if they want to participate in the 
vaccination service. The IPU is now preparing to put 
in place appropriate training for pharmacists. The 
IPU is scheduled to meet with the PSI on 16 August 
to discuss appropriate standards for the vaccination 
service to ensure patient safety.
 d.  Medicines Use Review to deliver improved patient 
compliance and reduced costs.
   Pharmacists are already engaged in a number 
of important patient and public health pilot 
programmes – including Medicine Use Reviews 
(MUR).  The introduction of a structured Medicines 
Use Review, particularly for patients on complex 
medicine regimes, would enhance patients’ health 
outcomes and generate savings in the long term. Real 
value is only achieved when patients take the right 
medicines and take them correctly. This is critical for 
patient care, patient safety and for the Exchequer. 
   This vision is not revolutionary. To the contrary, it is 
tried and trusted in several jurisdictions across the 
European Union. In the Netherlands, for example, 
Repeat Dispensing, Emergency Contraception, 
Diabetes Management, Hypertension Management, 
Homecare Services and Medicines Use Reviews are all 
examples of services being provided by community 
pharmacies in other countries. 
   The implementation of any initiative must be 
predicated upon patient safety and quality assurance 
and based on a shared objective of more efficient, 
accessible and cost effective services for patients 
in the community and outside of acute hospital 
settings.  
 e.  Health Promotions to deliver services including 
smoking cessation, weight management, diabetes 
and cholesterol screening to keep people healthy.
   Recently community pharmacist installed private 
consultation areas where patients can discuss their 
health issues in private with their pharmacist, thus 
enhancing their experience of using a pharmacy. 
Pharmacist did not receive any grants or subsidies to 
help with the installation of these rooms and bore 
the significant costs themselves. 
   Clearly these new consultation facilities make a 
whole range of patient services more feasible as 
well as more patient friendly. These are the ideal 
locations for providing diabetes and cardiovascular 
screening, cholesterol testing, blood pressure testing, 
INR testing, helping patients manage their chronic 
illnesses and for delivering services locally – at times 
and in locations that meet the diverse needs of 
people in the community.
4. CONCLUSIONS - TIME FOR A NEW APPROACH
  Government health policy has as its central aim the 
delivery of health services in the community and creating 
capacity in other areas of the health service at the 
lowest level of complexity. Pharmacists can deliver these 
services. In that context, discussion between the DoH and 
the IPU should now take place with a view to facilitating 
these developments. There is also a need to review 
all existing administrative, contractual and payment 
arrangements. The HSE has highlighted a number of 
areas they wish to address in any new pharmacy contract 
and pharmacists would also like to reduce the level 
of administrative burden currently placed on them to 
enable them to spend more time treating their patients. 
  In a separate process the IPU made a submission to 
the Irish Medicines Board (IMB) on 31 July on the Legal 
Supply Classification of Medicinal Products [Appendix 
II]. This submission highlights the role of community 
pharmacists in supporting patients in what is known 
as self-care, which is the treatment and prevention of 
illness through improved lifestyle and the use where 
appropriate of medicines available without prescription, 
also known as self-medication. Patients are no longer 
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passive recipients of healthcare and advice. Greater 
health literacy and greater access to information, 
combined with increased individual interest in personal 
health and personal choice, is leading to more and more 
patients actively looking after themselves. In addition, 
public awareness has increased the importance of 
certain lifestyle factors, such as avoidance of smoking 
and keeping a well-balanced diet, in maintaining health 
and preventing illness. Irish patients see health education 
and advice from the pharmacist as key ways to help them 
take care of their health and minor ailments.  In this 
context, self-care can be seen as the most common form 
of healthcare. As pressure grows on the Irish healthcare 
system, self-care will be seen as a means of controlling 
and rationalising healthcare and medication costs.
  Better patient care as well as future savings and 
efficiencies can be achieved by adopting an integrated 
and holistic approach to all issues of concern to all 
stakeholders. Now is the time for a new approach. 
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1. COMMUNITy PHARMACISTS 
Members of the IPU aim to provide the best possible 
professional pharmacy service to all members of the public. 
They are committed to delivering a quality, accessible, 
personal and professional service that puts the patient first 
and has as its primary goal the optimisation of the health 
and wellbeing of society. Pharmacists are accountable 
for their professional conduct and strive to maintain the 
confidence and respect of their patients, customers, the State 
and other professionals in the healthcare field.
2. PHARMACIES – OPEN DOORS  
Community pharmacists know the difficulties our patients 
face. As citizens we know the difficulty our country is in. 
Our challenge, the challenge that the IPU is prepared for, is 
to make community pharmacy the open door to Ireland’s 
entire continuum of health care. And every pharmacy is 
an open door. We are Ireland’s most accessible health 
care professionals. We see our patients from early till late 
and often seven days a week. We are best placed to offer 
a wide range of additional treatments and services that 
Irish patients need. In a country in real difficulty and a 
health system facing hard choices, utilising the professional 
skills of pharmacists and utilising the open door access of 
pharmacies is not an option, it is a must-do. 
3. IPU’S 5 POINT PLAN
Our agenda is clear. It is constructive and specific. 
Pharmacists this year are, for the first time, delivering 
Emergency Hormonal Contraception and Seasonal Flu 
Vaccinations all over Ireland. Because of change that we have 
advocated and led a better primary health service is being 
delivered for patients. 
We advocate and we are ready to implement generic 
substitution. We are qualified and ready to deliver Medicines 
Use Review, Repeat Dispensing, Diabetes Management, 
Hypertension Management and Homecare Services.  These 
are specific next steps for community pharmacy.
The IPU’s 5 Point Plan to enable community pharmacy deliver 
a better Health service for patients has the following key 
elements:
 1.  Open Door Policy to deliver better healthcare for 
patients who require access to Chronic Disease 
Management.
 2.  Generic Substitution to deliver cost savings to the 
State.
 3.  Provision of Vaccination Service to deliver vaccines 
such as the flu vaccine through their local pharmacy.  
 4.  Medicines Use Review to deliver improved patient 
safety and reduced costs.
 5.  Health Promotion to deliver services including 
smoking cessation, weight management, diabetes 
and cholesterol screening to keep people healthy. 
Prevention is always better and more cost effective 
than the cure.
In addition to the key points in the IPU 5 Point Plan there are 
a number of specific points that Budget 2012 should address.
4. GENERIC SUBSTITUTION 
A key aspect of the IPU’s 5 Point Plan is the implementation 
of a pharmacy-led policy of generic substitution. In an 
era of ageing populations and rising healthcare costs, 
generic medicines allow patients to access safe, effective, 
high-quality medicines at lower prices. In this way, generic 
medicines support the sustainability of healthcare provision 
and contribute to controlling pharmaceutical expenditure. 
The IPU believes that generic substitution should be 
implemented in advance of a reference pricing system. This 
would be beneficial in two ways. Firstly it would give advance 
notice and a sufficient lead in period to the changes for 
patients and, secondly, it would yield immediate savings to 
the State. 
It had been the Department of Health’s intention that 
reference pricing and generic substitution be implemented 
at the same time. However, the recently published Legislative 
Programme states that the Health (Pricing and Supply of 
Medicines) Bill, which would introduce generic substitution 
and reference pricing, has been delayed and is now expected 
to be published in 2012.
The development of a generic medicines market needs to 
be carefully thought out and actively sustained by a generic 
medicines policy and requires both supply-side measures 
relating to pricing and reimbursement, and demand-side 
incentives for pharmacists. In light of the delay to the 
reference pricing legislation, the IPU strongly supports 
the implementation of generic substitution which can 
yield savings immediately after further consideration and 
discussion with the IPU. 
5. PRESCRIPTION LEVy 
The introduction of the prescription levy has given rise to 
considerable difficulties for some patients and also imposed 
a significant cost burden on community pharmacists, 
who were handed the responsibility of collecting the 
charges. Pharmacists were left to inform patients about 
the introduction of the levy and to manage their fears and 
concerns. 
IPU Submission to the Department of Finance on Budget 2012
21 October 2011
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If public policy dictates that the levy should continue, then 
there are a number of patients who should be exempt 
from the charges altogether and the cost involved is not 
significant. In particular, The IPU advocates that Budget 2012 
exempts the following patient cohorts from prescription 
charges:
 l Patients in nursing homes; 
 l  Patients receiving treatment under the Methadone 
Treatment Scheme in respect of other medication 
that they may be taken;
 l  Patients receiving psychiatric medicines;
 l  Homeless patients including those in homeless 
shelters;
 l  Patients who have their medicines changed on a 
weekly/daily basis including palliative care patients;
 l  There also needs to be some restrictive provision that 
would allow pharmacists to exercise their discretion 
to dispense medicines in situations where patients 
refuse, or cannot afford, to pay for their medication.
It is not possible in many instances to collect levies from 
these patients, leaving some pharmacies in a minus situation 
as the levy is automatically deducted from their payments 
whether the levy is collected or not. 
The IPU appreciates the current budgetary constraints that 
the Government is facing but the cost associated with these 
exemptions would be very small in the overall context of the 
yield from the charges and would be of great assistance to 
these most vulnerable of patients. Indeed, the cost to health 
expenditure is far greater every time these patients do not 
take their medication as a consequence of the charges. 
6. FEMPI – FRIDGE ITEMS
Since the FEMPI Regulations were issued on 20 June 2011 
most pharmacies that dispense a fridge item to a patient 
will be doing so at a loss. Unlike some other drugs supplied 
through pharmacy, fridge items are medicines for which 
pharmacists normally pay the full invoice price and are 
not subject to any business arrangements that may be 
negotiated between the pharmacist and their wholesaler. 
Over the past few years, the Department and the HSE have 
both accepted that this is the case. In the Health Regulation 
2009, fridge items were excluded on this basis. There 
has been no change since 2009; therefore the decision 
to reimburse these drugs at less than the cost to the 
pharmacist should be reversed immediately. 
7. SELF-CARE
The IPU believes that the encouragement of responsible 
self-care and appropriate self-medication should be an 
explicit objective of public health policy and that more 
should be done to empower patients to take care of their 
own health in a safe, convenient and cost effective manner 
with the assistance of their pharmacist. This would entail 
making a much greater range of medicines available without 
prescription from pharmacists – particularly those with 
long established safety profiles, many of which are available 
without prescription in other jurisdictions. 
Patients and consumers want to actively manage their own 
health and are taking greater individual responsibility for 
their healthcare and their health choices. This could help to 
reduce unnecessary cost burdens on primary and secondary 
care systems and would bring health, social and economic 
benefits for all.
8. REGULATORy RED TAPE
At present pharmacists can face inspection from many 
different regulatory bodies such as the PSI, HSE, HSA, 
Revenue, Department of Agriculture, and NERA. We very 
much welcome the commitment in the Programme for 
Government to reduce the cost of Government imposed 
red-tape on business, in part by streamlining regulatory 
enforcement activities out of a merger and rationalisation of 
existing structures, which will hopefully reduce the amount 
of regulatory paperwork that pharmacists are presently 
required to perform. The IPU advocates that Budget 2012 
introduce specific, tangible and measurable policy changes 
to give effect to the Government’s commitment.
9. BUSINESS COSTS
It is vital that costs to small businesses, such as pharmacies, 
including rates, waste and local charges are reduced in order 
to support and grow employment in small business generally 
and the pharmacy sector particularly. Our experience is of 
over 1600 jobs lost in the pharmacy sector over the last 
eighteen months. The pharmacy sector is experiencing a 
significant drop in retail sales as well as coping with very 
large direct and indirect reductions to their payments 
from the State over the same period. The CSO Retail Index 
for June – August 2011 shows that the retail sector as a 
whole declined by 2.6% in value and by 3.3% in volume. The 
pharmacy sector for the same period shows a decline of 7.1% 
in value and 8.1% in volume.
The IPU advocates that Budget 2012 take specific and positive 
steps to address difficulties that small businesses, including 
pharmacies, are facing just to keep their business alive and to 
maintain employment.
10. RENT REVIEWS
There is a consistent call from the retail sector for reform of 
the Upward Only rent reviews in the retail sector. The IPU 
advocates that Budget 2012 commit to specific measures 
to ensure that the issue of rent reviews is immediately 
addressed. 
11. RATES
Rates are a universal issue for all retailers across the country. 
Rates are calculated on values that relate to value of 
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businesses in the centre of the boom. Income is declining 
but there has been no parallel reduction in local authority 
rates. The IPU advocates that Budget 2012 include measures 
that address rates relief for small and medium enterprises 
especially. 
12. WITHHOLDING TAX
The application of withholding tax is causing significant 
cash flow problems for small businesses. The IPU is 
recommending a review of this tax with a view to reducing 
the amount of the tax to reflect falling revenues and profits. 
13. CONCLUSION
The IPU believes that developing the role of the pharmacist 
will deliver better patient outcomes as well as generating 
efficiencies and savings. The 5 Point Plan provides the basis 
to advance this agenda. However, it is vital that the capacity 
of the community pharmacy network is not undermined 
further by continuing arbitrary and ill-conceived cuts in 
payments. Since July 2009, pharmacists suffered direct and 
indirect cuts in payments of 32% or €153m. On 31 March 2011, 
a further cut amounting to €36 million in a full year was 
announced and has since being implemented. The challenge 
now is to ensure that community pharmacy is enabled to 
deliver more and this requires a new and more strategic 
approach to be agreed for the delivery of community based 
health care. The IPU is ready for this challenge.  
Apart from the professional and healthcare role of 
pharmacies, they are small businesses and a key source of 
employment. It is estimated that employment in the sector 
has declined by 1600 over the past two years. It is vital that 
this trend does not continue. For this reason, the IPU is 
calling on the Government to review and if possible reduce 
direct and indirect costs on small businesses to maintain 
viability and employment in these difficult times. 
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EXECUTIVE SUMMARy 
The pharmacy profession plays a critically important role 
in the Irish healthcare system, being the most accessible 
and efficient element of the national primary healthcare 
network. The cost-effective nature of the pharmacy service, 
and the significant potential offered for the generation of 
additional system-wide cost savings, has been acknowledged 
by the Government and other agencies. 
However, the community pharmacy business model has, 
and continues to, come under serious threat due to a variety 
of policy, environmental and regulatory developments. In 
particular, the reductions which have taken place since 2009 
introduced under the FEMPI Act are having a fundamental 
impact on the profitability, stability, services to patients and 
viability of the community pharmacy sector.
The challenges facing the profession also include a difficult 
economic environment, a lack of credit availability, pressures 
on consumer spending, as reflected in a sharp decline in 
the value of pharmacy sales, falling retail pharmacy prices, 
increased regulatory compliance costs and pressure on 
incomes as a result of last year’s cuts and reductions to the 
price of IPHA and APMI medicines. 
Pharmacy has contributed €171 million in direct savings 
to the Exchequer since 2009. This represents over a 
30% reduction in payments which is far in excess of the 
contributions made by other sectors. Indirectly, pharmacists 
have also contributed €30 million as a consequence of 
reductions to the cost of medicines through the AMPI and 
IPHA reductions. It is also important to note that that it 
has been only three months since the FEMPI cuts in June 
2011, therefore the impact of that reduction cannot be fully 
calculated at this time. 
There is no further scope for any further cuts. The IPU is 
calling on the Minister to:
1.  eliminate the €4.50 and €3.50 fee bands, which are 
currently unsustainable. Pharmacists previously propped 
up an unsustainable dispensing business. This would go 
some way to introducing stability to the pharmacy sector 
and continuity of services in marginalised and rural areas;
2.  restore the reimbursement price of fridge items to the 
actual cost to pharmacists as they cannot be forced to 
continue to supply these medicines at a loss;
3.  implement generic substitution in advance of a reference 
pricing system. This would be beneficial in two ways. 
Firstly it would give advance notice and a sufficient lead 
in period to the changes for patients. And secondly, it 
would yield immediate savings to the State; and
4.  engage with the IPU in discussions to ensure that a cost-
effective healthcare service is delivered to patients which 
at the same time delivery efficiencies to all stakeholders 
(as discussed with the Minister last July).
Executive Summary of IPU Submission to FEMPI Review
4 November 2011
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1. BACKGROUND
In September 2010 the IMB Working Group decided that 
Flea Allergic Dermatitis (FAD) could manifest as a range 
of dermatologically different clinical presentations, that 
treatment and control of FAD were complex matters, and 
that the health and welfare needs of animals were better 
served by restricting all products with an FAD indication to 
Prescription Only Medicine (POM). Notwithstanding the IMB 
policy, the IPU respectfully does not agree with this decision 
for reasons which are outlined below and requests that you 
review this matter. 
2. POSITION IN THE UK
We should point out that antiparasitic products for 
companion animals which have a claim for FAD in the UK 
can be supplied under the category ‘NFA-VPS’. This means 
that the product can be supplied to the animal owner (as a 
product for non-food animal [NFA] by veterinary surgeons, 
pharmacists and Suitably Qualified Persons [SQPs], without a 
prescription. Such products carry the statement: the product 
can be used as part of a treatment strategy for the control of 
Flea allergy Dermatitis (FaD) where this has been previously 
diagnosed by a veterinary surgeon. The IPU understands that, 
in the UK, such products continue to be safely administered 
by the animal owner and that the indication for FAD for such 
products has not resulted in any animal welfare or public 
health problems. In fact, the IPU believes that the IMB is 
alone amongst the Member States of the European Union 
in this regard. Respectfully, the IPU requests the IMB to 
reconsider whether the basis of its policy is correct. 
3. CONTACT WITH PHARMACEUTICAL COMPANIES
Following the IMB decision, in order to provide for the 
supply of antiparasitic medicines indicated for flea control in 
accordance with the IMB policy, Pharmachem communicated 
with a number of companies. They were asked if they would 
consider removing FAD from the indication, thus facilitating 
a change of classification to POM(E). 
However, this has posed too big a hurdle for the companies 
who felt that the change would also have to apply to their 
UK product (most of which have common UK/Irish labels), 
and which would require further agreement with the UK 
authority, the Veterinary Medicines Directorate (VMD). Apart 
from the cost factor associated with introducing a change 
in Ireland to remove reference to FAD, this would require 
significant resources and might put at risk the companies’ 
current UK supply status. The companies concerned are 
unable to comprehend that, in Ireland, the claim for FAD 
requires the product to be categorised as a POM product, 
given that the same wording is deemed acceptable in the 
UK for the product to be supplied as a NFA-VPS product. They 
are concerned that a new wording, that might meet the 
demands of the IMB, might prove unacceptable to the UK 
VMD. The Irish market is not large enough to justify either 
committing the resources or risking the current status of 
a route of supply that applies in every other country in the 
EU. Pharmachem has spoken to six different suppliers of the 
relevant branded or generic products and all were interested 
but the previous issues kept arising. 
4. POM VS POM(E)
The POM(E) classification is a vital part of the medicine 
market from a pharmacist’s perspective. This method is used 
for animal remedies which, by therapeutic classification, 
would be expected to be POM but, because they do not 
require veterinary diagnosis, can be otherwise supplied. 
POM(E) confers a level of importance to a veterinary 
medicine in that only a vet or a pharmacist can personally 
supply to the end user. Like all other POM(E) medicines, these 
medicines always require advice to be given at the time of 
supply, including details on administration, reconstitution, 
storage after a container is opened and, ultimately, disposal 
of used containers and residual material. POM(E) provides for 
efficient access to medicines, particularly from pharmacists 
who, by definition, are always available six or seven days 
a week; therefore, we submit, the number of veterinary 
medicines in this classification should be further expanded. 
5. POM(E) FOR SPOT-ON TREATMENTS
The major advantage of using the POM(E) route of 
distribution is that the pet owner will meet a vet or 
pharmacist on each occasion to purchase a spot-on 
treatment. By listening to the owner, it can be quickly 
assessed by a vet or pharmacist, both of whom are experts in 
their respective fields, whether previous applications of spot-
on treatments were effective. Alarm bells will sound if the 
client is complaining; a pharmacist, having eliminated under-
dosing, incorrect application technique, etc., will immediately 
suspect FAD and direct that veterinary intervention is 
required. If FAD is diagnosed, the vet will proceed with 
treatment. If FAD is absent, product failure may be the reason 
and the relevant adverse reaction reporting forms will be 
processed and submitted to the licence holder and the IMB 
under pharmacovigilance obligations.
The POM(E) category ensures that a balance is achieved 
between the availability of suitable medicines for routine use 
in otherwise healthy animals on the one hand, and the need 
to ensure professional input and advice to safeguard public 
and animal health on the other.
It should also be borne in mind that, in terms of the Single 
Market, we share a common border with the UK, where these 
products are available without prescription. Irish consumers 
IPU & Pharmachem Submission to the Irish Medicines Board on 
Classification of Veterinary Medicines for Companion Animals
30 January 2012
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are currently purchasing spot-on treatments in the UK, 
Northern Ireland, on the internet, or in any other country in 
the EU. What safeguards, if any, can maintaining the POM 
classification offer to Irish pet owners and their pets?
In the opinion of the IPU, POM is the worst option as a route 
of distribution for spot-on treatments if animal welfare is a 
consideration. POM will ensure that FAD will be a routinely 
missed diagnosis, which is far less likely to occur if spot-on 
treatments are classified as POM(E). The IMB must make 
decisions on scientific principles, but at the same time 
should avoid inadvertently monopolising the sales of spot-on 
treatments to veterinary practices.
6. POM(E) FOR PERMETHRIN
We would also like to take the opportunity to further 
comment on Permethrin-containing products. As we have 
previously said, preparations containing Permethrin are 
licensed for human use (e.g. Lyclear) and are available without 
prescription. However, the IMB Working Group was minded 
to designate Permethrin-containing products as POM, as 
they are toxic to cats. It seems incredible that pharmacists 
can supply head lice treatments to human patients without 
a prescription yet cannot supply similar products for 
eradicating fleas from domestic pets. It is worth noting that 
the consumer of both products may be the same person. 
A scenario may arise where a parent applies Lyclear to a 
two year old child, achieves satisfactory results, washes 
the itching pet dog with excellent results and then applies 
the remainder to the pet cat, which will kill it. The question 
arises as regards to who is responsible, as there is no 
warning on Lyclear not to use it on cats; there is a warning 
on the Advantix product not to apply it to cats. All medicinal 
products, human and veterinary, carry attendant risks and 
the right balance must be found between the risk and 
benefits to the treated animals.
The POM(E) category ensures that, at all times, a professional, 
vet or pharmacist, will directly supply the end user with 
the correct preparation, at the correct dose rate, mode of 
application, application time and treatment interval; this 
is the way to proceed in this situation. Pharmacists are 
healthcare professionals who provide medicines on a daily 
basis directly to patients and animal owners. We believe that 
there are no justified grounds for confining such spot-on 
treatments to POM status.
7. POM(E) VET REFERRAL
In relation to FAD, the points we made back in 2010 still 
stand. If the spot-on treatment was POM(E) and was 
supplied to a customer from a pharmacy and the animal 
had a problem afterwards, the pharmacist would refer the 
customer to the vet. However, as it stands, if the customer 
goes to the veterinary surgery, where a ‘responsible person’ 
can dispense POMs, then the customer will be supplied with 
the spot-on treatment and only if they return with a problem 
will the vet be consulted. We submit that this puts the 
pharmacist at a disadvantage and does not serve to maintain 
animal welfare standards. 
Continuing with the last scenario, should the owner return, 
the next step in the process will then be, for example, a dog, 
presenting with FAD, will require examination by a vet. If the 
vet diagnoses FAD, a course of treatment will be initiated, 
involving successive applications of an appropriate spot-on 
treatment, supplied with or without prescription. If FAD is 
not present, the vet may proceed to supply an alternative 
spot-on treatment. Should the IMB’s Advisory Committee 
for Veterinary Medicines (ACVM) consider that a differential 
diagnosis is required for FAD, then each dog must be 
examined and the appropriate route of distribution becomes 
Veterinary Practitioner Only (VPO). This has animal welfare 
implications, as pet owners are expected to be in a position 
to present their animals for examination at three-month 
intervals throughout the year to ensure absence of FAD. A 
repeat prescription, if the designation is POM, will not satisfy 
disease surveillance for FAD, in that it may emerge at any 
time after the initial examination and before the prescription 
is finally “dispensed” - up to twelve months.
The IPU submits that, in point of fact, there is not a 
requirement for a vet to actually see an animal before 
writing a prescription. The initial and all further dispensing 
on that prescription may be carried out by a non-qualified 
staff member of the practice, or a responsible person from 
a licensed merchant’s premises. This means that a dog 
owner can access POM medication throughout the life of a 
dog, without ever presenting the dog for examination and 
availing of professional advice from a vet or pharmacist.
There is no requirement for a vet to even write a prescription, 
as a pet owner can waive his right to have a prescription 
under S.I. 786 (2007), Regulation 28(6)(a): 
“notwithstanding Paragraph (4)(b), a registered veterinary 
practitioner need not write a veterinary prescription in respect 
of an animal remedy prescribed for a companion animal, other 
than an equid, if he or she offers a veterinary prescription to 
the owner or person in charge of the animal and the offer is 
declined. “
8. CONCLUSION
Pharmacists have had the supply of dog vaccines effectively 
removed from them by assigning them to POM, making 
pharmacists unable to supply them to owners and breeders. 
This has had consequences for the dog population, as there 
was a drop in sales of dog vaccines of over 20% in 2008 
and a similar drop in 2009, with very little recovery in 2010. 
This has consequences for animal welfare and also puts 
greyhounds at risk of an outbreak, which would have severe 
consequences for them in spite of these being preventative 
treatments for which some minor protocols would provide 
adequate protection for the animals. For those valuable 
animals which require a certificate of vaccination, they would 
still have to be supplied by a vet. 
We would ask the IMB to reconsider its decision on this 
matter. We look forward to hearing from you. 
In the event that you consider it necessary to convene a new 
Working Group on the Supply of Antiparasitic Veterinary 
Medicinal Products to Companion Animals, we would 
ask that the Group would have community pharmacist 
representation and the IPU would be happy to nominate 
suitable candidates for consideration by you.  
ANNUAL REPORT 2012
42
APPENDIX VIII
The IPU is the representative body for community 
pharmacists - both pharmacist owners and employee 
pharmacists and, as a registered trade union, holds a 
negotiation licence. The sole purpose of the IPU is to 
represent and promote the interests of its members. It has no 
role outside of this. The IPU uses the resources provided by 
its members to work with and brief officials and politicians 
on matters of mutual interest as and when required. These 
discussions can take place at the request of either party. 
There are also regular and on-going discussions with public 
officials on a whole range of policy issues and other proposed 
changes. This type of collaboration and engagement is 
essential to safeguard the public interest.    
 In jurisdictions, such as Australia and New Zealand, the 
primary focus of the legislation is to register lobbyists 
who make themselves available to be hired by any party 
that has a particular issue or perspective that they wish to 
communicate to Government. The role of organisations that 
represents members of a particular sector or profession, 
such as the IPU, are clear and transparent and are generally 
exempt from the requirement to register as lobbyists in 
these two jurisdictions. The IPU believes that the same 
approach should be adopted in the proposed Irish legislation. 
There is no public benefit to be gained by requiring 
representative bodies, whose purpose is self-evident, to 
register under the proposed legislation. To introduce such a 
requirement would give rise to unnecessary bureaucracy and 
costs on all sides. In any event, should representative bodies 
engage the services of a professional lobbyist then this 
engagement will presumably be covered by the proposed 
legislation.
IPU Submission to the Department of Public Expenditure and Reform 
on the Regulation of Lobbyists
20 February 2012
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1. INTRODUCTION 
The Irish Pharmacy Union (IPU) is making this submission 
to the Health Service Executive (HSE) on foot of a request 
to participate in the HSE Review of the Medical Card 
Centralisation. In light of the short timeframe, we did 
not have time to canvass our full membership. Therefore, 
included in this submission is the feedback we have received 
from the IPU’s Pharmacy Contractors’ Committee, which we 
believe would reflect the views of patients across Ireland.
2. INCOMPLETE CLAIMS PROTOCOL
Over the past two years the IPU and the HSE have worked 
together as part of the Joint Consultative Group to 
implement the Incomplete Claims Protocol. This Protocol 
ensures that patients receive their medicine in a timely 
manner and that the pharmacist is paid for the medicine 
dispensed in good faith. It has also led to a significant 
reduction in the number of claims with an invalid or expired 
card with the pharmacists directing the patient to contact 
the PCRS when any query arises with their eligibility.
Having a Protocol such as this one has allowed pharmacists 
to provide medicines to those vulnerable patients in need, 
while at the same time helping the PCRS to clean up its 
database of medical cards. It allows the patient to continue 
to access medicines while the administrative issues around 
their card are being dealt with or their eligibility is being 
reviewed.  This is a welcome development and the IPU is 
committed to working with the PCRS initiative.
3. PATIENT FEEDBACK
Many of the patients are elderly and/or have a chronic illness. 
The primary focus, therefore, must be to ensure that patients 
have continuing and timely access to treatment and they 
should not be deprived of this while application forms and 
reviews are being processed. Appropriate communications 
are critical in this regard. Some specific issues that our 
members hear from patients on an ongoing basis are as 
follows: 
a. Key Impacts of Centralisation
 One general complaint being made by patients is around 
the lack of local knowledge of the patient’s circumstances / 
medical conditions; e.g. patients who are accessing Palliative 
Care. This leads to a perceived lack of understanding from the 
PCRS’s side and is one of the downsides of the centralisation 
of services.
b.  Customer Application Form and Processes 
Communications & Customer Engagement 
A reminder notice should be sent to patients a few months 
before the expiry date of their card.  This could be done by 
letter, email, or text or a combination of all three.
 The feedback is that the customer application form is too 
long, too complicated and should be simplified. This needs 
to be addressed and the patient should be informed of the 
steps that will be taken in processing the application and the 
likely timeframe involved. 
Once the application form is received the PCRS should send 
an acknowledgement of receipt within seven working days. 
The application should also be assigned a unique tracking 
number. By using this tracking number it should be easy for 
the PCRS and the patient to track what stage the application 
is at. This could be done online, if the patient wishes.
 There appears to be a lack of communication with the 
patient regarding waiting time following the submission 
of a “properly completed” application form. The tracking 
number may help in this regard. Many medical card patients 
are vulnerable and do not have someone to assist them in 
looking after their affairs. They are generally elderly people 
living alone. There are also cases where English may not be 
the patient’s first language. These patients struggle when 
filling out any type of form. They do not fully understand the 
application process or the importance of the process and, 
in many instances, their medical card is inactivated without 
them realising it. Perhaps this cohort of patients could be 
given a more interactive application process which would not 
rely on letter correspondence alone but would also involve 
telephone contact.
c. Customer Service – Experience 
 Again the tracking number would be helpful for both the 
patients and the PCRS staff dealing with calls from patients. 
There is a frustration that when they contact the PCRS there 
is a lack of knowledge of their application or it cannot be 
found.
 Patients complain about the forms going missing and being 
told to ring back next week. This is a huge irritation for the 
patients who do not have the money to continually ring the 
PCRS.
d. Technology and Integration
 Given the profile of many of these patients, technology and 
integration issues will not in themselves improve personal 
communication with them but may, of course, streamline 
internal PCRS procedures and processes, which will benefit 
applicants in the medium term.
4. CONCLUSION
It is vital that the administration of the medical card scheme 
is improved, that the application form and process are 
simplified and that communications to applicants are timely 
and appropriate to the particular patient cohort. Ultimately, 
patients’ access to treatment or medicines must be the 
primary concern.  
IPU Submission to the HSE PCRS Review of Medical Card Centralisation
21 February 2012
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FEMPI
FEMPI – Letter 1
From Assistant Secretary General, Department of Health to 
Secretary General 
[20 June 2011]
Health Professionals (Reduction of Payments to Community 
Pharmacy Contractors) Regulations 2011
I wish to advise that the Minister for Health made 
Regulations under the Financial Emergency Measures in the 
Public Interest Act 2009, on 20 June 2011 to reduce payments 
to pharmacists in respect of certain services rendered to or 
on behalf of the Health Service Executive under the GMS and 
community drug schemes. The details of the reductions are 
set out below.
l  Reduction in wholesale mark-up on drug items from 10% 
to 8%.
l  Reduction in wholesale mark-up on controlled drugs from 
17.66% to 8%.
l  Reduction in wholesale mark-up on fridge items from 
17.66% to 12%.
l  Reduction in retail mark-up on non-drug items from 50% 
to 20%
l  Reduction in High Tech non-dispensing fee from €62.03 
to €31.02.
l  Reduction in allowance on Stock Orders from 25% to 20%.
The HSE will notify in writing each community pharmacy 
contractor of the revised fees and of their rights under 
section 9(* of the 2009 Act to withdraw their service, on the 
basis of the revised fee, if they so wish following 30 days 
written notice of their intention to do so.
FEMPI – Letter 2
From Assistant Secretary General, Department of Health to 
Secretary General 
[23 December 2011]
I wish to inform you that the Minister for Health, in 
accordance with Section 9(13) of the Financial Emergency 
Measures in the Public Interest Act 2009, has completed 
his review of the operation, effectiveness and impact of 
the amounts and rates fixed by the Health Professionals 
(Reduction of Payments to Community Pharmacy 
Contractors) Regulations 2011.
The Minister has decided to make no change to the 
Regulations at this time.
REFERENCE PRICING
From Secretary General to Assistant Secretary General, 
Department of Health
[24 February 2012]
I have been asked by the Pharmacy Contractors’ Committee 
(PCC) to write to you on this matter. We understand that the 
legislation to implement a Reference Pricing system is at an 
advance stage and will be brought to Government over the 
coming months. 
The objective of reference pricing is to reduce ingredient 
costs, while preserving the highest possible level of patient 
care. Such a system needs to be introduced cautiously as it 
has the potential to lead to further short supply of medicines 
for patients. It will also place a significant additional cost 
on pharmacists in ensuring patient welfare and safety in 
counselling patients on the use of generic alternatives. In 
any system, pharmacists must be rewarded adequately for 
their professional input in ensuring that the introduction of 
reference pricing does not affect patient care.
The IPU has already expressed its intention to work with 
the Minister in introducing this initiative. It is also vitally 
important that we are part of the discussion on how these 
changes will be implemented and the time frame for 
doing so. In the meantime, we would welcome a discussion 
with officials so that we can understand the implications 
of such a change for our IT systems and plan accordingly. 
Some Key Letters and Responses Received Throughout the Year
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This is imperative so that we can update our IT systems 
to incorporate these changes and ensure a seamless 
changeover for the patient.
In light of the Departments’ previous assurance that further 
consultations with stakeholders would take place in advance 
of the implementation of the legislation, I wish to request 
that this meeting on the IT issues take place within the next 
few weeks.
MEMORANDUM OF UNDERSTANDING
From Secretary General to Mr A Chopra, C/o Department of 
Finance
[20 June 2011]
As the representative body for pharmacists in Ireland, I 
am writing to you in relation to a proposal in the Irish 
Memorandum of Understanding to: ‘ensure the recent 
elimination of 50 per cent mark-up paid for medicines under 
the State’s Drugs Payment Scheme is enforced’.
While it is not clear what the objective of this proposal is, I 
would like to clarify a number of issues for you. 
The Financial Emergency Measures in the Public Interest Act 
introduced by the Government in February 2009 states that: 
‘the Minister for health and Children may, with the consent 
of the Minister for Finance, by regulation, reduce, whether by 
formula or otherwise, amount or the rate of payment to be 
made to health professionals, or classes of health professionals, 
in respect of any services that they render to or on behalf of a 
health body’ [emphasis added]
The Health Professionals (Reduction of Payments to 
Community Pharmacy Contractors) Regulations enacted in 
July 2009 refers to payments that are made to a community 
pharmacy contractor in respect of services rendered 
by the pharmacist on behalf of the State. Since these 
regulations were enacted in July 2009, the Government 
has reduced the mark-up paid to pharmacists under the 
Drugs Payment and Long Term Illness schemes from 50% to 
20%.  Therefore we can confirm that the proposal contained 
in the Memorandum has been enforced since 2009 in 
respect of services provided by pharmacists on behalf of 
the Government. It should be pointed out that 75% of the 
medicines are dispensed under the Medical Card Scheme, on 
which no mark-up is paid. 
Apart from the services provided on behalf of Government, 
pharmacists also dispense medicines to private patients who 
do not qualify for full or part payment under Government 
schemes. The normal rules of competition apply to these 
transactions and the patients will go to the pharmacy where 
they achieve the best value in terms of price and service. 
Any attempt to interfere in these transactions would fly in 
the face of Competition Law, erode the capacity of small 
businesses to determine their own business strategies, and 
indeed their viability, and would not be in the interests of 
patients or consumers.
Turning to the structure of the Irish pharmacy sector, there 
has been much ill-informed comment recently about 
a supposed need to increase competition among Irish 
pharmacies. In fact, Ireland already has the most liberal and 
competitive pharmacy market in the EU. There are a higher 
proportion of pharmacies per head of population in Ireland 
than almost any other country in the EU with an average of 
1:2,800 people compared to a European average of 1: 5,100. 
A restriction preventing foreign-trained pharmacists from 
establishing new pharmacies (which was not unique to 
Ireland and which remains a feature of regulation in several 
other EU member states, including Britain, France, Germany, 
Netherlands and Portugal) was abolished in 2007 with the 
passing of the new Pharmacy Act. 
We are one of the few countries where there are no 
restrictions on who can establish or operate a pharmacy; 
in the majority of EU states only pharmacists can own 
a pharmacy and there are population or geographical 
criteria restricting the opening of new pharmacies in many 
jurisdictions. 
In 2005, the European Free Trade Association (EFTA) 
completed a Europe-wide study of the regulation of 
professions, including pharmacists, and found that Ireland 
had the most de-regulated pharmacy market of all 25 
EU member states. Similarly, a separate study, entitled 
Competition in Professional Services, published that same 
year by the European Commission, concluded that Ireland 
has the least regulated pharmacy market in Europe. 
There have been substantial falls in the prices of hundreds 
of medicines in recent years, all of which have been passed 
on to patients by pharmacists who have themselves suffered 
dramatic cuts in their payments for providing medicines 
to patients on behalf of the State. The two main drivers of 
the increased cost of the national medicines bill are the 
increased number of medical cards (a by-product of soaring 
unemployment) and greater use of very expensive high-
tech medicines, both of which schemes 0% mark-up for 
pharmacists.
In conclusion, the pharmacy sector in Ireland has been 
subject to much misinformed comment in recent months. It 
is one of the most competitive pharmacy sectors in Europe. 
Apart from the two large chains, it comprises mostly of 
small businesses that have seen their payments cut by 
Government by almost 40% over the past two years.
The IPU would welcome an opportunity to meet with you 
and your colleagues to discuss this matter further.
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PHARMACy ACT
Pharmacy Act – Letter 1
From Director of Pharmacy Services to PSI President
[22 August 2011]
Re: Proposed Amendments to the Pharmacy Act 2007  
I am writing to you on behalf of the Irish Pharmacy Union 
(IPU) in relation to the Pharmacy Act 2007 (the Act) and the 
proposed amendments to the Act which we believe to be at 
the initial stages of formulation at present. 
Since the commencement of the Act, it has come to our 
attention and to that of our members that there are a 
number of issues of concern with regard to the procedures 
and system as established for the regulation, monitoring and 
administration of the profession. 
The Act conferred particular powers on the Pharmaceutical 
Society of Ireland (PSI) with regard to the provision of 
advice to the Minister for Health in matters relating to its 
function. We have assumed that due to the valued position 
of the PSI under the Act, it will be heavily involved with 
the Department of Health in matters which concern any 
amendment to the Act. 
It is on this basis, and on the basis of our constructive 
relationship in developing the Act, that we write to outline, 
in general, certain proposed amendments to the Act which 
we view as crucial in terms of increasing the efficiency and 
effectiveness of the Act and to the profession as a whole. 
We have set out below a number of proposed amendments 
to the Act and where necessary, to relevant Regulations in 
order to effect the changes. Once you have reviewed our 
proposed amendments, we would welcome the opportunity 
to meet to discuss the matter in greater detail and to benefit 
from any insights which the PSI may have. 
1st Proposed Amendment:
The current Section of the Act: Section 14(1)(f) of the Act 
provides that ‘the Council shall register a person in the 
pharmacists’ register if the person – is not an undischarged 
bankrupt.’
The IPU’s concern: This provision effectively removes the 
right of a person capable as registering as a pharmacist to 
earn a livelihood, which in turn removes his or her ability to 
discharge a bankruptcy. This is not a requirement for medical 
practitioners and it is unclear why pharmacists should be 
subject to this requirement, particularly as it relates to their 
personal financial situation.
Proposed amendment to the Act: This provision should be 
removed as a limitation to being registered to ensure that a 
pharmacist is allowed to continue to work and earn income.
Note: If this is removed, the change should follow through to 
the removal of Section 25 (2)(b) of the Act. 
2nd Proposed Amendment:
The current Section of the Act: Section 17(4) of the Act 
provides that ‘a change in ownership of a retail pharmacy 
business shall have the effect of cancelling its registration.’
The IPU’s concerns: This provision may render a change in the 
legal structure of a pharmacy from a sole trader to a limited 
company as a ‘change in ownership’ thus requiring the 
pharmacy owner to pay another registration fee. A pharmacy 
owner pays a sum of €3,500 when he or she first registers a 
retail pharmacy business and pays a continuing registration 
fee in the sum of €2,250 thereafter.  If a pharmacy changes 
from a sole trader to a limited company, the registration fee 
becomes due again, even if the fee has been paid recently. 
This provision is financially onerous to a pharmacy owner / 
pharmacy in such a position.
The Pharmaceutical Society of Ireland (Fees) Rules 2008 
(the ‘2008 Rules’) deal with the matter of pharmacy fees. Of 
concern is Regulation 5(1) of the 2008 Rules which provides 
that the registration fee payable by the pharmacist is non-
refundable if the pharmacist does not open the pharmacy. 
There can be a period of sixty days between registration and 
opening and it is always possible that circumstances may 
change which prevents the pharmacy from opening. 
Another concern in relation to fees is when a pharmacist 
carries out a refit on the property of the registered retail 
pharmacy business and moves to temporary premises. In 
this circumstance, the pharmacist would have to pay the 
registration fee for the temporary premises and again when 
he or she moves back to the refitted premises.  This amount 
has been lowered from the standard registration fee for 
each move by virtue of the Pharmaceutical Society of Ireland 
(Fees) (Amendment) Rules 2010 . However, we would find it 
to be a prohibitive measure to discourage pharmacists from 
restoring or refitting premises. 
Rule 23 of the 2008 Rules provides in the Schedule of Fees 
that a change in Superintendent Pharmacist requires 
payment of a fee in the sum of €85. In cases where the 
Superintendent Pharmacist is off on short-term leave, such 
as sickness leave or maternity leave, the pharmacy may 
potentially incur fees in the sum of €170 for two changes 
of staff within a short-term period which we would view as 
unnecessary. 
Proposed amendments to the Act/Regulation: Amend this 
provision such that it would not apply where a change in 
structure from sole trader to company does not involve 
a change in the beneficial ownership of the pharmacy 
or, at the very least, provide for a pro rata payment of the 
registration fee in cases where the continuing registration 
fee has already been paid for the year.
The registration fee should be refundable if the pharmacist 
does not open the premises for which he or she registered.
The registration fee to move back to the refitted premises 
is waived if the move occurs from the temporary relocated 
pharmacy within one year from the date of the opening of 
the temporary retail pharmacy premises.
There should be no fee for change of registration of the 
Superintendent Pharmacist which results in the return 
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of a previous Superintendent Pharmacist, provided that 
Superintendent Pharmacist returns within one year of 
leaving the position and if the original reason for leaving was 
proposed to be temporary in nature. The rationale for the fee 
is the processing of the statement discussed in the following 
proposed amendment. 
3rd Proposed Amendment:
The current Section of the Act: Section 28(a) of the Act 
provides that where the business is carried on by a corporate 
body there is a requirement for the registered pharmacist 
to provide the registrar with ‘a statement - (i) specifying the 
name of the pharmacist and declaring whether he or she is 
a director of the corporate body or office holder in the other 
body referred to in section 26(1)(b), and (ii) signed by the 
pharmacist and on behalf of the corporate body or other body.’
The IPU’s concern: Given that it is possible to renew the 
annual registration of a retail pharmacy business online 
using secure passwords provided by the PSI, it stands to 
reason that the same process ought to be acceptable for the 
purposes of submitting the statement referred to above.
Proposed amendment to the Act: The section should be 
amended to provide for the acceptance of an electronic 
signature of this statement. 
4th Proposed Amendment:
The current Section of the Act: Section 35(6) of the Act 
provides that ‘the Council shall take all reasonable steps to 
ensure that a complaint is processed in a timely manner.’
The IPU’s concern: In practice this time frame is much too 
long. A pharmacist is currently waiting 4-5 months before the 
matter is referred to the Preliminary Proceedings Committee 
and then another 9-12 months before an inquiry is held.
Proposed amendment to the Act: This section should be 
amended with the addition of the following to the end 
of Section 35(6) of the Act, ‘… and in all cases within six 
months of the date of the complaint, save where exceptional 
circumstances may apply.’
5th Proposed Amendment:
The current Section of the Act: Section 43(1)(d) of the Act 
provides that ‘a Committee of inquiry shall have all the 
powers, rights, privileges and duties of the Court or a judge 
of the Court that relate to – awarding and authorising the 
recovery of costs.’
The IPU’s concern: This may be particularly onerous on a 
pharmacist in light of the fact that different fractions of 
the PSI will often each be represented by legal counsel. This 
may result in high legal costs if numerous senior and junior 
barristers are in attendance on each matter. Furthermore, 
if costs are to be recovered from the pharmacist there is 
less incentive on the part of the PSI to deal with the matter 
before it goes to a full inquiry.
Proposed amendments to the Act: Remove the ability to 
award costs; or 
Provide that, if they are to be awarded at all, they are only to 
be awarded in favour of the pharmacist where he or she is 
found not to have breached a regulation and the Committee 
of Inquiry deems it appropriate; or 
Provide that costs are only to be awarded in cases where one 
party has acted maliciously or vexatiously.
Note: If the possibility of an award of costs is removed 
entirely, this change must follow through to Section 43(6) 
of the Act. The possibility of costs should remain in Section 
43(8) of the Act as this refers to the failure or refusal to 
comply with a request of the Committee of Inquiry or the 
Court.
6th Proposed Amendment:
The current Section of the Act/Regulation: Regulation 4(4) 
of the 2008 Regulations provides that ‘the pharmacy owner 
shall provide and maintain a safe or cabinet that meets the 
requirements of regulation 5 of the Misuse of Drugs (Safe 
Custody) regulations 1982 (as amended by regulation 26(2) 
of the Misuse of Drugs regulations 1988 (Si no. 328 of 1988)) 
and shall ensure that the said safe or cabinet has a sufficient 
capacity to permit the orderly storage and safe keeping of 
all the relevant controlled drugs, including such veterinary 
medicinal products as are relevant controlled drugs, as required 
by the aforementioned regulation 5.’ 
The IPU’s concern: Regulation 5 of the Misuse of Drugs (Safe 
Custody) Regulations 1982 requires safes to be compliant 
with the specifications set out in the standard specification 
(Burglar-Resistant Cabinets for the Storage of Controlled 
Drugs) Declaration 1985 (I.S. 267:1985). Safes or cabinets with 
the relevant marking for I.S. 267:1985 are no longer available 
to purchase in the market. Therefore, the pharmacist must 
obtain a signature from a member of the Garda (ranking 
Superintendent or higher) certifying that the safe or cabinet 
provides a degree of security which, in his or her opinion, in 
all the circumstances of the case is at least equivalent to the 
requirements set out in the schedule. This certification lasts 
for two years, meaning that every pharmacist in the country 
who did not purchase a safe or cabinet before the cessation 
of the IS marking must obtain this signature again every two 
years.
Proposed amendment to the Act/Regulations: The reference 
to the non-existent standard should be removed to avoid 
confusion and non-compliance. The requirement to obtain 
Garda certification should only be necessitated once and, 
thereafter, only if significant changes to the controlled drugs 
safe or cabinet occur. This can be indicated on the annual 
return form on which the pharmacist already indicates if 
any significant changes have been made to the premises. It 
would be simple enough to add another question whereby 
the pharmacist confirms that no significant changes have 
been made to the controlled drugs safe or cabinet.
7th Proposed Amendment:
The current Regulation: Regulation 12 & 13 of the Regulation 
of Retail Pharmacy Businesses Regulations 2008 (the ‘2008’ 
Regulations) refer to the ‘keeping of records in respect of 
medicinal products’ and the ‘keeping of records, marking of 
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prescriptions and other related matters in respect of veterinary 
medicinal products’. Regulation 12 of the 2008 Regulations 
refer to Regulation 10(3) of the Medicinal Products 
(Prescription and Control of Supply) Regulations 2003 (the 
‘2003 Regulations’) which note that medicinal prescriptions 
need to be kept for a period of 2 years from the relevant date. 
Regulation 34(b) of the European Communities (Animal 
Remedies) (No. 2) Regulations 2007 (the ‘2007 Regulations’) 
notes that certain records as referred to need to be kept for 
a period of 5 years from the date of receipt, sale, supply or 
administration of the animal remedy.
It would appear from Regulation 10(5) of the 2003 
Regulations that such medicinal records need to be kept 
in both electronic and physical format. It is not precisely 
clear as to the required format of animal remedy records 
however Regulation 42(1) of the 2007 Regulations would 
seem to suggest that the records are to be kept in physical 
form due to the reference that such records are to held at the 
‘premises’ of the pharmacy.  
The IPU’s concern: The requirement to keep physical hard 
copies of invoices at the premises for such a lengthy period is, 
particularly in the case of a pharmacy with restricted space, 
quite onerous and unreasonable, and is, in any event, entirely 
unnecessary in light of the fact that storing or accessing 
invoices electronically is efficient and would allow for 
immediate retrieval of a hard copy if necessary. 
Proposed amendment to the Regulations/Act: The 
Regulations should be amended to provide for the storing of 
such invoices in an approved electronic format. 
Please feel free to contact us to arrange a meeting to discuss 
the proposed amendments in further detail. 
Pharmacy Act – Letter 2
From Secretary General to Registrar PSI 
[7 September 2011]
Re: Implementation of the Pharmacy Act 2007    
Further to the letter from Pamela Logan to the President of 
the PSI on 22 August 2011 in relation to amendments to the 
Pharmacy Act 2007 (the Act), I am now writing to you on a 
number of issues in relation to the implementation of the 
Act as it currently stands.
The IPU very much supports the objectives of the Act and the 
role of the Pharmaceutical Society of Ireland (PSI). However, 
there are a number of issues of concern to our members with 
regard to the procedures for the regulation, monitoring and 
administration of the profession that we would like to have 
considered. Once you have reviewed this letter, we would 
welcome the opportunity to meet to discuss the matter in 
greater detail as well as the issues raised in our letter of 22 
August 2011 and to benefit from any insights which the PSI 
may have. 
FTP Process
Apart from the primary objective of protecting patient 
safety, it is our understanding that one of the intentions and 
objectives of Part 6 of the Act, relating to Fitness to Practise 
(FTP), was to limit the number of pharmacists who ended up 
in the courts. Rather than taking years and costing hundreds 
of thousands of euros, the FTP process would create a system 
for dealing with and resolving professional practice issues 
which would be timely and cost-effective for all parties; 
however, this does not appear to be the case in practice. 
FTP Costs
A significant element of the cost relates to the number of 
legal advisors involved in FTP matters. As we understand 
it, there could be at least six legal advisors involved in 
some cases if the Registrar, Preliminary Proceedings 
Committee (PPC), Council, Committee of Inquiry, PSI and 
defendant require legal counsel. Whilst we acknowledge 
the requirements arising out of the Prendiville decision that 
there are independent legal advisors for the disciplinary 
tribunals, the Pharmacy Act was passed on the 21 April 2007 
and the Prendiville decision was handed down on the 14 
December 2007. Therefore, we would be of the view that the 
Oireachtas did not envisage the possibility that a pharmacist 
could be made liable for the costs of possibly six different 
legal teams when it passed the Act. While we appreciate 
that costs may not be awarded in every case, the mere 
possibility of such an award of costs is very distressing for 
the defendant pharmacist who is already in a highly stressful 
situation.
We would suggest that either the changes we proposed 
in our previous letter in relation to the award of costs be 
enacted into law or, alternatively, immediate steps be 
taken to limit both the number of legal advisors involved in 
particular cases and the circumstances when PSI costs can be 
awarded against pharmacists.
Mediation
One option to reduce the number of cases going into costly 
proceedings would be to take advantage of the mediation 
mechanism as provided for in Section 37 of the Act. This 
would provide the PPC with an option to deal with issues 
other than referral to a Committee of Inquiry. Mediation 
would provide a cost-effective and efficient way of handling 
complaints received by the PSI. This would ensure that 
the Committees of Inquiry would not get bogged down 
in unnecessary matters and could concentrate on matters 
which are particularly serious. To this end, we would 
welcome the use of mediation as this would be far more 
cost-effective for the PSI and our members.
PPC to carry out Preliminary Investigations
One aspect which might be of assistance would be to 
provide for the PPC to investigate the complaints on its own. 
For example, if a pharmacist makes a dispensing error, the 
PPC can send an inspector to the pharmacy who should be 
able to determine if the error was a once-off or if it was an 
error that happened because of a lack of proper procedures 
or generally poor professional standards in the pharmacy. 
This would enable the PPC to deal with matters in the most 
effective and efficient manner possible including mediation 
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in the full knowledge of the circumstances in each case. This 
would also cut down on the number of hearings before the 
Committees of Inquiry, which would save money and time. 
The reality is, FTP hearings can cost pharmacists at least 
€20,000 and take up to nine months to a year, and that is 
without an award of costs against them. 
FTP Timescales
At a human level, the time it takes from a complaint being 
lodged with the PSI through to final decision is too long. 
To have a matter such as a complaint hanging over a 
pharmacist is unfair to the pharmacist, not only in terms of 
his or her health and well-being but also his or her business. 
It should be possible to streamline the process and get 
these matters dealt with within six months. Our proposals 
regarding mediation and PPC investigations above would go 
some way to addressing this.
Building a Precedent Library
We appreciate that the FTP process is new and there is an 
interest in considering a number of cases in order to build up 
a precedent library for use by future Committees. However, 
this raises concerns on two fronts. First there is a concern 
among members that matters are being pushed through for 
a full inquiry simply to create the precedent library, where a 
full inquiry is not necessary. Secondly, there is a concern that 
a precedent library will likely dictate how future, similar cases 
are dealt with as there will be a reluctance to change.  
Replacing a Superintendent Pharmacist
Under the Act, if an owner dies, the pharmacy can continue 
to trade as long as there is a Superintendent Pharmacist in 
place. However, if a Superintendent Pharmacist dies or goes 
on long-term leave, a pharmacy might have difficulty staying 
open without violating the provisions of the Act. We would 
envisage that a sufficient period of time should be allowed 
during which a pharmacy may replace a Superintendent 
Pharmacist who has had to leave due to illness or maternity 
leave, or who has passed away, particularly where the 
pharmacy is owned by a sole trader. 
Standard Operating Procedures
We are concerned with the number of Standard Operating 
Procedures (SOPs) required by the PSI. The Society has 
produced a number of guidelines to date, which are a great 
source of information and comfort to pharmacists. However, 
each of these guidelines may require up to twenty or thirty 
SOPs to be generated by a pharmacy. Realistically, in a busy 
working pharmacy, these SOPs will sit on a shelf in a binder 
and never be referenced after they have been drafted. 
This also runs the risk that the really important aspects of 
practice may be lost in a melee of paper.
Conclusion
The IPU fully supports the objectives of the Act to protect 
patients and is pleased that all parts of the Act are being 
implemented. We would hope that the Act can be improved 
upon and changed so it will prove to be an effective method 
of safeguarding patient safety and governing and regulating 
the profession. In particular, the punishment, processes 
and costs must be appropriate to the particular case under 
investigation and we believe this can be achieved over time. 
The above comments are intended to assist in this and we 
look forward to discussing this, and the issues raised in our 
letter of the 22 August 2011, with you. Perhaps you could let 
us know when you will be in a position to meet with us.  
Pharmacy Act – Letter 3
From Director of Pharmacy Services to Chief Pharmacist, DoH
[14 December 2011]
Re: Proposed Amendments to Pharmacy Act 2007    
I am writing to you on behalf of the Irish Pharmacy Union 
(IPU) in relation to the Pharmacy Act 2007 (the Act) and the 
proposed amendments to the Act which we believe to be at 
the initial stages of formulation at present. 
Since the commencement of the Act, it has come to our 
attention and to that of our members that there are a 
number of issues of concern with regard to the procedures 
and system as established for the regulation, monitoring and 
administration of the profession. 
The Act conferred particular powers on the Pharmaceutical 
Society of Ireland (PSI) with regard to the provision of 
advice to the Minister for Health in matters relating to its 
function. We have assumed that due to the valued position 
of the PSI under the Act, it will be heavily involved with 
the Department of Health in matters which concern any 
amendment to the Act. It is on this basis, and on the basis of 
our constructive relationship in developing the Act, that we 
met with the PSI on 24 October 2011 to outline, in general, 
certain proposed amendments to the Act which we view as 
crucial in terms of increasing the efficiency and effectiveness 
of the Act and to the profession as a whole. 
We have set out below a number of proposed amendments 
to the Act and, where necessary, to relevant Regulations in 
order to effect the changes. Once you have reviewed our 
proposed amendments, we would welcome the opportunity 
to meet to discuss the matter in greater detail.
1. Bankruptcy
Section 14(1)(f) of the Act provides that ‘the Council shall 
register a person in the pharmacists’ register if the person – is 
not an undischarged bankrupt.’ This provision effectively 
removes the right of a person capable as registering as 
a pharmacist to earn a livelihood, which in turn removes 
his or her ability to discharge a bankruptcy. This is not a 
requirement for medical practitioners and it is unclear 
why pharmacists should be subject to this requirement, 
particularly as it relates to their personal financial situation. 
The IPU proposes that this provision should be removed as a 
limitation to being registered to ensure that a pharmacist is 
allowed to continue to work and earn income. 
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2. Fees
Section 17(4) of the Act provides that ‘a change in ownership 
of a retail pharmacy business shall have the effect of 
cancelling its registration.’ This provision may render a change 
in the legal structure of a pharmacy from a sole trader to a 
limited company as a ‘change in ownership’ thus requiring 
the pharmacy owner to pay another registration fee. A 
pharmacy owner pays €3,500 when he or she first registers a 
retail pharmacy business and pays a continuing registration 
fee of €2,250 thereafter.  If a pharmacy changes from a sole 
trader to a limited company with the sole trader or traders 
as the only shareholders, the registration fee becomes due 
again, even if the fee has been paid recently. This provision 
is financially onerous to a pharmacy owner / pharmacy in 
such a position. The IPU proposes that this provision would 
not apply where a change in structure from sole trader 
to company does not involve a change in the beneficial 
ownership of the pharmacy.
Regulation 5(1) of the PSI (Fees) Rules 2008 provides that the 
registration fee payable by the pharmacist to open a new 
pharmacy is non-refundable if the pharmacist does not 
subsequently open the pharmacy. There can be a period of 
sixty days between registration and opening and it is always 
possible that circumstances may change which prevent 
the pharmacy from opening. The IPU proposes that the 
registration fee should be refundable if the pharmacist does 
not open the premises for whatever reason.  
Another concern in relation to fees is when a pharmacist 
carries out a refit on the property of the registered retail 
pharmacy business and moves to temporary premises. In 
this circumstance, the pharmacist would have to pay the 
registration fee for the temporary premises and again when 
he or she moves back to the refitted premises.  This amount 
has been lowered from the standard registration fee for 
each move by virtue of the PSI (Fees) (Amendment) Rules 
2010. However, we would find it to be a prohibitive measure 
to discourage pharmacists from restoring or refitting 
premises. The IPU proposes that the registration fee should 
be waived in these circumstances if the move occurs from 
the temporary relocated pharmacy within one year from 
the date of the opening of the temporary retail pharmacy 
premises.
Rule 23 of the 2008 Rules provides that a change in 
Superintendent Pharmacist requires payment of a fee 
in the sum of €85. In cases where the Superintendent 
Pharmacist is off on short-term leave, such as sickness leave 
or maternity leave, the pharmacy may potentially incur fees 
of €170 for two changes of staff within a short-term period 
which we would view as unnecessary. The IPU proposes 
that there should be no fee for change of registration of 
the Superintendent Pharmacist which results in the return 
of a previous Superintendent Pharmacist, provided that 
Superintendent Pharmacist returns within one year of 
leaving the position. 
3. Electronic Signatures
Section 28(a) of the Act provides that where the business 
is carried on by a corporate body there is a requirement for 
the registered pharmacist to provide the Registrar with ‘a 
statement - (i) specifying the name of the pharmacist and 
declaring whether he or she is a director of the corporate 
body or office holder in the other body referred to in section 
26(1)(b), and (ii) signed by the pharmacist and on behalf of 
the corporate body or other body.’ Given that it is possible to 
renew the annual registration of a retail pharmacy business 
online using secure passwords provided by the PSI, it stands 
to reason that the same process ought to be acceptable for 
the purposes of submitting the statement referred to above 
and therefore the section should be amended to provide for 
the acceptance of an electronic signature of this statement. 
4. Complaints Procedure
Section 35(6) of the Act provides that ‘the Council shall take 
all reasonable steps to ensure that a complaint is processed 
in a timely manner.’ In practice, this time frame is much too 
long. A pharmacist is currently waiting 4-5 months before the 
matter is referred to the Preliminary Proceedings Committee 
and then another 9-12 months before an inquiry is held. The 
IPU proposes that this section should be amended with the 
addition of the following to the end of Section 35(6) of the 
Act, ‘… and in all cases within six months of the date of the 
complaint, save where exceptional circumstances may apply.’ 
5. Awarding of Costs
Section 43(1)(d) of the Act provides that ‘a Committee of 
inquiry shall have all the powers, rights, privileges and duties 
of the Court or a judge of the Court that relate to – awarding 
and authorising the recovery of costs.’ This may be particularly 
onerous on a pharmacist in light of the fact that different 
fractions of the PSI will often each be represented by legal 
counsel. This may result in high legal costs if numerous 
senior and junior barristers are in attendance on each 
matter. Furthermore, if costs are to be recovered from the 
pharmacist there is less incentive on the part of the PSI to 
deal with the matter before it goes to a full inquiry. The IPU 
proposes that the ability to award costs be removed; or if 
they are to be awarded at all, they are only to be awarded in 
favour of a pharmacist where he or she is found not to have 
breached a regulation and the Committee of Inquiry deems 
it appropriate; or that costs are only to be awarded against a 
party who has acted maliciously or vexatiously. 
6. CD Safe Requirements
Regulation 4(4) of the Regulation of Retail Pharmacy 
Businesses Regulations 2008 provides that ‘the pharmacy 
owner shall provide and maintain a safe or cabinet that meets 
the requirements of regulation 5 of the Misuse of Drugs (Safe 
Custody) regulations 1982 (as amended by regulation 26(2) 
of the Misuse of Drugs regulations 1988 (Si no. 328 of 1988)) 
and shall ensure that the said safe or cabinet has a sufficient 
capacity to permit the orderly storage and safe keeping of 
all the relevant controlled drugs, including such veterinary 
medicinal products as are relevant controlled drugs, as required 
by the aforementioned regulation 5.’ Regulation 5 of the 
Misuse of Drugs (Safe Custody) Regulations 1982 requires 
safes to be compliant with the specifications set out in the 
standard specification (Burglar-Resistant Cabinets for the 
Storage of Controlled Drugs) Declaration 1985 (I.S. 267:1985). 
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Safes or cabinets with the relevant marking for I.S. 267:1985 
are no longer available to purchase in the market. Therefore, 
the pharmacist must obtain a signature from a member 
of the Garda (ranking Superintendent or higher) certifying 
that the safe or cabinet provides a degree of security which, 
in his or her opinion, in all the circumstances of the case 
is at least equivalent to the requirements set out in the 
schedule. This certification lasts for two years, meaning 
that every pharmacist in the country who did not purchase 
a safe or cabinet before the cessation of the IS marking 
must obtain this signature again every two years. The IPU 
proposes that the reference to the non-existent standard 
should be removed to avoid confusion and non-compliance. 
The requirement to obtain Garda certification should only 
be necessitated once and, thereafter, only if significant 
changes to the controlled drugs safe or cabinet occur. This 
can be indicated on the annual return form on which the 
pharmacist already indicates if any significant changes have 
been made to the premises. 
7. Electronic Invoices
Regulations 12 & 13 of the Regulation of Retail Pharmacy 
Businesses Regulations 2008 refer to the ‘keeping of records 
in respect of medicinal products’ and the ‘keeping of records, 
marking of prescriptions and other related matters in respect 
of veterinary medicinal products’. Regulation 12 of the 2008 
Regulations refer to Regulation 10(3) of the Medicinal 
Products (Prescription and Control of Supply) Regulations 
2003 which note that medicinal prescriptions need to be 
kept for a period of 2 years from the relevant date. Regulation 
34(b) of the European Communities (Animal Remedies) 
(No. 2) Regulations 2007 notes that certain records as 
referred to need to be kept for a period of 5 years from the 
date of receipt, sale, supply or administration of the animal 
remedy. It would appear from Regulation 10(5) of the 2003 
Regulations that such medicinal records need to be kept 
in both electronic and physical format. It is not precisely 
clear as to the required format of animal remedy records 
however Regulation 42(1) of the 2007 Regulations would 
seem to suggest that the records are to be kept in physical 
form due to the reference that such records are to held at 
the ‘premises’ of the pharmacy.  The requirement to keep 
physical hard copies of invoices at the premises for such 
a lengthy period is, particularly in the case of a pharmacy 
with restricted space, quite onerous and unreasonable, 
and is, in any event, entirely unnecessary in light of the fact 
that storing or accessing invoices electronically is efficient 
and would allow for immediate retrieval of a hard copy if 
necessary. The IPU proposes that the Regulations should be 
amended to provide for the storing of such invoices in an 
approved electronic format. 
I look forward to hearing from you on this matter and would 
welcome the opportunity to meet to discuss the matter in 
greater detail.
TEMPORARy ABSENCE
Temporary Absence – Letter 1
From Secretary General to Registrar, PSI 
[13 December 2011]
Re: Temporary Absence Cover      
At our meeting of 24 October 2011, we discussed the issue of 
Pharmaceutical Assistants providing cover in the temporary 
absence of a pharmacist. When the Pharmacy Act was being 
drafted, we understood that the Pharmaceutical Society of 
Ireland (PSI) was not minded to be too prescriptive about 
the definition of temporary absence, as the cohort of 
Pharmaceutical Assistants was finite and had not given the 
PSI any cause for concern.
At the meeting, we raised the issue of PSI inspectors insisting 
that pharmacists abide by the Code of Practice drafted by 
the old PSI, i.e. that the Pharmaceutical Assistant must be 
employed for a minimum of 15 hours per week, under the 
supervision of a pharmacist, before they can cover in the 
temporary absence of the pharmacist, such as lunches, 
one day off per week and unscheduled short absences. You 
explained at the meeting that your main concern was to 
ensure that Pharmaceutical Assistants were not covering 
the pharmacy on their own for a significant period of the 
opening hours of the pharmacy. We put forward the view 
that having a Pharmaceutical Assistant working one day per 
week in the pharmacy every week to cover the pharmacist’s 
day off was preferable, from a patient safety and continuity 
of care perspective, to a different locum being employed 
each week. When we left the meeting, we felt we were in 
agreement that it would be necessary to adopt a reasonable 
and flexible approach in dealing with matters of this nature.
It has since been brought to our attention that PSI inspectors 
are still requiring pharmacies to comply with the old Code 
of Practice. In one recent example, a pharmacy who has had 
a Pharmaceutical Assistant working one day a week every 
week for the past 20 years has been told that they must 
either increase this Pharmaceutical Assistant’s hours to 
comply with the code or replace them with a pharmacist. It 
makes no sense that such long service and continuity of care 
should be replaced by ad hoc locums.  
I would ask that you reconsider the PSI’s position on this 
issue as a matter of urgency. I look forward to hearing from 
you.
Temporary Absence – Letter 2
From Registrar, PSI to Secretary General 
[18 January 2012]
Re: Temporary Absence Cover     
I wish to refer to your letter of 13th December last in relation 
to the above.
As you are aware section 30 of the Pharmacy Act 2007 
provides that where a registered pharmaceutical assistant 
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(PA) acts on behalf of a registered pharmacist during the 
temporary absence of the registered pharmacist, no offence 
is committed under section 26 of the Act. You will note that 
the PA does not act hi his or her own right but acts only 
on behalf of the registered pharmacist who is temporarily 
absent. It should also be noted that a PA is not personally 
accountable under the Pharmacy Act 2007, in that they 
are not amenable to the provisions of Part 6 of the Act nor 
are they required under the Act to undertake continuing 
professional development.
While section 30(2) of the act allows the Council, with the 
consent of the Minister, to make rules regarding what 
constitutes the temporary absence of a pharmacist and 
to set out what may or may not be done by a registered 
PA when acting on behalf of a registered pharmacists, the 
Council have yet to exercise this function. Therefore the 
terms of the previous agreement as entered into by the “old” 
Council continue to apply.
This agreement stipulates that a PA who will be performing 
the professional duties of the pharmacist in his/her 
temporary absence shall be employed in the pharmacy 
concerned on a permanent basis for not less than 15 hours 
per week. In circumstances where the PA is so employed the 
agreement provides that the assistant may act on behalf of 
the registered pharmacist during the temporary absence of 
the registered pharmacist.
You suggest in your letter that it’s better have a PA work one 
day per week to cover the pharmacist’s day off than to have a 
different locum employed each week. I would contend that it 
is preferable to have the pharmacy covered by a pharmacist 
who is qualified and personally accountable  than a person 
who is not qualified as a pharmacist, who cannot be held 
accountable for their conduct under part 6 of the Pharmacy 
Act and who is not required to participate in continuing 
professional development. Surely that is the distinction 
between a professional and non-professional.
The PSI is committed to extending the range of professional 
services offered by pharmacists and pharmacies and the 
recent roll-out of the flu vaccination service is a particularly 
good example of this. Pharmaceutical assistants were not 
considered eligible to participate in this service on the 
basis that they were not subject to the provision of Part 
6 of the Act. The position is that the further provision of 
similar services in future can only be offered on the basis 
of a professional service being offered by professional staff 
who are amenable and fully accountable under the statutory 
Code of Conduct of Pharmacists, the provisions of Part 6 
of the Act and who meet the requirements for continuing 
professional development.
I would point out that it is not the intention of the PSI to 
impact on the proper, appropriate and ongoing employment 
of PAs as employees. However, you will appreciate that the 
PSI must act in the interest of patient safety and public 
protection at all times.
VETERINARy MATTERS
From Secretary General to Minister for Agriculture,  
Marine and Food
[21 September 2011]     
As this is the first occasion that the Irish Pharmacy Union 
(IPU) has communicated with you as Minister, I would like to 
congratulate you on your appointment and wish you every 
success in the position. 
The issue we wish to raise with you today is the issue of 
veterinary medicines. You were recently quoted in the Irish 
Examiner expressing the view that there was a need to drive 
down costs in the farming sector. Your call was echoed by 
the President of the ICSA who also called for lower medicine 
prices.  
As the representative body for pharmacists the IPU would 
like to put forward some ideas and concerns that we 
have about the veterinary medicines market in Ireland. 
Currently, many medicines are prescribed and dispensed by 
veterinarians, which makes it extremely difficult for other 
suppliers to compete in this market. While there are some 
medicines that can only be prescribed and administered by 
veterinarians, there are many other medicines where farmers 
and consumers should be facilitated in purchasing medicines 
from sources other than their vet. 
The operation of the Animal Remedies Regulations has led 
to reduced choice and increased costs for farmers and other 
animal owners. Pharmacists see very few prescriptions and 
this makes it virtually impossible for them, and indeed other 
suppliers, to stay in the veterinary market. Pharmacist’s share 
of this market has dropped from 12% to 8% over the past ten 
years and from 24% twenty years ago.  Ultimately, farmers 
and animal owners pay a heavy price as more and more 
pharmacists exit this market. Currently, it is estimated that 
just twenty pharmacies account for 70% of the pharmacy 
share of the veterinary market. However we believe that 
with some changes to the regulations, this does not have 
to continue.  Over the same period the share of the market 
controlled by Veterinarians has almost doubled.
The Prescription Only Medicine (Exempt) POM(E) 
classification is a vital part of the medicine market from a 
pharmacist’s perspective. This method is used for animal 
remedies which, by therapeutic classification, would be 
expected to be POM but, because they do not require 
veterinary diagnosis, can be otherwise supplied. POM(E) 
confers a level of importance to a veterinary medicine in that 
only a veterinary practitioner or a pharmacist can personally 
supply to the end user. In particular, medicines that have 
preventative, rather than therapeutic, effects are classified 
as unnecessarily classified as POM. Like all other POM(E) 
medicines, these medicines always require advice to be given 
at the time of supply, including details on administration, 
reconstitution, storage after a container is opened and, 
ultimately, disposal of used containers and residual material. 
POM(E) provides for efficient access to medicines, particularly 
from pharmacists who, by definition, are always available six 
to seven days a week therefore the number of medicines in 
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this classification should be further expanded. 
The classification of some medicines as prescription 
only cannot be justified on either practical or scientific 
grounds. For example, spot-on flea treatments for dogs are 
prescription-only here in Ireland, unlike other jurisdictions, 
including the UK. As we understand it, it is up to the 
manufacturer to seek a particular route of supply, e.g. 
prescription-only, non-prescription, etc. when applying for 
a product authorisation. There is reluctance on the part of 
the pharmaceutical industry to change their approach out 
of loyalty perhaps to existing suppliers. This forces farmers 
and animal owners to unnecessarily visit their vet to obtain 
a prescription and in most instances they feel obliged 
to purchase the product directly from the vet. It seems 
incredible that pharmacists can supply head lice treatments 
to human patients without a prescription yet cannot supply 
similar products for eradicating fleas from domestic pets. 
There are many other similar examples.
In conclusion, pharmacists have the skills and competencies 
to play a much greater role in this market without in any 
way compromising public health or animal welfare. If they 
are facilitated in doing that, farmers and other consumers 
will have increased choice and consequently, there will be 
increased price competition. Pharmacists spend four years 
as undergraduates reading pharmacy to B.Sc. degree level 
where a veterinary module is included. These years are 
spent preparing to dispense prescriptions and to counsel 
on the safe and effective use of medicines. On graduation, 
pharmacists spend one year under the supervision of a 
tutor pharmacist further developing their dispensing and 
counselling skills. It is only then that a pharmacist assumes 
professional responsibility. In addition given the pharmacist’s 
training and accessibility, it is vital for consumers that 
pharmacy retains a strong role in the distribution of 
veterinary medicines and vaccines and the operation and 
regulation of the sector needs to be reviewed.
The IPU would welcome your consideration of these issues 
and an opportunity to meet with you to expand further on 
our views.
PSyCHIATRIC SCHEME
From Secretary General to Minister of State, Department of 
Health
[8 November 2011]
Re: Psychiatric Scheme 
I am writing to you concerning changes to the Psychiatric 
Scheme which operated in the greater Dublin since 1998. The 
scheme enabled all patients (Medical Card, Drugs Payment 
and Private) to present a prescription issued by one of the 
clinics operated by the Community Mental Health Services 
at a community pharmacy and subsequently obtain their 
medication free-of-charge. Changes to these arrangements 
were introduced over the past year which the IPU would like 
to bring to your attention because of their consequences for 
the patients concerned.
The main changes introduced were,
l  All GMS Psychiatric Patients who attend the clinics 
must now go back to their GPs to have their medicines 
transcribed on a GMS prescription before they can get 
their medicines from their community pharmacy; and
l  Non-GMS Patients, who up until now received their 
medicines free of charge, must now pay for their 
medicines.
These developments have negative consequences both in 
terms of patient safety and access to medicines.
The fact that GMS patients must now obtain a medical card 
prescription from their GP before they are able to obtain 
their medication means that patients must get a list of their 
medication from the clinic and then go to their GP to have 
the list transcribed onto a medical card prescription. This 
gives rise to transcribing errors. In addition the patient’s GP 
may not be located in the same county as the clinic which 
leads to a potential delay in the patient receiving their 
medication.
To ensure patient safety it is essential that the patient’s 
pharmacist has sight of the original list of medicines from 
the clinic as well as the transcribed prescription from the GP 
surgery. 
It would also help on this regard if the current Hospital 
Emergency Scheme, which allows community pharmacists 
to dispense a seven day supply to GMS patients who have 
been discharged from hospital, be extended to include 
patients who use the service. This will give the patient time 
to attend their GP to have the medicines transcribed onto a 
medical card prescription without having to delay either the 
commencement or continuation of their treatment. 
DPS and private patients continue to receive prescriptions 
as normal from the Community Mental Health Services. 
However, they must now pay for their medicine. This is a 
significant change for the patients as up until now they have 
obtained their medicines free of charge.  In order for patients 
to benefit from the medicines they are prescribed it is vitally 
important that they adhere to their medicine treatment 
regime. The introduction of a charge for their medicines is 
placing an obstacle to recovery for some patients and can 
hamper their ability to manage independently in their own 
community. 
The Report of the Commission on Patient Safety and Quality 
Assurance 2008 stated that “when patients move from one 
care setting to another…a significant level of discrepancy 
between actual medication treatment and what was 
intended can arise.” Recent national research found that, 
when prescriptions issued by acute general hospitals were 
transcribed, 30% of medicines were transcribed incorrectly. 
This error rate was found to be consistent for all transcribed 
prescription items over a six month period. Anecdotally we 
have heard of a number of cases where pharmacists have 
picked up transcribing errors. In some instances pharmacists 
have reported over 50% of prescriptions contain transcribing 
errors. 
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Our proposals would also assist in the de-stigmatisation of 
mental illness.
I would ask you to review these arrangements.
TRANSFER OF SICK PAy RESPONSIBILITy
From Secretary General to Minister for Social Protection
[21 November 2011]
I am writing to express the concerns of our members with 
regard to the proposal to transfer responsibility for paying 
sick pay in the first month of illness from the Department to 
individual employers. 
The IPU is the representative body for over 1600 pharmacies 
throughout Ireland and we are uniquely positioned as a body 
as we represent both employers and employees.  
The IPU acknowledges the difficult financial state the 
country is in; however we believe this proposal would be a 
retrograde step for the following reasons:
l  Employees will be put in a situation where they will not 
take necessary time off due to illness as the expense to 
their employers and the extra expense of replacing the 
lost work time from already tightly run rosters would 
have a negative effect on the viability of their employer’s 
business;
l  Employers will inevitably have to take account of time 
lost by employees and prospective employees when 
decisions are made about hiring and employment 
contracts and terms.
This proposal equates to a tax on employment. At present, 
employers make obligatory PRSI contributions to support 
social welfare provision so if this proposal were to go ahead 
it will be a double tax on employers. This will ultimately put 
employment in small businesses, such as pharmacies, at 
further risk of closure and put further pressure on the social 
welfare system. 
The pharmacy sector is experiencing a significant drop 
in retail sales as well as coping with very large direct and 
indirect reductions to their payments from the State over 
the same period. Over 1600 jobs have already been lost in 
the sector. It is vital that costs to small businesses, such 
as pharmacies, are reduced and not added to, in order to 
support and grow employment in small business. 
I would ask that our views be taken into account in coming 
to a decision on this matter. 
REDUCTIONS IN COST OF MEDICINES
From HSE Contract Manager to Assistant Secretary General, 
Department of Health
[20 February 2012]
I wish to refer to the review of the cost of medicines covered 
by the Irish Pharmaceutical Healthcare Association (IPHA) 
Agreement 2006. We understand that consultations 
between the Department and IPHA are currently taking place 
with a view to the Department achieving further savings 
from the cost of medicines.
The IPU is requesting that the Department give adequate 
notice of any reductions to the cost of medicines. The IPU 
and pharmacists should be alerted well in advance of the 
implementation date. A minimum of 4 to 6 weeks’ notice is 
necessary to allow sufficient time for the IPU to update our IT 
system and to allow pharmacists adequate time to dispense 
stock reimbursed at the higher price. 
You will remember that pharmacy contractors experienced 
significant loss to the cost of their stock as a direct result of 
the lack of notice provided by the Department in January 
2011. It is important that pharmacists are not put in this 
position again.
OUTSTANDING ISSUES
From Secretary General to Minister for Health
[28 February 2012]
I have been asked by the Pharmacy Contractors Committee 
(PCC) to write to you in relation to the recent Financial 
Emergency Measures in the Public Interest (FEMPI) Review. 
The IPU has put forward considerable evidence to 
demonstrate that there is no further scope for cuts and 
therefore welcomes the decision not to reduce pharmacy 
payments further. However, we are deeply concerned that a 
number of issues, fundamental to the provision of pharmacy 
services, were not dealt with as part of the review. 
We are now asking the following issues be reviewed 
immediately:
l  Elimination of the low level dispensing fees
  A PricewaterhouseCooper (PwC) report for 2009, 
commissioned by the IPU, shows that in the calendar year 
2009, when the FEMPI Regulations had been in operation 
for only six months, 14% of pharmacy contractors 
reported net losses after tax. Combined, these contractors 
account for 20% of the national network of pharmacies. 
This is clear evidence that the current dispensing fees 
are inadequate. Pharmacists previously propped up an 
unsustainable dispensing business using resources which 
are no longer available. The €4.50 and €3.50 fee bands 
are currently unsustainable and should be eliminated 
immediately. 
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 The Dorgan Report, commissioned by your predecessor, 
 recommended that dispensing fees ranging from €6 
 - €7 should be paid in the sector. It is acknowledged that 
 this was in the context of eliminating mark up on other 
 schemes; nevertheless the recommendation highlights 
 the inadequacies of the current fees. 
l  Reversal of the Fridge Items Decision
  The FEMPI Regulations, of 20 June 2011, means that every 
pharmacist who dispenses a fridge item to a patient 
is doing so at a loss of 4.8%. Unlike other medicines 
supplied through pharmacy, fridge items are medicines 
for which pharmacists pay the full invoice price and are 
not subject to any business arrangements that may be 
negotiated between the pharmacist and their wholesaler. 
In order to provide the health care service to its patients, 
pharmacists are being forced to purchase medicines at a 
higher price than the reimbursement price. This is unfair, 
unreasonable and inequitable, and cannot be sustained. 
The decision to reimburse these drugs at less than the 
cost to the pharmacist has to be corrected immediately.
l  Review of the Reimbursement Price to Pharmacists
  The 8.2% reduction in the reimbursement price of 
medicines significantly undermines the pharmacy 
business model. The model had been significantly 
dependent on the ability of pharmacists to negotiate 
terms with distributors to subsidise payments from 
Government. Over the past twelve months, there have 
been further pressures on the entire pharmaceutical 
sector, leading to a state of flux in the wholesale market. 
Some of the key players are experiencing considerable 
financial difficulties and this is seriously threatening 
the current level of wholesale discounts. The financial 
viability of many community pharmacies is now at 
tipping point. Many pharmacies have reached the point 
where they are now purchasing their medicines at a loss 
because they are not in a position to negotiate a level of 
discount that would enable them to purchase medicines 
at the reimbursable price. The IPU has highlighted this 
issue as an area of concern in previous submissions and 
is now calling for an immediate review of the level of 
reimbursement prices.
l  Immediate Introduction of Generic Substitution
  The IPU believes that generic substitution should be 
implemented in advance of a reference pricing system. 
This would be beneficial in two ways: firstly, it would 
give advance notice of generic substitution to patients 
and provide a sufficient lead-in period for them to get 
accustomed to that change before the implementation 
of reference pricing and, secondly, it would yield 
immediate savings to the State. Reference pricing is a 
complex issue that will require considerable discussion 
with the IPU in advance of implementation. In the 
meantime, we would welcome an early meeting with 
officials to explore the implications of substitution and 
reference pricing for our IT systems.  
l  Review of Remuneration for New Services
 Pharmacists are now delivering Emergency Hormonal 
Contraception, Influenza Vaccination and participating in 
the Needle Exchange Service. In each of the above initiatives 
inadequate consideration was given to the complexity of 
the service. This has resulted in a fee that does not reflect 
a sustainable model for the future. The development of 
an agreed framework to facilitate a fair pricing model 
for pharmacy services is needed now. The IPU is open to 
discussing a model based on the statement from the HSE 
from April 2008.
The issues outlined above need to be reviewed immediately. 
The IPU is open to engaging with the Minister and the 
Department in discussions on these issues. 
SUPPLy AGREEMENT BETWEEN IPHA AND THE STATE
From Chief Executive, IPHA, to Secretary General 
[15 December 2011]
As you know, the current supply agreement between IPHA 
and the State on the supply of innovative medicines to the 
Irish market is due to expire on 1 March 2012.
Although formal negotiations have yet to commence, IPHA is 
currently preparing its position with a view to entering such 
negotiations with the State early in the New Year.
Accordingly, I would like to invite the IPU, as a key stakeholder 
of IPHA to appraise us of any issues, timelines and 
administrative concerns you would like us to be cognisant of 
when implementing the provisions of any new Agreement 
that may be concluded.
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1. PROFESSIONAL MATTERS
26 June 2011
Pharmacists welcome Government proposals for bigger role 
for Pharmacists in health care delivery 
Opens possibility of Pharmacists providing vaccinations and 
health screening services
People may soon be dropping in to their local pharmacist 
to get a vaccination according to the President of the Irish 
Pharmacy Union, Darragh O’Loughlin. O’Loughlin was 
welcoming comments by the Minister for Primary Care, 
Roisin Shortall TD about the Government’s commitment 
to finding a bigger role for pharmacists in the delivery of 
health care in Ireland. The IPU, which represents over 1,600 
pharmacists in Ireland has welcomed the statement and 
said that they will pursue the issue when they meet with the 
Minister for Health, Dr James Reilly, on the 18 July.  
Speaking today, O’Loughlin said: “this is great news. 
Pharmacists have the potential to deliver much greater 
efficiencies for the health services and we’re keen to expand 
our role. We look forward to discussing in concrete terms how 
we can play a role in more efficiently rolling out these services 
in the community when we meet the Minister next month.”
Monday 18 July 2011
Pharmacists at first Meeting with Minister for Health
Call on Minister to implement a 5 Point Plan to deliver a 
better and more cost-effective primary care system for 
patients
The Irish Pharmacy Union (IPU) today called on the Minister 
for Health to implement its proposed 5 Point Plan to deliver a 
better health service for patients. In its first official meeting 
with Dr James Reilly, Minister for Health, the IPU set out 
proposals on ways to expand the role of pharmacists to 
optimise their role in the health services.   
The 5 Point Plan proposals are:
1.  Open Door Policy to deliver better healthcare for patients 
who require access to Chronic Disease Management 
(pharmacists are the most accessible part of the primary 
care network in Ireland). 
2.  Generic Substitution to allow patients access to safe, 
effective, high-quality medicines at lower prices therefore 
delivering cost savings to patients and the State.
3.  Provision of Vaccination Service to act as advocates and 
educators to patients and deliver vaccines such as the flu 
vaccine through local pharmacies.  
4.  Medicines Use Review to enhance patient safety, deliver 
improved outcomes, and reduce downstream healthcare 
costs through structured medicines use reviews. Real 
value can only be achieved when patients take the right 
medicines and take them correctly.
5.  Health Promotion to deliver services including smoking 
cessation, weight management and diabetes and 
cholesterol screening; all to keep people healthy.
President of the IPU Darragh O’Loughlin said, “as healthcare 
professionals we are committed to delivering a quality, 
accessible, personal and professional service that puts patients 
first. We are open to working with the Minister to play our 
part in delivering on his healthcare agenda. Our 5 Point Plan 
clearly states how savings can be achieved by expanding 
our professional role within a partnership approach of all 
stakeholders. this we believe will deliver a better health service 
for patients which are at the centre of the change agenda for 
healthcare in this country.” 
The IPU also called on the Minister for Health to appoint an 
independent Chairman to lead discussions and negotiations 
with the IPU to review all existing administrative, contractual 
and payment arrangements to allow pharmacists play this 
more centralised role in healthcare delivery.   
Monday 15 August 2011
Pharmacists meeting Minister of State Róisín Shortall
l Pharmacists Seek Expanded Role in Primary Care Delivery
The Irish Pharmacy Union (IPU) (tomorrow Tuesday) will 
meet for the first time with Minister for Primary Care, Róisín 
Shortall, to present its views and recommendations on the 
role pharmacists can play in primary care and the delivery 
of a better health service to patients.  Minister Shortall has 
already said she wants “to see pharmacists getting engaged 
more” in providing additional services. 
President of the IPU, Darragh O’Loughlin, said, “Community 
pharmacy is at the coalface of primary care.  the availability 
and accessibility of pharmacists who provide expert 
professional healthcare advice means we can deliver a 
quality, accessible, personal and professional service that puts 
patients first.  Our commitment is to do just that by delivering 
chronic disease management, medicine use reviews, health 
promotions and the provision of a vaccination service.  
A Selection of Press Releases Issued to the National Media during the 
Year on Various Matters
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Our meeting with the Minister will set out the central and 
expanded role that pharmacists can play in health care, in 
communities and in patients’ lives.” 
Today’s meeting follows on from a similar meeting with 
Minister for Health, Dr James Reilly, last month which 
resulted in the Minister announcing the provision of a flu 
vaccination service through local pharmacies for patients 
this autumn. 
7 September 2011
1,000 Pharmacists sign up to Vaccination Training
Over 1,000 pharmacists around the country have signed 
up to vaccination training so that they will be able to 
offer patients the flu vaccine this autumn/winter. The 
training, which began this week, is being provided by the 
Irish Pharmacy Union (IPU) in conjunction with Hibernian 
Healthcare. This follows the announcement by the Minister 
for Health, Dr James Reilly, that he wants a pharmacist-led 
vaccination service for the flu vaccine this winter.
17 October 2011
Statement from the Irish Pharmacy Union
The article on pharmacy prices in today’s Irish Independent is 
flawed because it analyses only one, relatively small, part of 
a pharmacist’s business [the supply of medicines to private 
patients] and ignores the rest.  It also focuses on the margins 
applied to low cost drugs ignoring the fact that the advice 
required to be delivered when dispensing prescription drugs 
doesn’t become cheaper simply because the medicine is 
cheaper to buy.  
The fact is that pharmacists operate on a wafer thin margin 
for their business as a whole with one in five pharmacists 
operating at a loss and the rest recording an average net 
profit of approximately 4% of total turnover [2009 figures 
– likely to have fallen further as a result of recent cuts in 
payments].
The article also ignores the fact that 3 out of every 4 
medicines are dispensed by pharmacists on the medical 
card scheme on which NO mark-up is paid. In these cases, 
pharmacists are paid a basic dispensing fee that ranges from 
€3.50 to €5.00 for delivery of this scheme to patients.   
The past three years have seen the State impose a series 
of savage cuts on pharmacists – beyond any cuts imposed 
on any other sector in the health services. Payments to 
pharmacists for delivering services on behalf of the State 
have been reduced by over 40% over the past two years and 
the State only pays pharmacists 91.8% of the invoice price of 
medicines dispensed as a mechanism to claw back discounts 
that pharmacists may be able to earn from suppliers. 
In relation to international comparisons, a report previously 
produced for the HSE expressed the view that international 
comparisons of prices cannot be relied on as each market is 
different in terms of size, structure and regulations. Unlike 
Ireland for example, most EU countries restrict ownership of 
pharmacies to pharmacists and also have tight regulations 
governing new openings.  
Pharmacy remains a profession under massive pressure and 
suffering huge Government interference and the outlook for 
the profession remains very challenging.
25 November 2011
Statement by the Irish Pharmacy Union
The IPU welcomes the conclusions of the interim report 
of the Pharmaceutical Society of Ireland that the public 
can have confidence in the vaccination service provided by 
pharmacists. 
The vast majority of pharmacists who have been trained 
administered the vaccine correctly. Equally, the vast 
majority of patients were given the correct dose. Those 
that administered the incorrect dose followed the incorrect 
instructions given during a small number of training 
programmes. Regrettably this resulted in some patients 
receiving an incorrect dose. Those patients are now being 
recalled and will be revaccinated shortly. The error was 
identified and reported to the relevant authorities by 
pharmacists.
Patients can have every confidence in the skills and 
competencies of pharmacists to provide this service safely. 
The IPU and its members will continue to co-operate with 
all statutory authorities in taking whatever steps are 
necessary to ensure that an error of this nature never occurs 
again in any training programmes provided for healthcare 
professionals.  
5 March 2012
Irish Pharmacy Union Graduation Day
l  Pharmacy Technicians strengthen Local Pharmacy 
Services
l  Public Health to benefit from up-skilling of Pharmacy 
Staff
Local pharmacy services were strengthened with the 
graduation of 104 pharmacy technicians who were awarded 
with a level-three National Vocational Qualification (NVQ) 
from City and Guilds at a special ceremony held in Dublin 
today. Pharmacy technicians provide a vital supporting role 
to pharmacists in the delivery of a high-quality front-line 
healthcare service in the community.  
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Presenting the graduates with their certificates, Darragh 
O’Loughlin, President of the Irish Pharmacy Union, said: 
“Pharmacy technicians have always played a key role in our 
pharmacy teams. the future of pharmacy lies in developing 
the professional role of the pharmacist in areas such as 
medicine use reviews, health promotion, health screening 
and chronic disease management. in order for pharmacists 
to develop these new roles, it is essential that we have a 
professional and experienced pharmacy team to work 
alongside us to ensure that the highest possible standards in 
the dispensing process are maintained.”
“it is only in developing our professional role that we can 
maintain our position as an integral part of primary health 
care and secure the future of the essential services we provide 
to our patients,” Mr O’Loughlin said.
 The comprehensive two-year training course for pharmacy 
technicians is delivered and administered by the Irish 
Pharmacy Union in conjunction with the National Pharmacy 
Association in the UK and City and Guilds. 
12 March 2012
Pharmacists Welcome New Dosage Instructions for 
Children’s Liquid Paracetamol Medicines
l  Recommendations will assist parents and carers with 
dosage of medicines to children.
The Irish Pharmacy Union (IPU), which represents 1,800 
pharmacists in Ireland, has welcomed new recommendations 
by the Irish Medicines Board (IMB), announced today 
(Monday 12 March), to introduce new dosage instructions 
for liquid paracetamol medicines for children. The medicines 
affected include Calpol®, Panadol Baby®, Paralink® and other 
Paracetamol products.
The new, clearer, instructions will assist parents and carers 
in providing the optimal dose of liquid paracetamol to 
children for their age. The recommendations divide doses of 
paracetamol liquid for children into narrower age bands with 
a specific dose for each band.
Commenting today, IPU President, Darragh O’Loughlin, said, 
“today’s announcement by the iMB is positive as it will make 
it easier for parents and carers to know exactly how much 
paracetamol medicine they should give their children. 
“the change in recommendations is not in response to any 
safety concerns. Paracetamol continues to be a safe and 
effective method of short-term pain and fever relief in children 
when used according to the patient information supplied 
with the medicine. however, if parents have any queries, they 
should ask their pharmacist for advice.
“Overall, the new measures will remove uncertainty around 
dosing, improve patient safety and so enhance the benefits of 
liquid paracetamol medicines, all of which is to be welcomed,” 
concluded Mr O’Loughlin. 
27 March 2012
Pharmacists Dispute Irish Heart Foundation’s Warning 
against Over-the-counter Meal Replacement Products
l  With the proper guidance and advice, over the counter 
meal replacements can work for individuals attempting 
to lose weight.
The IPU has strongly disputed a claim made by the Irish 
Heart Foundation that “pharmacists are in danger of 
encouraging a cycle of failure in people attempting to manage 
their weight”, by selling over-the-counter meal replacement 
products. The IPU, in response, has outlined that, with 
the proper guidance and advice, over-the-counter meal 
replacements can work for individuals attempting to lose 
weight. 
According to IPU Vice-President Rory O’Donnell, “as a 
healthcare professional, every pharmacist’s primary concern is 
the wellbeing of their patients. Pharmacists are ideally placed 
to advise the public and to provide them with information 
in finding solutions to obesity. Obesity is a major problem in 
our society and the pharmacy sector continuously supports 
and promotes sensible weight loss. it is too flippant to claim 
that pharmacists are promoting meal replacement products 
without taking into account the impact on their patients.”
“the reality is that individuals have used meal replacement 
products as part of a sensibly controlled balanced diet, 
which has resulted in long lasting weight loss. it is important 
that individuals take advice from their pharmacist or gP 
before they decide to undertake a weight loss programme”, 
concluded O’ Donnell. 
2. PRESCRIPTION LEVy
14 November 2011
l  Pharmacists Call for Vulnerable Patients to be excluded 
from Prescription Levy
Pharmacists are calling on the Minister for Health to abolish 
the Prescription Levy for vulnerable patients, including 
homeless people and palliative care patients. Pharmacists 
are responsible for collecting Prescription Levy on behalf of 
the HSE and according to Darragh O’Loughlin, President of 
the Irish Pharmacy Union (IPU), the levy has “given rise to 
considerable difficulties for some patients”. 
In particular, the IPU advocates the following patients be 
exempt from prescription charges:
l Patients in nursing homes; 
l Patients with intellectual disabilities; 
l  Patients receiving treatment under the Methadone 
Treatment Scheme in respect of other medication that 
they may require; 
l Patients receiving psychiatric medicines; 
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l  Homeless patients including those in homeless shelters; 
and
l  Palliative care patients and other patients who have their 
medicines changed on a daily/weekly basis.
Mr. O’Loughlin said, “Quite apart from the added financial 
impact of the levy, it is causing unnecessary stress to certain 
patients.  in extreme cases some patients are choosing not to 
take their medication at all. 
“if public policy dictates that the levy must continue, 
then certain patients should be exempt from the charges 
altogether. there needs to be some restrictive provision that 
allows pharmacists to exercise their discretion to dispense 
medicines in situations where vulnerable patients refuse, or 
cannot afford, to pay for their medication. 
“in these circumstances, the cost to the health service is far 
greater every time the charge prevents these patients from 
taking their medication.”  
The IPU has highlighted their concerns to the Government in 
two recent submissions –Submission to the Department of 
Finance on Budget 2012 and Submission to the Department 
of Health under the FEMPI Review.
As the levy is automatically deducted from payments to 
pharmacists regardless of whether the levy is collected or 
not, it means that pharmacists don’t currently have any 
discretion as to whether they should collect the levy or not. 
In comparison, the cost to the state in exempting certain 
vulnerable patients is minimal, according to the IPU.
23 November 2011
Pharmacists oppose increase in Prescription Levy
Pharmacists have cautioned against proposals to increase 
the Prescription Levy for medicines from 50 cent to €2 and to 
introduce a €50 charge for a Medical Card.
 Darragh O’Loughlin, President of the Irish Pharmacy Union 
(IPU), said, “an increase of this magnitude - effectively 
quadrupling the current charge - could present a significant 
barrier for people who are already facing real financial 
hardship and would lead to many of these patients simply not 
taking the medicines prescribed for them. even the current 
50 cent levy has given rise to difficulties for some vulnerable 
patients. any increase in costs would increase the number of 
patients struggling to continue taking their medicines.” 
The IPU has called on the Minister for Health to introduce 
Medicines Use Reviews to make sure patients are getting 
the full benefit from their medicines and to ensure patients 
are taking only those medicines which are clearly necessary 
for their treatment.  This would ensure better outcomes for 
patients and reduced downstream healthcare costs.
The IPU has also called for vulnerable patients to be exempt 
from the Levy and have highlighted their concerns to 
the Government in two recent submissions, including a 
Submission to the Department of Finance on Budget 2012. 
In the submission, the IPU advocates for the following 
patients to be exempt from the Levy: 
l Patients in residential care settings; 
l Patients with intellectual disabilities; 
l  Patients receiving treatment under the Methadone 
Treatment Scheme in respect of other medication that 
they may require; 
l Patients receiving psychiatric medicines; 
l  Homeless patients including those in homeless shelters; 
and
l  Palliative care patients and other patients who have their 
medicines changed on a daily/weekly basis. 
Last year, prescription charges were abolished in Northern 
Ireland and Wales. 
Mr. O’Loughlin said, “in extreme cases some patients are 
choosing not to take their medication at all. if people don’t 
comply with their medicine regimes, it could end up costing 
the State more.” 
Pharmacists are responsible for collecting the Prescription 
Levy on behalf of the HSE, and, as the levy is automatically 
deducted from payments to pharmacists, pharmacists don’t 
have any discretion as to whether they should collect the 
levy or not.
3. OTHER MATTERS
June 2011
Pharmacists to encourage customers to ask more about 
health
Pharmacists throughout the country are seeking to 
encourage more customers to ask them about health issues. 
The Irish Pharmacy Union is launching a major advertising 
campaign and members across the country will be 
supporting the initiative. 
The ‘Ask Your Pharmacist First’ campaign continues to 
urge patients to call in for advice before heading straight 
to their doctor. Confidential advice can be obtained from 
any pharmacist, and there is generally no lengthy wait to 
see someone about an ailment. The guidance provided by 
trained health professionals is as accurate as possible and 
can reassure customers seeking assistance. 
Speaking today the President of the IPU said that pharmacies 
could do much more to help alleviate queues and delays in 
GP surgeries and A&E departments; “we want more people 
to use pharmacies as a source of expertise on health related 
issues. We are particularly concerned at the growing trend 
for people using the Internet to diagnose what may be 
wrong with them and we want more people to drop in and 
ask their local pharmacist for advice.”
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5th July 2011
As country gears up for Oxegen Festival...Pharmacists give 
tips for a healthy weekend
Unprotected sex, dehydration, sunburn and diarrhoea are 
the top threats to the health and safety of festival goers 
so pharmacists have urged those heading to Oxegen this 
weekend to look after their health.
Speaking today Pharmacist Rory O’Donnell from Donegal 
[Vice President of the IPU] said festival goers should be 
especially cautious about the risks of unprotected sex; “Music 
Festivals and sports events are generally linked to higher than 
normal incidents of unprotected sex and we would often note 
a rise in requests for the Morning after Pill after such events.” 
O’Donnell also warned that normal oral contraception can 
become ineffective if the person is suffering from vomiting 
or diarrhoea. “We’re warning people to plan ahead if they 
believe there is any chance of an unplanned sexual encounter. 
Condoms are also essential to protect against Sexually 
transmitted infections.”
O’Donnell also offers advice on what other essential items 
you might need for the weekend. “a few small items can 
help if you do become unwell such as medication for stomach 
upsets or diarrhoea; antiseptic cream for bites, stings or cuts.  
it is important to have sunscreen of SPF 15 or higher and 
antiseptic hand gel is always handy to have at outdoor events.”
Tuesday 16 August 2011
Getting Ahead of Head Lice
l  Pharmacists advise parents on steps to minimise the risk 
of getting Head Lice
Pharmacists are advising parents to screen children routinely 
for head lice every week when children return to school in 
two weeks’ time. It is estimated that one in ten children 
suffer from head lice at any one time with 80% of head 
lice infestations occurring in children between the ages of 
4 and 16. “there is no way of preventing head lice but the 
earlier the infection is detected, the easier it is to get rid of the 
lice according to Ann-Marie Horan, Local Pharmacist from 
Terenure.
“We are advising parents to check their children’s heads for 
head lice and nits routinely every week by wet combing the 
hair.   Parents who perform regular checks will find that the 
problem is manageable.  in the long run, screening saves time 
and distress to children, parents and other family members 
who will also need to be treated if an infestation occurs”, Ms 
Horan said.  
Pharmacists are also warning parents never to treat their 
child as a precaution.  Products used to treat head lice do not 
prevent the infection from occurring and children should 
not be exposed to treatment unless it is necessary. It is 
also important for parents to check with their pharmacist 
to discuss the most appropriate treatment for their child 
especially where a child suffers from asthma, a pre-existing 
skin condition such as eczema, or allergies. 
Head Lice Tips from Pharmacists
1. Screen the hair every week by wet combing it. 
2. Treat hair immediately if you find nits or lice.
3.  Tie up long hair in a pony-tail and avoid head-to-head 
contact, which is common during play at school and at 
home.
4.  Do not share items such as hairbrushes, hair clips, combs, 
hats, scarves, towels etc. 
5.  Regularly clean things such as car/booster seats, pillows/
cushions, head phones etc. if they are sharing these items 
with other children. Avoid using these items if they have 
been used recently by someone who had lice.
6.  Wash bed linen and other clothes to kill eggs and lice if 
an outbreak has occurred.
7. Repeat the treatment after a period of a week to 10 days. 
8.  Inform the school, contacts and friends immediately if 
your child has nits or lice so everyone can check and treat 
their own children if necessary.  
9.  If you have any questions about treating head lice, ask 
your pharmacist first.
1 September 2011
Pharmacists warn of dangers of using internet for health 
advice
The Irish Pharmacy Union (IPU) has today warned of the 
dangers of turning to the internet for healthcare advice.
The warning comes following the findings of a study by 
Quinn Healthcare, which found 46% of people surveyed 
going online for health advice.
“The findings from the Quinn Healthcare study come as 
no surprise to pharmacists,” said IPU Treasurer and Co 
Meath pharmacist Kathy Maher. “We are concerned at the 
growing trend for people using the internet to self-diagnose. 
the information online may not always be correct and your 
symptoms could worsen if you are not properly diagnosed. We 
encourage people to drop in and ask their pharmacist first for 
advice.”
Community pharmacists have led the way in raising public 
awareness about the dangers of seeking health advice 
online. This year the IPU ran a nationwide campaign dealing 
with this issue. A website, www.watercooleradvice.ie, was set 
up to highlight the fact that people often go online or ask 
friends or relatives for health advice. The IPU also ran radio 
and online ads encouraging patients to Ask Your Pharmacist 
First for healthcare advice. 
Pharmacists are the most accessible part of the health 
service and the first port of call within the healthcare system.
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3 October 2011
One in three families affected by diabetes1 
43% have never been tested for diabetes1
Figures from a new study released reveal the startling 
penetration of diabetes into Ireland, with 33% of people in 
Ireland reporting a family member with the condition. One in 
five people (21%) have a family member with Type 2 diabetes 
and overall, three in four people (77%) know someone who 
has diabetes.1 
“We have been saying it for years, but these figures really bring 
the message home – diabetes is everywhere in ireland. it’s in 
urban and rural communities, in rich areas and less well-off 
areas. We’re facing a national crisis,” said Professor Seamus 
Sreenan, consultant endocrinologist and medical director of 
Diabetes Federation of Ireland.
The figures were released to coincide with a new Know 
your numbers! campaign, which promotes awareness of 
an important change to the HbA1c clinical measurement 
for diabetes that will come into effect on January 1, 2012. 
The campaign is a joint initiative between the Diabetes 
Federation of Ireland, healthcare company Sanofi, the Health 
Service Executive, and the Irish Pharmacy Union. Next 
year, HbA1c, which measures how well your diabetes has 
been controlled in the previous two to three months, will 
see its mode of expression come in line with the standard 
measurement used worldwide.  
Complications
Nine out of ten (89%)2 people with diabetes say developing 
a complicating illness as a result of their condition is their 
biggest fear. But awareness of complications of diabetes 
among the public is low. Unprompted, 46% of people in 
Ireland recognise that uncontrolled diabetes can lead to 
blindness, but only 16%  know it can cause kidney problems 
and just 18% know it can lead to amputation.1 In Ireland, half 
of all lower limb amputations (50%) carried out between 
2005-2010 were linked with diabetes3.  
Risk factors & symptoms 
The study showed that people in Ireland are aware of some 
of the risk factors for diabetes – being overweight (95%), 
not getting enough exercise (72%), but awareness levels fall 
on another risk factor – being over 45 (46%).  There is good 
awareness about the symptoms of the condition. 80% and 
74% recognise severe thirst and fatigue as a symptom of 
diabetes respectively.1 
Professor Sreenan said, “In reality there are a lot of symptoms 
for diabetes – but in some people they may not present 
for years or it may be just as a thirst or repeated infections. 
What you have to bear in mind is that, on average, there is a 
12-year period between the onset of Type 2 diabetes and its 
diagnosis3. This fact, and the wide range of symptoms, make 
it difficult for people to spot a problem and seek treatment 
early. Unfortunately, many people are only diagnosed 
after they have already suffered a complicating illness of 
diabetes such as a heart attack or stroke and often when 
the symptoms of diabetes are pointed out to them they 
recognise maybe two or more.”
Susan Sunderland, Project Manager, Sanofi, said, “We are 
proud to support any campaign that helps people with 
diabetes. Sanofi focuses on diabetes all over the world, and 
we are very happy to maintain our partnership with the DFI 
and other organisations in Ireland.”
Testing for diabetes
The study shows that 43% of people in Ireland say they have 
never been screened for diabetes, and 18% say they have 
been screened only once. It is estimated that one in eight 
Irish people over 60 years has diabetes, yet 21% say they 
have never been screened for diabetes and a further 17% say 
they have been screened only once1. There are approximately 
30,000 people in Ireland with undiagnosed diabetes, and 
figures released last month suggest that 146,000 people in 
Ireland have undetected pre-diabetes and will have Type 2 
diabetes within the next 5 years unless they take action.4 
“given the time it takes for the condition to develop, people 
– especially people over 45, or those who exhibit other risk 
factors for diabetes – should get tested on a more regular 
basis”, said Professor Sreenan. 
The campaign is also supported by the IPU.
“More than half of people with diabetes (52%)1 in ireland 
consult their pharmacist about the management of their 
condition, and we are delighted to be able to expand this 
facility further by supporting the Know your numbers 
campaign. Pharmacists are ireland’s most accessible primary 
healthcare resource. We would invite people with health 
concerns to seek the advice of their pharmacist, just as people 
with diabetes do,” said Darragh O’Loughlin, President of the 
Irish Pharmacy Union (IPU).
Know your numbers!
The Know your numbers! campaign aims to help people with 
diabetes minimise their risk of developing a complication 
related to their condition. Medical research shows that a 
patient who keeps good control – keeps their HbA1C – at an 
optimum level (48-59 mmol/mol - millimoles per mole - in 
the new measurement), significantly reduces their chances 
of developing diabetes complications. 
HbA1C is the name given to a chemical reaction that causes 
glucose to stick to the haemoglobin in the red blood cells. 
The more glucose there is in the blood, the more glucose 
there will be attached to the haemoglobin. Measuring this 
glucose gives a good indication of the average glucose levels 
in the blood over the past 10-12 weeks and a recording in the 
new measure of mmol/mol in the 50’s reduces the risk of 
diabetes complications.  
“When people measure their blood glucose level – which 
they should still do, they only learn what their blood glucose 
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level is at that moment in time. The HbA1C test which is done 
by the healthcare team determines how well their diabetes 
control has been over the previous two to three months, 
The new units for reporting HbA1c will prevent any mix-up 
between glucose and HbA1c results.” said Dr Ned Barrett, 
consultant clinical biochemist.
People with diabetes are aware of the HbA1C measurement 
(83%), and two thirds of them understand what it is (67%), 
but just one in four (27%) people with diabetes keeps their 
HbA1C at the optimum level2. The Know your numbers! 
campaign will seek to change this by highlighting the 
importance of good control. The campaign is supported by 
posters and patient cards that raise awareness in medical 
environments, and in pharmacies throughout Ireland. The 
Irish Pharmacy Union (IPU) is supporting the campaign all 
over the country by giving every person with diabetes a 
Know Your Numbers card with their monthly prescription 
during October and November. 
Finally, the Know your numbers! campaign welcomes the 
support of solicitor Gerald Kean, who generously offered 
to help raise awareness of the issue among people with 
diabetes and the wider public. 
“I am delighted to be a part of this campaign. The 
complications associated with diabetes are truly frightening, 
so anything that helps people with diabetes to reduce their 
risk of such illnesses has my full support.” 
References:
1.  September 2011 - Nationally representative research in 
terms of age, gender, social class, geographical location, 
conducted by Behaviour & Attitudes, on behalf of the 
Diabetes Federation of Ireland and Sanofi 
2.  July 2011 – Research of people with diabetes only 
conducted by Behaviour & Attitudes, on behalf of the 
Diabetes Federation of Ireland and Sanofi
3.  Diabetes Federation of Ireland: http://www.
diabetesaction.ie/campaign-archives/2010/09/podiatry-
campaign/10
4.  Diabetes Federation of Ireland: http://www.
diabetesaction.ie/diabetes-in-ireland 
18 November 2011 
Antibiotic Awareness Day - Pharmacists warn overuse of 
antibiotics is putting patients’ health at risk
l  Pharmacists advise “Antibiotics are wasted on colds  
and flu”
Pharmacists are warning patients that they may be putting 
their health at risk through the inappropriate or incorrect 
use of antibiotics. Helping to launch European Antibiotic 
Awareness Day, which takes place today, pharmacists are 
advising patients not to take antibiotics for common colds 
and flu. Patients who are feeling unwell should visit their 
local pharmacist who can advise them on whether a visit to 
the GP is necessary. 
Darragh O’Loughlin, pharmacist and President of the Irish 
Pharmacy Union, said, “antibiotics are used to treat infections 
caused by bacteria; however, they are not effective against 
viruses.  the common cold and sore throats are generally 
caused by viruses and will ultimately clear up on their own. as 
antibiotics are not effective against viruses, they are not the 
correct treatment for these illnesses. your local pharmacist can 
advise on appropriate medications to relieve your symptoms.”
“taking antibiotics for the wrong reason, or taking them 
incorrectly, can cause bacteria to develop resistance against 
antibiotics.  not alone can resistance develop in the individual 
patient, but there is an extended risk to the effectiveness of 
antibiotics in the wider population in the future.  
“the message is simple: ‘when you have a cold or flu, 
antibiotics just won’t do’”, Mr. O’Loughlin added. 
For those patients who do genuinely need to take an 
antibiotic, pharmacists are issuing the following advice:
1.  Take the antibiotic exactly as prescribed and follow the 
advice given by your pharmacist about how and when to 
take them.
2.   Complete the full course of antibiotics, even if you feel 
better.
3. Do not share your medication with others.
4.  Know the potential side effects of antibiotics and how 
they might be avoided.  (Side effects can include stomach 
upsets, diarrhoea, thrush and, occasionally, allergic 
reactions).
Mr O’Loughlin said, “if medication has been prescribed for 
you, never give them to a sick friend or relative.  as well as 
potentially causing unwanted side effects, some people can 
experience a severe allergic reaction to certain antibiotics.  So 
never take them unless they have been specifically prescribed 
for you by your doctor.”
Information leaflets for patients on the correct use of 
antibiotics are available in pharmacies nationwide.
8 December 2011
Pharmacists give tips on how to stay healthy over Christmas
With Christmas just a couple of weeks away, pharmacists 
have prepared some top tips to stay healthy this Christmas.
Pharmacist Kathy Maher says “Christmas may be a time of 
good cheer but it can have its own inevitable hazards.  Minor 
ailments, as well as cold and flu, are common over the festive 
season, so it’s wise for people to be prepared in advance. We 
recommend that people consult their local pharmacist to get 
advice on what essentials to have in the medicines cabinet in 
the run up to Christmas.”
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Pharmacists also want to ensure patients are not left 
without their medicines during the Christmas period, as 
last year’s bad weather left patients unable to visit their 
pharmacist. 
“It is important that if you are on medication, that you have 
enough to last over Christmas. Some pharmacies may be 
closed for a few days over Christmas also. Speak to your 
pharmacist about what arrangements can be made, and if 
you should run short, contact your pharmacist,” Kathy added.
l  Keep Healthy – Christmas can be stressful on a number 
of fronts so make sure you exercise and get enough sleep 
to help boost your immune system. Multivitamins and 
supplements can be helpful, especially if you are feeling 
weak and tired. Washing your hands frequently with anti-
bacterial soap reduces the chances of picking up germs.
l  Mind your Stomach – Overindulgence in rich food over 
Christmas can result in heartburn and indigestion, 
which can be very uncomfortable, so eat small amounts 
regularly.  Ask your pharmacist for advice on the most 
appropriate remedies.  
l  Never Mix Medicines and Alcohol – Over-the-counter 
cough and cold remedies, painkillers, antihistamines and 
travel sickness pills may cause drowsiness and affect 
concentration and co-ordination.  When mixed with 
alcohol these effects - even when taken hours apart - are 
enhanced. If you are taking any medication, always check 
with your pharmacist to see if it is safe to drive.  
l  Be Prepared – The festive season is a good time to check 
medicine supplies. Some pharmacies will close for a 
couple of days over Christmas so stock up on medicines 
for common ailments in advance. 
  It is useful to have medicines for stomach complaints 
and diarrhoea, and liquid paracetamol for children.  Some 
form of pain relief is always useful to have. Rehydration 
sachets to replace lost fluids and salts are also important 
to have for diarrhoea.
l  Treat Cold and Flu Appropriately - The common cold 
and sore throats are generally caused by viruses and 
will ultimately clear up on their own; antibiotics are not 
effective against them.  Your local pharmacist can advise 
on appropriate medications to relieve your symptoms.
  Many different cold and flu preparations and painkillers 
contain paracetamol so never take more than one 
paracetamol-based preparation at a time. 
l  Give Up Smoking – If you are one of the many people 
planning to give up smoking after Christmas, why not 
consult with your pharmacist to get support and advice 
on how to kick the habit.  There are over-the-counter 
nicotine replacement therapy products that can be 
helpful, especially in the initial phase of giving up. 
Your pharmacist is a medicines and healthcare expert. Ask 
your pharmacist first.
18 January 2012
Succeeding in New year’s Health Resolutions: Ask your 
Pharmacist First
As the New Year begins, healthy resolutions are made and 
with Operation Transformation fever hitting the nation, the 
Irish Pharmacy Union (IPU) is encouraging members of the 
public to ask their local pharmacist for advice and support on 
any health concerns they may have for 2012. Whether it is to 
lose some weight or stop smoking, pharmacists, as trained 
healthcare professionals, can help.  Pharmacists can also offer 
guidance and assistance on managing particular illnesses or 
conditions such as diabetes, asthma, high blood pressure or 
cardiovascular disease.
Pharmacist Kathy Maher said, “We are encouraging people 
to ‘ask your Pharmacist First’ in relation to achieving their 
healthcare goals for the new year.
“For example, with a patient trying to give up smoking, we can 
help by providing information and advice about the different 
smoking cessation medications available.  Managing nicotine 
cravings and withdrawal symptoms can be challenging and 
we can provide general strategies on helping people to quit.
“in relation to type 2 diabetes, one of the main contributory 
factors is increasing obesity. 33% of families are now reporting 
a member of the family with the condition. We can provide 
counselling on prevention and management of this condition 
where a healthy diet is extremely important.”
You can ask to speak to your pharmacist in private, and no 
appointment is required.  
12 February 2012
Pharmacists Welcome Medical Card Commitment
The Irish Pharmacy Union (IPU), which represents over 1,700 
pharmacists in Ireland, has welcomed the commitment from 
the Department of Health that patients can continue to use 
their out-of-date medical cards until their new cards have 
been issued.
IPU President Darragh O’Loughlin said, “this will come as 
a relief to a significant number of patients, especially those 
who are worried about getting their medicines while they are 
waiting for their medical cards to be renewed.”
Mr O’Loughlin went on to say “the health and wellbeing of 
patients is our main concern. nobody benefits if people stop 
taking their medicines - in fact, it could end up costing the 
State even more if those patients end up becoming seriously ill 
or are hospitalised as a result.”
The IPU has been working with the HSE Primary Care 
Reimbursement Service for some time to resolve these issues 
in order to ensure that patients can continue to get their 
medicines under the medical card scheme even if there is a 
problem with their card.
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